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GENERAL INTRODUCTION
Terminology
Tenosynovial giant cell tumours (TGCTs) are a rare family of proliferative and 
inflammatory diseases.1 They are benign, usually mono-articular lesions arising 
from the synovium, bursae and tendon sheaths, and present either as a single 
nodule (localised) or as multiple noduli (diffuse).2 Clinically, TGCTs can exhibit a 
range of behaviours, from favourable to locally aggressive, and can consequently 
have a major impact on daily life.3-6
 The disease was first described in 1852 by the French surgeon M. Chassaignac, 
who overstated the biological potential of the tumour by referring to it as ‘a cancer 
of the tendon sheath’.7 The first generally accepted clinical description was published 
in 1941 by H. L. Jaffe et al.,2 who reported 20 cases with joint and tendon involvement 
and proposed a classification using location and histology. 
 The histopathological, clinical and radiological definition of TGCT remained 
undefined for decades, with many different names for the same entity used inter-
changeably. The nomenclature outlined by Granowitz et al.8 in 1976 was modified 
by the World Health Organization (WHO) in 2002, and was used to classify giant- 
cell containing tumours by their origin; bone, soft tissue, synovium and tendon 
sheath. The two known subtypes, localised and diffuse, were renamed by the 
WHO; ‘localised pigmented villonodular synovitis (PVNS)’ was changed to ‘giant 
cell tumour of the tendon sheath (GCT-TS)’ and ‘diffuse PVNS’ became ‘diffuse-type 
giant cell tumour (Dt-GCT)’.9 In 2013, the denomination was adjusted again, and 
TGCT was suggested to replace both names.1 Within the localised TGCTs, a 
distinction was made between TGCT affecting digits and TGCT occurring in and 
around larger joints.10,11 Currently, there is still disagreement on the nomenclature 
of these diseases, and a new WHO classification is in preparation. In clinical 
practice, the ‘PVNS’ terminology is still used to maintain a clear distinction 
between giant cell tumours of the soft tissues (TGCT) and giant cell tumours of the 
bone, whereas pathologists and researchers use the most recently available WHO 
classification from 2013, which distinguishes localised- and diffuse-type TGCTs.1 
 An international multidisciplinary agreement on disease terminology and 
classification is important to ensure the reproducibility of diagnostic criteria, 
which would enable more accurate predictions about the biological potential of 
the tumour as well as facilitate the development of customised treatment 
regimens. Adequate and standardised disease names/terminologies, including 
meaningful classifications, will also make TGCT research more comparable and 
reliable.
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CHAPTER 1
Aetiology of pathogenesis
For more than a century, the pathogenesis of TGCT has been poorly understood. 
Numerous hypotheses were studied, including neoplastic, inflammatory, traumatic, 
metabolic and viral pathways, but none of them could be confirmed as the causal 
mechanism.8 In recent years, TGCT was found to be a clonal process associated 
with specific genetic changes, frequently due to a specific translocation: t(1;2) 
CSF-1:COL6A3*. Typically, a reactive component was also involved, causing the 
proliferation and recruitment of colony-stimulating factor 1 receptor (CSF-1R)- 
expressing cells such as macrophages, giant cells and osteoclasts. This is known as 
the ‘paracrine landscape effect’,12-14 a concept which could lead to the development 
of new targeted treatment strategies. Targeted therapies are beneficial because 
they specifically block the growth of tumour cells by interfering with molecules 
needed for carcinogenesis and tumour growth, rather than by simply interfering 
with all rapidly dividing cells as is the case for traditional treatments such as 
chemotherapy.15,16
Epidemiology
TGCT affects adults predominantly between 20 and 50 years of age, with equal sex 
prevalence.1,5 The overall annual incidence has been estimated at 11 cases per 
million US inhabitants, including 9.2 localised and 1.8 diffuse cases per million.4 
This incidence is low, not only because of its rarity but likely because of the 
consequential unfamiliarity of doctors with the disease, which would probably 
lead to the underreporting and underdiagnosing of TGCT. Due to the chronic 
character of the disease, the prevalence should be much higher than was previously 
estimated; Ehrenstein et al. reported a prevalence of 44.3 and 11.5 per 100,000 
people for localised- and diffuse-type TGCT, respectively.17 Of the large weight- 
bearing joints, the knee is most often involved, followed by the hip, ankle, shoulder 
and elbow.2,4,18
Clinical presentation
The diagnosis of TGCT can be difficult because of the variety of clinical symptoms, 
age and history of the patients, which means diagnosis is often delayed.3,4 The 
disease mimics many other mono-articular pathologies due to the non-specific 
nature of its symptoms. Localised TGCT can present with locking or clicking 
sensations of the affected joint,4,8 while the diffuse disease is relatively painless, 
524982-L-bw-Verspoor
Processed on: 3-10-2018 PDF page: 13
13
1
GENERAL INTRODUCTION
although it can cause discomfort and swelling.3,4 Patients can also present with 
stiffness or a limited range of motion, and haemorrhagic effusions are common.19 
At the time of initial diagnosis, the symptoms have often been present for a long 
time, sometimes even years.3,4 Patient complaints may increase as the disease 
progresses and becomes disabling, with a negative impact on daily life and 
activities; however, the exact impact is difficult to quantify because very little 
research exists on this topic.6,20,21
Figure 1  Arthroscopy of the knee joint demonstrates localised-type TGCT.
 
Nodular lesion at the synovial lining of the anterior knee compartment.
Source: left, courtesy of www.boneschool.com  by Dr. T. Dwyer; right, Loriaut et al.22
Figure 2  Intra-operative arthroscopic pictures of diffuse-type TGCT.
 
Both pictures demonstrate the brown or reddish synovial proliferation typical for diffuse- type TGCT. 
The image on the right demonstrates a mirror view of the diffuse-type TGCT on a femoral prosthesis. 
Source: left Mohanlal et al.24; right, Chen et al. 25
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CHAPTER 1
In patients with knee complaints who undergo an arthroscopy, TGCT may be 
recognised because of its macroscopic features.23 Localised TGCT is well circumscribed 
and typically lobulated (figure 1), and is white to grey with yellowish and brown 
areas. Diffuse-type TGCT is often a large (> 5 cm) firm or sponge-like yellow-brownish 
lesion (figure 2). The typical villous pattern (for which it was previously named 
pigmented villonodular synovitis) is usually lacking in extra- articular tumours.1
 Very rarely, patients with diffuse-type TGCT develop metastatic disease, 
initially mostly pulmonary metastases, which are ultimately fatal.26 Remarkably, 
this aggressive stage can present with inflammatory symptoms, such as fever, 
sweating, anorexia and weight loss, which might be caused by cytokines.26-28 
The pattern of synovial gene expression and protein activities in TGCT is similar 
to those in the activated macrophages in rheumatoid arthritis, while the phenotype 
of multinucleated giant cells, characteristic of the osteoclasts, suggests that there 
is a common autocrine mechanism in both diseases that might indicate the 
potential utility of a tumour necrosis factor (TNF)-alpha blockade.29 The systemic 
effect of the cytokines and their role in the inflammatory symptoms of TGCT 
requires further research.
Diagnosis
Previously, the diagnosis of TGCT was solely based on histopathology; however, 
magnetic resonance imaging (MRI) is now commonly used for the diagnosis, 
staging and follow-up evaluations of the disease.30-32 Haemosiderin deposition 
occurs in the majority of TGCT cases and is most prominent in the diffuse intra- 
articular form of the disease (figure 3).30 Haemosiderin is an iron-storage complex 
deposited in proliferative synovial tissues, resulting in spotty or extensive 
low-signal areas in T1- and T2-weighted images that can be best seen on fast-field 
echo sequence MRI images.33 These deposits, which are obscured by fat-suppressed 
sequences, are highly diagnostic of TGCT.30
 In the localised disease, MRI reveals a conspicuous nodular proliferation of 
the synovium (figure 4). Diffuse-type TGCTs mostly present as poorly defined 
peri-articular villous masses, which are frequently associated with degenerative 
joint disease and cystic lesions in the adjacent bone (figure 5).34 Currently the 
literature lacks specific MRI discriminating features by which to describe or 
quantify the tumour extent in relation to clinical outcome. The development of 
uniform MRI descriptions is therefore of the utmost importance for clinical and 
research purposes.
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GENERAL INTRODUCTION
Histopathologically, localised- and diffuse-type TGCT are indistinguishable;35 their 
microscopic appearances are variable, depending on the proportion of mononuclear 
cells (mainly small histiocytic-like cells), multinucleate giant cells, foamy macro- 
phages, siderophages and the amount of stroma (figure 6). Haemosiderin deposits 
are always present (figure 7), and the stroma shows variable degrees of hyalinisation.1 
Cleft-like spaces are less frequently observed in localised-type than diffuse-type 
TGCTs.1
Figure 3  Magnetic resonance imaging of recurrent diffuse-type TGCT with haemosiderin 
deposition.
 
Sagittal T2-weighted MR image shows recurrent villous proliferation of the posterior compartment of 
the left knee with haemosiderin deposition (arrow).
Figure 4  Magnetic resonance imaging of localised-type TGCT in a left knee.
 
Sagittal view T1-weighted turbo spin echo images. The fat-saturated (left) and proton-density (right) 
sequences show a nodular lesion at the synovial lining of the anterior knee compartment (arrow).
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CHAPTER 1
Treatment
Little progress has been made in the treatment of TGCT, particularly for the diffuse 
subtype.11,36 To date, surgical resection is the primary treatment for both subtypes 
(figure 8); however, despite being a generally benign neoplasm, diffuse-type TGCT 
can behave aggressively at a local level and is challenging to remove completely.37,38 
The pathologic tissue is widely spread, surrounding vital structures such as the 
cruciate ligaments, collateral ligaments, menisci, and rarely even infiltrating the 
neurovascular bundle.39,40 Residual disease is therefore often accepted to spare 
these structures, which are of vitally importance for joint function and stability.36 
Surgery often requires one or multiple synovectomies, in certain cases a joint 
Figure 5  Magnetic resonance imaging of diffuse-type TGCT.
 
Left knee: sagittal (A) and coronal (B) T2-weighted images show extensive intra- and extra-articular 
villous proliferation of the synovium (arrow). Right knee: sagittal (C) T2-weighted images show extensive 
villous proliferation of, in particular, the posterior compartment with haemosiderin deposition (arrows).
Figure 6  TGCT histological samples depicting mononucleated and some multinucleated 
giant cells and the inflammatory reaction (haematoxylin and eosin stain).
A B C
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GENERAL INTRODUCTION
replacement, and in exceptional cases even amputation.41-43 In these exceptional 
aggressive cases, there is invasive growth in the bone and soft tissue. Amputation 
follows a process of multiple treatments for extensive disease or is the final resort 
after (major) complications, for example peri-prosthetic infections.43
 For diffuse-type TGCTs there is little consensus about the most appropriate 
type of surgery. Both arthroscopic and open surgical excisions are commonly 
used, and the synovectomies can either be partial or complete.44,45 In patients with 
extensive and/or recurrent TGCT, other treatment modalities may include a 
radiation synovectomy,46 external beam radiation therapy,47 immunotherapy48 
and cryo surgery,49 the effects of which are controversial.3,19,50-59 No randomised 
controlled trials comparing these different treatments, including surgical 
resection, have been performed, meaning all available evidence is based on 
retrospective case series. These existing case series are difficult to compare because 
different disease locations, subtypes, and primary and recur rent TGCTs are 
grouped together to increase patient numbers,11,51 while various outcome 
measures are used to assess the treatment success.41,44,51,60 
 In recent years, targeted therapy has been added to the armamentarium. 
Patients with extensive, recurrent or metastatic TGCTs were previously treated 
with imatinib or nilotinib, but currently more specific inhibitors of CSF-1R (figure 9), 
including emactuzumab (RG7155)61 and cabiralizumab62 (FPA008, Five-Prime), 
have shown promising clinical activity in patients with diffuse-type TGCT.16, 63-65 
Pexidartinib (PLX3397)66, a selective inhibitor of CSF-1R, Kit (Kit receptor is a 
transmembrane protein), and FLT3-ITD (Fms-like Tyrosine Kinase 3- Internal 
Tandem Duplication), showed promising results in a randomised, placebo-con-
trolled, phase 3 study.63-65
Figure 7  TGCT histological sample demonstrating brown granular deposits of haemosiderin 
(haematoxylin and eosin stain).
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Outcome 
The surgical treatment for TGCT is guided by its clinical and radiological presentation. 
Localised-type TGCT comprises a single nodular or pedunculated lesion and has a 
favourable course, rarely recurring (10–15% recurrence) after marginal surgical 
excision.3,19,41 The less common diffuse-type TGCT tends to be more aggressive 
and involves the synovial lining and the surrounding structures. It is associated 
with a significant risk of recurrence, ranging from 9% to 46% depending on the 
joint involved and the duration of follow up, and may result in a chronic disease, 
hampering the normal func tion of the affected joint.1,3,50,68 In rare cases, 
diffuse-type TGCT is capable of malignant transformation;26,30 there is no available 
information on the aetiology of this malignant transformation, no curative treatment 
is available, and the prognosis is dismal. The currently available targeted 
treatments do not have a documented effect on metastatic diffuse-type TGCT, and 
are given on a ‘compassionate use’ basis outside trials due to a lack of alternative 
treatments. Genomic alterations might influence the sensitivity of tumour cell to 
specific inhibitors of CSF-1R.69,70 A very rare observation was a systemic effect from 
Figure 8  Intra-operative pictures of an open surgical synovectomy of diffuse-type TGCT 
in the knee.
 
Intra-operative pictures of an open surgical synovectomy showing brown synovial proliferation of the 
anterior compartment of the knee caused by haemosiderin deposition typical of diffuse-type TGCT.
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local radiotherapy resulting from an abscopal effect in a patient with metastatic 
diffuse type-TGCT, which resulted not only in a response in the right irradiated 
hilar lesion, but also in the left non-irradiated pulmonary metastasis (figure 10).26
 The primary end point in oncologic clinical trials is often overall survival, but 
this is not appropriate for TGCT which is rarely lethal.71 Alternate endpoints include 
response rates, progression free survival, and time without active treatment. 
Quality of life (QoL) and functional scores are of utmost importance, but mostly 
absent or described for small, heterogeneous patient groups.20 These outcome 
measures demonstrate the clinical relevance and impact of treatments in patients 
with this benign chronic disease.72
Figure 9   Mechanisms of action of the CSF-1R inhibitors67.
 
Intra-operative pictures of an open surgical synovectomy showing brown synovial proliferation of the 
anterior compartment of the knee caused by haemosiderin deposition typical of diffuse-type TGCT.
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Figure 10  Abscopal effect of radiotherapy in a patient with metastatic diffuse-type 
TGCT.26
 
Computed tomography (CT, left column), FDG-positron emission tomography (PET, middle column), and 
combined FDG-PET-CT image (right column), before the start (pre) and after the completion (post) of 
radiotherapy. (a) High uptake of FDG in the right hilar diffuse-type TGCT metastasis before the start of 
radiotherapy with an impressive decrease in FDG-uptake three weeks after the completion of 
radiotherapy, corresponding with the metabolic response. (b, c) Abscopal effect in the left pulmonary 
metastases (b) and mediastinal lymphadenopathy (c), showing a volume response in the pulmonary 
lesions on the CT and a metabolic response on the FDG-PET-CT images, as well as an increased uptake in 
a mediastinal lymph node on FDG-PET-CT, in keeping with an immunological reaction.
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Aim and outline of this thesis
TGCT presents at a relatively young age and can have a major impact on life; 
however, most clinicians are not familiar with the disease and its consequences. 
Some patients with diffuse-type TGCT experience evident morbidity, as a result of 
the disease itself or its treatments. Despite these issues, the only available evidence 
is based on retrospective case series.
 The aim of this thesis is to investigate the incidence, diagnosis, treatments 
and outcomes of patients with TGCT in large joints to enhance the quality and 
efficiency of diagnostics and treatments for patients affected by this (chronic) 
condition. Ultimately, this should lead to improvements in patient outcomes.
 The only available data on the incidence of TGCTs were published in 19804 
and the surprisingly low rates are likely to reflect the underreporting and under-
diagnosis of this rare disease. Chapters 2 and 3 present a nationwide incidence 
study, which was undertaken to map the true incidence of TGCT in adults and 
children. The characteristics of TGCT in children were compared with those of 
adults to define the similarities and differences, including in relation to the 
aggressiveness of the disease.
 Using MRI, we can visualise the characteristic features of TGCT that enable 
the distinction between the localised and diffuse subtypes of the disease.30 
Clinically, patients present with a more or less aggressive diseases of a single 
subtype. In chapter 4, the objective MRI characteristics of TGCT are described, 
and a radiology-based severity classification for patients with TGCT in large joints 
is presented, enabling the objective differentiation between the severity stages of 
TGCT. This classification should enhance the information given to patients, provide 
insights into recurrence risk and improve personalised treatment regimens; for 
example, more aggressive disease types may require a different treatment regime 
than milder forms of the disease.
 Several multimodal treatments have been applied in addition to or after 
surgical synovectomies in an attempt to reduce recurrences. In chapter 5, the 
broad spectrum of available treatments (e.g., surgery, radiation synovectomy, 
external beam radiation therapy and systemic treatments) is further explored, 
and their effects are evaluated in a systematic review of the literature. Based on 
this research, guidelines are formulated to support physicians in making optimal, 
consistent treatment plans for patients with TGCT.
 Subsequently, the outcomes for subgroups of patients who receive these 
multimodal treatment(s) were retrospectively analysed. Chapter 6 reports on the 
outcome of arthroplasty in the treatment of TGCT, while chapter 7 describes 
cryosurgery in addition to a surgical synovectomy.
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CHAPTER 1
Another treatment option is imatinib mesylate. TGCTs are rare CSF-1-driven 
proliferative disorders, and one of the targets of imatinib mesylate is CSF-1R.16 
Chapter 8 reports the results of an international, multicentre study on the 
long-term effects of treatment using imatinib mesylate in patients with TGCT, 
including the prolonged activity after discontinuation, as well as its safety.
 In chapter 9, the treatment effects of a very select subgroup of patients with 
TGCT in the temporomandibular joint are studied. TGCT in the temporomandibular 
joint is even less common than rare malignancies such as sarcomas or metastases.73 
The temporomandibular joint is a difficult location to treat due to its proximity to 
the brain and other vital structures. In cases of extensive or recurrent illness, 
TGCT in the temporomandibular joint cannot be radically treated with surgery 
alone. Other treatments, such as external beam radiation or target therapy, were 
provided to the patients, and the results of three new cases are reported in addition 
to a review of the existing literature.
 Adequate documentation on the outcomes of TGCT treatment is lacking. 
Previous case studies have used relatively short follow-up times and often combine 
locations or disease subtypes to increase patient numbers. In chapter 10, the long- 
term outcomes of a large consecutive series of patients with TGCT are analysed. 
Overall survival is often the primary end point in oncologic clinical trials, but it is 
not appropriate for TGCT as the disease is rarely lethal.71 Alternate endpoints include 
response rates, progression-free survival, and the avoidance of morbid therapies. 
Quality of life (QoL) and functional scores demonstrate the clinical relevance and 
impact of treatments in benign diseases, but are largely absent in TGCT research.72 
In chapter 11, pre- and post-operative patient-reported outcome measures (health-
related QoL and joint function) are investigated in patients with TGCT.
 In chapters 12 and 13, the results of this thesis are summarised and discussed. 
The thesis is concluded with future perspectives, including suggestions for further 
research using collaborative, better-organised and international approaches.
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CHAPTER 2
Abstract
Tenosynovial giant cell tumors (TGCT) are rare, benign tumors, arising in synovial 
lining of joints, tendon sheaths, or bursae. 2 types are distinguished: localized, 
either digits or extremity, and diffuse lesions. Current TGCT incidence is based 
on 1 single US-county study in 1980, with an incidence of 9 and 2 per million 
person-years in localized (including digits) and diffuse TGCT, respectively. We aim 
to determine nationwide and worldwide incidence rates (IR) in TGCT affecting 
digits, localized-extremity TGCT and diffuse- type TGCT.
 Over a 5-year period, the Dutch Pathology Registry (PALGA) identified 4,503 
pathology reports on TGCT. Reports affecting digits were solely used for IR calculations. 
Reports affecting extremities were clinically evaluated. Dutch IRs were converted 
to world population IRs.
 2,815 (68%) digits, 933 (23%) localized-extremity and 390 (9%) diffuse-type 
TGCT were identified. Dutch IR in digits, localized-extremity, and diffuse-type 
TGCT was 34, 11 and 5 per million person-years, respectively. All 3 groups showed 
a female predilection and highest number of new cases in age category 40–59 
years. The knee joint was most often affected: localized-extremity (46%) and 
diffuse-type (64%) TGCT, mostly treated with open resection: localized (65%) and 
diffuse (49%). Reoperation rate due to local recurrence for localized-extremity was 
9%, and diffuse TGCT 23%.
 This first nationwide study and detailed analyses of IRs in TGCT estimated a 
worldwide IR in digits, localized-extremity and diffuse TGCT of 29, 10, and 4 per 
million person-years, respectively. Recurrence rate in diffuse type is 2.6 times 
higher, compared with localized extremity. TGCT is still considered a rare disease; 
however, it is more common than previously understood.
524982-L-bw-Verspoor
Processed on: 3-10-2018 PDF page: 29
29
2
HIGHER INCIDENCE RATES THAN PREVIOUSLY KNOWN
Introduction
Tenosynovial giant cell tumors (TGCT) are a rare entity, affecting generally young 
patients (below the age of 40 years), with an equal sex distribution. The World 
Health Organization (WHO) classification of Tumors of Soft Tissue and Bone (2013) 
distinguishes 2 TGCT types: localized and diffuse lesions.1 Microscopically the 
2 types show no clear difference. However, on magnetic resonance imaging (MRI) 
discrimination between these types is made.30
 The localized type was previously described as giant cell tumor of tendon sheath, 
nodular synovitis or localized pigmented villonodular synovitis (PVNS). The typical 
macroscopic  aspect is a well circumscribed, small (about 0.5 to 4 centimeters) 
usually lobulated lesion, with white to grey, yellow and brown mottled areas1. 
Based on anatomical site of the localized-type tumor, differentiation is made into 
a group affecting digits and a group occurring in and around larger joints.74,75 
TGCT affecting digits is defined as a localization distal to metacarpal or metatarsal 
bones; localized-extremity TGCT is defined as all sites near joints proximal and 
including metacarpal and metatarsal joints.
 In localized TGCT, most lesions are found in the digits of hands and feet (figure 1). 
The majority of these lesions arise from the tendon sheath and less frequently 
from synovial lining of digital joints. Common treatment is marginal excision.76,77 
A systematic review showed a recurrence rate of 15%, after an average follow-up of 
37 to 79 months.78
Figure 1  MRI of localized-type TGCT, affecting digits. 
A 43-year-old male patient with a well-circumscribed tumor in the proximal phalanx of the third digit 
of the right hand. Left panel: A coronal T1-weighted MRI after intravenous contrast injection. Right 
panel: A clear coronal T1-weighted MRI without intravenous contrast injection.
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Fewer localized TGCT lesions are found around larger joints; they originate from 
synovial lining, tendon sheaths, or bursae (figure 2). The preferred treatment of 
these lesions is marginal excision by an arthroscopic or an open approach.76,77 
A systematic review reported an average recurrence rate of 6% after arthroscopic 
resection and 4% after open resection (with variable follow-up).37
The diffuse-type TGCT, previously called diffuse pigmented villonodular synovitis 
(PVNS) or synovitis (villo)nodularis pigmentosa (SVP), is a more destructive and 
locally aggressive tumor (figure 3). Diffuse TGCT is defined by the presence of an 
infiltrative soft tissue mass along synovial lining, showing villous projections of 
the proliferated synovial membrane, with or without involvement of the adjacent 
joint or other structures. Macroscopically, the diffuse type affects a large part of 
synovial lining and has a multinodular, multi-colored appearance, including 
white, yellow and rust-colored areas1. 75% are located around the knee joint37. 
Current treatment is surgical excision.76,77,79 However, it is often difficult to 
perform a marginal excision. Average recurrence rates after arthroscopy are 40% 
and after open resection 14%, with variable follow-up times.37 In extensive disease, 
perioperative radiotherapy might reduce recurrence rate. 80,81 Patients with 
(multiple) recurrences experience impaired quality of life.20
 According to the WHO classification of 2002 and 2013, the incidence rate (IR) 
in TGCT is not exactly.1,82 Current TGCT IRs are based on 1 single US-county study 
completed in 1980, with an IR of 9 and 2 per million person-years in localized 
(including digits) and diffuse TGCT, respectively .4 Verschoor and coworkers 
(personal communication 2015) performed the initial nationwide registry based 
Figure 2  MRI of TGCT localized-type, extremity. 
Sagittal T1-weighted turbo spin echo MRI of a 47-year-old female patient, affecting her right knee. A well- 
circumscribed lesion in Hoffa’s fat pad is seen. Left panel: Proton density weighted MRI. Right panel: 
Pre-saturation inversion recovery MRI.
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study on giant cell containing tumors and calculated an overall IR for TGCT of 
50 per million per year. Discrimination between localized and diffuse disease 
was not possible as additional clinical information was lacking. The difference in 
biological behavior, however, demands further stratification of this general IR in 
the 3 different TGCT groups. Therefore, we aimed to estimate the worldwide 
(WHO standardized) TGCT IR by investigating clinical data of affected joints, 
sex differences, 10-year age-specific categories, initial treatments, follow-up, and 
recurrence rate at individual patient level through extensive additional data 
collection at participating hospitals.
Material and methods
Data collection was performed by collaboration of physicians from the TGCT study 
group, and in special collaboration with Radboud University Medical Center and 
Medical Spectrum Twente, data collection was performed. Data capturing and 
analyses were performed in the Leiden University Medical Center.
 A search in PALGA, the non-profit nationwide network and registry of histo- 
and cytopathology in The Netherlands, was performed (Casparie et al. 2007). 
To find all patients with TGCT, between January 2009 and January 2014, the search 
terms ‘Tenosynovial Giant Cell Tumor’, ‘Pigmented Villonodular Synovitis’ and a 
variety of synonyms were used, either as a code or as free text (Verschoor 2015, 
personal communication) (Appendix, see Supplementary data). Received pathology 
Figure 3  MRI of diffuse-type TGCT. 
A 23-year-old male patient with an extensive proliferative synovial process around both cruciate ligaments, 
dominating the anterior and posterior knee compartments, intra- and extra-articular. Inside suprapatellar 
pouch and Baker’s cyst a blooming villonodular aspect shows typical iron depositions. Left panel: Sagittal 
proton density weighted turbo spin echo MRI. Right panel: Sagittal T2-weighted fast field echo MRI.
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reports provided limited and anonymous information on sex, age, date of tissue 
removal, and conclusion of the pathology report. In these reports, definitive 
diagnosis was frequently provided, but information on (localized/diffuse) type 
and affected joint was only sparsely available. Therefore, further investigation 
of additional clinical and radiological data was necessary. Reports with TGCT 
affecting digits were solely used for calculating incidence rate (for TGCT digits) 
and not further investigated clinically. PALGA interlinked 1,941 pathology reports 
to 95 Dutch hospitals of origin. Departments of pathology received a request to 
collaborate in this nationwide study. After approval, personal hospital identifiers 
were obtained and the departments concerned (mostly orthopedics and general 
surgery) were invited to confirm TGCT diagnosis and add detailed information on 
TGCT  type, affected joint, sex, age at first histologically proven TGCT, primary 
treatment, total surgeries related to TGCT, date of last follow-up, and follow-up 
status. Clinical and radiographic data were derived from medical files. Data were 
kept anonymous. 75 of 95 attributed hospitals collaborated, including all specialized 
and academic centers.
 Clinical evaluation started with1,941 eligible TGCT cases. In 1,576 (81%) cases, 
diagnosis was confirmed. 253 reports were determined to be in digits and amended 
in digits group. For included extremity TGCT cases (n = 1,323), incomplete evaluated 
clinical data were imputed for unknown data on TGCT type (n = 393), affected joint 
(n = 101), sex (n = 52), age (n = 54), and treatment (n = 484), using multiple imputation 
techniques. 10 datasets were imputed, and results were pooled according to standard 
Rubin’s rules83. All imputed data were checked for errors.
 Finally, 1,323 patients with histologically proven TGCT were included (figure 4). 
 In addition to the 2,562 patients with TGCT affecting digits that were already 
identified based on the pathology reports, 253 additional patients with TGCT 
affecting digits were discovered during clinical data evaluation. 2,815 patients 
with TGCT affecting digits were identified (2,649 fingers, 119 toes, 47 finger or toe), 
but not investigated in detail.
 Reoperation rate due to local recurrence was defined as surgery for recurrent 
TGCT, based on additional pathology reports in the same patient, at least 6 months 
after initial surgery until January 2015 (date of PALGA search).
Statistics
The Statistical Package for Social Sciences statistics (SPSS®) version 23 (IBM Corp, 
Armonk, NY, USA) was used for analyses. The IR was separately estimated for 
localized TGCT, either digits or extremity, and diffuse-type TGCT per year, by 
using the number of histologically proven cases of TGCT as numerator and the 
sum of individual person-years for The Netherlands as the denominator. IRs were 
reported for the overall study period, by calendar year, and stratified on type, 
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affected joints, sex, and 10-year age categories (age at TGCT diagnosis). The Central 
Bureau of Statistics (CBS) provided information on Dutch population during the 
examined period. Overall worldwide IRs were obtained by standardizing Dutch 
IRs to global IRs by using the direct method, applying age-specific IRs in each 
10-year age group to the world WHO standard population (http://seer.cancer.gov). 
Estimates of IRs were reported with 95% confidence intervals (CI). Patient demographics 
were reported as counts and percentages for categorical variables and as medians 
and interquartile ranges (IQR) for continuous variables.
The Kaplan–Meier method was used to evaluate reoperation due to local- recurrence-
free survival at 2 and at 5 years.
Ethics, funding, and potential conflicts of interest 
Research was performed in accordance with the ethical standards in the 1964 
Declaration of Helsinki. As this study does not involve subject-related research, 
it is not covered by Dutch law on human subjects research. The study was approved 
by the Institutional Review Board (CME) from our institution (registration number 
G16.024, 22 April 2016). No funding or benefits were received by any of the authors. 
There is no conflict of interest involving any of the authors.
Figure 4   Inclusion flowchart. 
a Localized TGCT affecting extremities, excluding digits.
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Results
During a 5-year period, 2,815 (68%) digits, 933 (23%) localized-extremity and 390 
(9%) diffuse-type TGCT were identified. TGCT affected digits 3 and 7 times more 
often compared with localized-extremity and diffuse TGCT, respectively. Dutch 
TGCT IRs were 34 (CI 33–35) in TGCT affecting digits, 11 (CI 11–12) in localized- 
extremity TGCT and 5 (CI 4–5) in diffuse-type TGCT per million person-years. 
Median age for TGCT affecting digits was 49 (IQR 38–59) years, for localized- 
extremity TGCT 45 (IQR 34–56) years, and diffuse TGCT 47 (IQR 32–61) years. 
Male:female ratio was about 1:1.5 for any type.
Table   Incidence rates (IRs) of localized and diffuse-type TGCT in The Netherlands. 
Person-years Localized TGCT:  
digits
Localized TGCT: 
extremity
Diffuse TGCT 
New a  
cases
IR b New a  
cases
IR b New a  
cases
IR b
Overall 83,226,498 2,815 34 (33–35) 933 11 (11–12) 390 5 (4–5)
Calendar year
2009 16,485,787 578 35 (32–38) 192 12 (10–13) 73 4 (4–6)
2010 16,574,989 561 34 (31–37) 183 11 (10–13) 82 5 (4–6)
2011 16,655,799 580 35 (32–38) 176 11 (9–12) 78 5 (4–6)
2012 16,730,348 563 34 (31–37) 188 11 (10–13) 77 5 (4–6)
2013 16,779,575 533 32 (29–35) 194 12 (10–13) 80 5 (4–6)
Sex
Female 42,032,934 1,698 (60) 40 (39–42) 544 (58) 13 (12–14) 236 (61) 6 (5–6)
Male 41,193,564 1,117 (40) 27 (26–29) 389 (42) 9 (9–10) 154 (39) 4 (3–4)
Age at diagnosis
0–9 9,528,271 13 (0) 1 (1–2) 6 (1) 1 (0–1) 2 (0) 0 (0–1)
10–19 10,012,994 98 (3) 10 (8–12) 57 (6) 6 (4–7) 26 (7) 3 (2–4)
20–29 10,178,289 259 (9) 25 (23–29) 108 (11) 11 (9–13) 49 (13) 5 (4–6)
30–39 10,673,194 411 (15) 39 (35–42) 169 (18) 16 (14–18) 62 (16) 6 (5–7)
40–49 12,894,743 650 (23) 50 (47–54) 211 (23) 16 (14–19) 70 (18) 5 (4–7)
50–59 11,456,662 704 (25) 62 (57–66) 193 (21) 17 (15–19) 71 (18) 6 (5–8)
60–69 9,466,681 503 (18) 53 (49–58) 133 (14) 14 (12–17) 58 (15) 6 (5–8)
70–79 5,680,080 155 (6) 27 (23–32) 41 (4) 7 (5–10) 37 (9) 7 (5–9)
80–89 2,860,556 22 (1) 8 (5–12) 15 (2) 5 (3–9) 15 (4) 5 (3–9)
Overall, by calendar year 2009–2013, sex and age categories. 
a New cases: number of cases, %.
b IR = incidence rate per million person-years (95% CI).
524982-L-bw-Verspoor
Processed on: 3-10-2018 PDF page: 35
35
2
HIGHER INCIDENCE RATES THAN PREVIOUSLY KNOWN
The Table shows IRs per million person-years for calendar years 2009 up to and 
including 2013, sex, and 10-year age-specific categories of the 3 different TGCT 
groups. In these 3 groups: IRs over disaggregated years were quite similar, female 
IRs were slightly higher compared with male IRs, and the majority of new cases 
were seen in age categories 40–49 and 50–59 years.
 In 2015, The Netherlands counted 16,900,726 inhabitants. According to calculated 
IR, 571 new TGCT affecting digits, 189 new localized-extremity and 79 new diffuse 
TGCT patients were diagnosed in 2015. The estimated standardized worldwide IRs 
were 29, 10, and 4 per million person-years for respectively localized-digits, localized- 
extremity and diffuse TGCT.
 As TGCT affecting digits were not clinically investigated, the following results 
were based on localized-extremity and diffuse-type TGCT. The majority of TGCT 
cases affected the knee joint; 46% and 64% in localized and diffuse TGCT, 
respectively (Figure 5), followed by the hand and wrist joint in localized-type and 
Figure 5  Skeleton, showing affected TGCT localization (fingers and toes excluded). 
3% in localized type and 1% in diffuse type is classified as “other”.
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the ankle and hip joint in diffuse-type TGCT. Sex distribution per affected joint 
was comparable. The initial TGCT treatment plan was open resection in 65% and 
49% in localized and diffuse lesions, respectively (Figure 6). TGCT was reported as 
an incidental finding during endoprosthetic replacement in 60 procedures.
According to the clinical charts, the majority of patients were lost to follow-up in 
both types (71% in localized and 55% in diffuse TGCT). Therefore, we decided to base 
recurrence rates on additional surgeries (defined by a second pathology report 
documenting recurrence of TGCT in PALGA). By evaluating the municipal personal 
records database (Gemeentelijke Basis Administratie (GBA)) for all patients, 8 patients 
(7 localized and 1 diffuse TGCT) were deceased at time of evaluation and were 
censored at time of death when no second surgery was performed.
 Reoperation rate due to local recurrence, calculated as a percentage from all 
TGCT patients, in localized TGCT was 9% and in diffuse TGCT 23%. Reoperation- 
free survival curves for localized and diffuse TGCT are shown in Figure 7. In the 
localized- extremity type, reoperation-free survival at 2 and at 5 years was 90% and 
83%, respectively. In the diffuse type, reoperation-free survival at 2 and at 5 years 
was 77% and 49%, respectively. 
 Only a minority (12%) of TGCT patients were primarily treated in a tertiary 
oncology center: 9% of localized type (excluding digits) and 18% of diffuse type.
Figure 6  Initial treatment for TGCT affecting extremities in The Netherlands, excluding 
digits.
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Discussion
Microscopically, localized-extremity and diffuse TGCT are identical.1 A distinction 
is made between localized-digits and localized-extremity TGCT, based on 
anatomical location and histological differences.74,75. TGCT lesions affecting digits 
are characterized as multiple, small (average 1 centimeter) nodules surrounded 
by a thin fibrous capsule, originating in synovial tissue of tendon sheaths or small 
joints of digits, with a small number of cleft-like spaces and thick bundles of 
collagenous tissue, rarely showing inflammatory cells. Conversely, localized- 
extremity TGCT are typically single, relatively large (average 2 centimeters) lesions 
covered by 1 or more layers of synovial cells, intra-articular, showing large or 
numerous pseudo-glandular spaces sometimes filled with foam cells and showing 
more inflammatory cells than digits.74
 Because of the rarity of the disease, the current TGCT literature contains 
predominantly retrospective, relatively small cohort studies, including hetero -
Figure 7  Reoperation due to local recurrence-free survival curve in localized- extremity 
and diffuse TGCT (Kaplan-Meier), excluding digits. 
Time zero is time of primary surgery. 8 patients died and were censored at time of death if a recurrence 
had not occurred.
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geneous data.75 Two previous studies described TGCT incidence: Myers and Masi 
(1980)4 reported 117 new cases of localized (including digits) and 49 new cases of 
diffuse-type TGCT between 1960 and 1976, resulting in an IR of 9 per million 
person-years for localized and 2 per million person-years for diffuse-type TGCT. 
A single hospital study was performed by Monaghan et al. (2001)84 and showed an 
IR of 20 new cases per million per year between 1990 and 1997 for localized-type 
TGCT (including digits). Compared with the initial US-county study4, our study 
showed a 5-fold higher IR in localized TGCT (combining localized-digits and 
localized- extremity), and a more than 2.6-fold higher IR in diffuse-type TGCT. This 
difference could be attributed to our nationwide coverage, our registry-based 
clinically verified character and because of increased knowledge about the disease.
 Localized and diffuse lesions are distinguished clinically and on MRI. To investigate 
these lesions separately, clinical and radiological confirmation is of utmost importance. 
Treatment in localized TGCT affecting digits or extremity is mostly 1 single excision. 
In contrast, multiple mutilating surgeries are often required for diffuse-type TGCT, 
with a continuous risk of recurrences. In an effort to find all TGCT patients, our 
search included specific pathology codes for TGCT and both TGCT and synonyms 
of TGCT as free text (appendix). Therefore, cases with “synovitis” or differential 
diagnostic TGCT were also represented in our search. In addition, PALGA data are 
based on input of physicians and sometimes lack specificity. For instance, affected 
joint: “upper extremity”, “hand”, or “wrist” could all turn out, after clinical 
evaluation, to be affected digits.
 In our search, 1,941 patients were clinically evaluated and 1,323 ascertained 
histologically proven TGCT extremity cases were included. Consequently, only 
68% of eligible TGCT patients had histologically proven TGCT of the large joints. 
Without clinical TGCT confirmation, the estimated IR would have been much 
higher.
 Despite our large number of patients with lack of follow-up, reoperation rates 
due to local recurrence were described, based on additional surgeries, defined by a 
second pathology report documenting recurrence of TGCT in PALGA (up to January 
2015, the date when the PALGA search was performed). Recurrences without treatment 
(no additional pathology report) were not included, therefore reoperation rate due 
to recurrence is not identical to recurrence rate. However, compared with the 
literature, we found comparable average recurrence rates for localized-extremity 
TGCT (9%) and for diffuse-type TGCT (23%).37 As local recurrence might develop 
years after initial surgery42, and PALGA provided pathology reports with a maximum 
time of 7 years after initial surgery, underestimation of the true recurrence-free 
survival is likely.
 There are some limitations to this study. Determined IR may be exposed to 
under- or overestimation. Primarily, our calculated IR could be slightly under-
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estimated, because our study is based on a search in PALGA, the nationwide 
network and registry of histo- and cytopathology in The Netherlands.85 TGCT 
patients without a biopsy or treatment are not represented in this pathology-based 
cohort. Second, our IR in localized-extremity and diffuse-type TGCT could be 
marginally over- or underestimated, because 21% of eligible TGCT patients were 
not clinically evaluated and were therefore imputed. Analyses with and without 
imputed data were comparable. PALGA identified 1,941 eligible TGCT patients, 
scattered over 95 Dutch hospitals. Regarding different hospital boards, the 
different departments concerned (pathology, orthopedics, general surgery), and 
different local legislation, it was challenging to evaluate all eligible TGCT patients.
 Third, a clinical distinction between localized-extremity and diffuse-type 
TGCT is difficult, especially for clinicians not familiar with this rare disease.86
 Subsequently, an overestimation of IR in localized-digits TGCT might be 
present. IR of digits is based solely on PALGA registry numbers, in contrast to 
localized- extremity and diffuse TGCT IRs, which were clinically evaluated.
 Global IR were estimated by using a direct standardization approach (http://
seer.cancer.gov). Even though this is a widely accepted method, there is no 
adjustment for other influences in global structure or possible risk factors in TGCT.
 To calculate prevalence rates, follow-up time and status are important. The 
majority of our investigated patients lacked clinical chart follow-up. It seemed 
unfair to estimate TGCT prevalence rates as the proportion of TGCT patients alive 
at the end of 2013 and diagnosed with TGCT: this assumes TGCT not to resolve and 
not to be cured.
 In The Netherlands, traditionally, larger orthopedic clinics have been treating 
TGCT or have diagnosed TGCT as an incidental finding during arthroscopy or 
endoprosthetic replacement. When (severe) complaints occur, patients are commonly 
referred to specialized tertiary sarcoma centers. In this study, we investigated 
primary patients to calculate incidence rate. No centralization of care of TGCT in 
these primary patients is shown, with only a minority of 12% primarily treated in 
a tertiary oncology center. Remarkably, only 18% of diffuse TGCT was primarily 
treated in tertiary oncology centers.
 In summary, this study is the first nationwide study and the first to offer 
detailed analyses of IRs in TGCT. IRs for TGCT of digits, localized-extremity and 
diffuse-type were calculated using additional hospital record evaluation of patients 
originally selected from a nationwide pathology registry. The worldwide estimated 
incidence rate in digits, localized-extremity, and diffuse TGCT is 29, 10, and 4 per 
million person-years, respectively. Despite high clinical variability in localized- 
extremity and diffuse lesions, both types show a predilection for the knee joint, 
a slight predisposition in female patients, median age around 47 years at first 
treatment, and are primarily treated with an open resection. The recurrence rate 
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in the diffuse type is 2.6 times higher compared with the localized-extremity type. 
TGCT is still considered a rare disease, though is more common than previously 
understood.
Supplementary data
An appendix is available as supplementary data in the online version of this 
article, http://dx.doi.org/ 10.1080/ 17453674. 2017.1361126
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Abstract
Tenosynovial giant cell tumor (TGCT) is a rare, benign, mono-articular entity. 
Many case series in adults are described, whereas TGCT is only incidentally reported 
in children. Therefore, its incidence rate and natural history in children are 
unknown.
Questions/ purposes
(1)  How many cases have been reported of this condition, and what were their 
 characteristics?
(2)  What is the standardized pediatric incidence rate for TGCT? 
(3)  Is there a clinical difference in TGCT between children and adults? 
(4)  What is the risk of recurrence after open resection in children compared with 
adults?
Data were derived from three sources:
(1)  a systematic review on TGCT in children, seeking sources published between 
1990 and 2016, included 17 heterogeneous, small case-series;
(2)  the nationwide TGCT incidence study: the Dutch pediatric incidence rate 
was extracted from this nationwide study by including patients younger than 
18 years of age. This registry-based study, in which eligible patients with TGCT 
were clinically verified, calculated Dutch incidence rates for localized and 
diffuse-type TGCT in a 5-year timeframe. Standardized pediatric incidence rates 
were obtained by using the direct method;
(3)  from our nationwide bone and soft tissue tumor data registry, a clinical data 
set was derived. Fifty-seven children with histologically proven TGCT of large 
joints, diagnosed and treated between 1995 and 2015, in all four tertiary sarcoma 
centers in The Netherlands, were included. These clinically collected data were 
compared with a retrospective database of 423 adults with TGCT. Chi-square test 
and independent t-test were used to compare children and adults for TGCT type, 
sex, localization, symptoms before diagnosis, first treatment, recurrent disease, 
follow-up status, duration of symptoms, and time to follow-up. The Kaplan- 
Meier method was used to evaluate recurrence-free survival at 2.5 years.
TGCT is seldom reported because only 76 pediatric patients (39 female), 29 localized, 
38 diffuse, and nine unknown type, were identified from our systematic review. 
The standardized pediatric TGCT incidence rate of large joints was 2.42 and 1.09 
per million person-years in localized and diffuse types, respectively. From our 
clinical data set, symptoms both in children and adults were swelling, pain, and 
limited ROM with a median time before diagnosis of 12 months (range, 1-72 months). 
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With the numbers available, we did not observe differences in presentation between 
children and adults in terms of sex, symptoms before diagnosis, first treatment, 
recurrent disease, follow-up status, or median time to follow-up. The 2.5-year  recurrence- 
free TGCT survival rate after open resection was not different with the numbers 
available between children and adults: 85% (95% confidence interval [CI], 67%-100%) 
versus 89% (95% CI, 83%-96%) in localized, respectively (p = 0.527) and 53% (95% CI, 
35%-79%) versus 56% (95% CI, 49%-64%) in diffuse type, respectively (p = 0.691).
 Although the incidence of pediatric TGCT is low, it should be considered in 
the differential diagnosis in children with chronic mono-articular joint effusions. 
Recurrent disease after surgical treatment of this orphan disease seems comparable 
between children and adults. With targeted therapies being developed, future 
research should define the most effective treatment strategies for this hetero -
geneous disease.
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Introduction
Tenosynovial giant cell tumor (TGCT) is a benign, mono-articular entity. Two 
histologically identical but clinically different types are distinguished: localized 
and diffuse lesions.1 This distinction can be made either on MRI or at the time of 
surgery. The localized type is deﬁned by the World Health Organization (WHO) 
Classiﬁcation of Tumors of Soft Tissue and Bone of 201387 as a well-circumscribed 
benign small lesion (ﬁgure. 1). By contrast, the diffuse type, previously named 
pigmented villonodular synovitis (PVNS), shows unclear boundaries with extensive 
involvement of the entire synovial membrane and inﬁltrative growth through 
adjacent structures (ﬁgure. 2).1 The knee is the most common large joint affected 
by TGCT with 46% of localized and 64% of diffuse-type TGCTs affecting that joint; 
the hand and wrist are the next most common joints affected by the localized 
form, and the ankle and hip are the next most common joints affected by diffuse 
TGCT.18 Delayed diagnosis is not uncommon as a result of different nonspeciﬁc 
clinical signs and symptoms,37,88 and the deﬁnitive diagnosis must be made 
histologically. The standard treatment remains surgical resection, but recurrence 
occurs in 4% to 6% patients with localized and 14% to 40% diffuse TGCT affecting 
the knee37. Histologic or radiologic risk factors for recurrent disease are unknown.
 All described case-series on TGCT concern adults, whereas TGCT is only 
incidentally reported in children. Owing to the rarity of the disease, the available 
Figure 1A-B  Localized type TGCT. 
MRI of a 6-year-old boy with TGCT in his left knee. (A) Sagittal T1-weighted image showing a well-circum-
scribed nodular lesion at the synovial lining of the anterior knee compartment. (B) Sagittal T1-weighted 
spectral presaturation with inversion recovery (SPIR) image after IV gadolinium administration shows 
hetero -geneous enhancement.
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evidence base on TGCT contains predominantly retrospective, relatively small 
cohort studies, including heterogeneous data.75 Sufficient data on pediatric patients 
with TGCT are lacking.
 We therefore combined a systematic review with analysis from a nationwide 
pediatric TGCT incidence study in The Netherlands18 and clinical data on TGCT in 
children and adults from four tertiary sarcoma centers in The Netherlands to 
answer the following questions: (1) How many cases have been reported of this 
condition, and what were their characteristics? (2) What is the standardized 
pediatric incidence rate for TGCT? (3) Is there a clinical difference in TGCT between 
children and adults? (4) What is the risk of recurrence after open resection in 
children compared with adults?
Patients and Methods
Children were defined as patients younger than 18 years at presentation. Large 
joints were defined as all joints proximal to the metatarsophalangeal and meta-
carpophalangeal joints.
 Data were derived from three sources: a systematic review, the nationwide 
TGCT incidence study, and from our bone and soft tissue tumor data registry.
A systematic review on TGCT in children was performed, seeking sources published 
Figure 2A-B  Diffuse type TGCT. 
MRI of a 16-year-old boy with TGCT in his left knee. (A) Sagittal T1-weighted turbo spin echo (TSE) image 
shows extensive intra- and extra-articular villous proliferation of synovium. Posterior is a large Baker’s cyst. 
(B) Transversal T2-weighted TSE image with heterogeneous low to intermediate signal of the TGCT 
anterior and posterior (straight arrow). Baker’s cyst is shown posteriorly (curved arrow).
524982-L-bw-Verspoor
Processed on: 3-10-2018 PDF page: 48
48
CHAPTER 3
Table 1   Literature overview on TGCT affecting all joints in children, including at least  
two TGCT cases (1990-2016, English language)*
Study Year Number Sex Mean age 
(years; range)
Symptoms 
before 
diagnosis
Mean duration 
of symptoms 
(months; range)
TGCT type Joint Primary  
surgeries
Recurrent  
disease
Mean follow-up  
(months; range)
Givon et al.90 1991 2 1 M, 1 F 7 (7-7) S, W, LROM 60 (both patients) 1 L, 1 D 2 knee 1 AS, 1 US 0 24 (12-36)
Rosenberg et al.†91 2001 2 2 M 12 (10-14) S NA 1 L, 1 D 2 knee 1 OS, 1 US NA NA
Neubauer et al.|| 92 2007 5 3 M, 2 F 12 (8-15) S,P 10 (2-24) 5 unknown 4 knee, 1 ankle 5 AS 1 36 (12-84)
Gholve et al.|| 89 2007 11 6 M, 5 F 12 (7-16) S, P 10 (1-24) 11 L 2 knee, 3 ankle, 4 foot, 
1 hand, 1 wrist
11 OS 0 54 (15-130)
Pannier et al.† 93 2008 6 2 M, 4 F 12‡ NA NA 2 L, 4 D 5 knee, 1 ankle 5 US, 1 MT 2 58‡
Baroni et al.88 2010 9 4 M, 5 F 11 (7-15)¶ S, P, LROM 18 (2-48) 4 L, 5 D 9 knee 4 AS, 5 OS 0 82 (46-143)
Current 2017 57 24 M, 33 F 14 (4-18) S, P, LROM 16 (1-72) 28 L, 29 D 32 knee, 11 ankle,  
5 foot, 4 hip, 2 hand,  
2 other, 1 wrist 
9 AS, 47 OS,  
1 WS
23 55 (0-260)
Also adult cases included
Abdul-Karim et al.94 1992 2 2 M 10 (10-10) S, P NA 2 D 1 foot, 1 ankle 1 US, 1 AP 0 132 (108-156)
de Visser et al.19 1999 5 4 M, 1 F 16 (12-18) NA NA 5 D 4 knee, 1 ankle 4 US, 1 RS 5 residual disease 30 (21-75)
Perka et al.95 2000 2 2 F 12 (8-16) S, P, LROM 12‡ 2 L 2 knee 2 US 0 NA
Somerhausen and Fletcher96 2000 4 3 M, 1 F 14 (3-18) S 7 (6-8) 4 D 1 knee, 1 foot,  
1 buttock, 1 thigh
4 US 0/1 NA 44.5 (0-114)
Gibbons et al.97 2002 3 1 M, 2 F 11 (8-15) S 28 (6-96)§ 3 L 3 foot 3 US 0 NA
Bisbinas et al.98 2004 5 5 F 14 (12-15) S 2‡ 5 L 5 ankle 5 OS 0 46 (12-150)
Brien et al.99 2004 3 1 M, 2 F 13 (12-15) S, P 7 (1-24)§ 3 D 2 foot, 1 ankle 3 US 2 NA
Sharma et al.100 2006 4 2 M, 2 F 14 (8-17) S, P 2‡ 4 unknown 4 ankle 4 US 0 37.5 (19-65)
Sharma et al.101 2007 3 2 M, 1 F 17 (16-18) S, P 5 (2-9) 3 D 3 knee 3 OS 1 96 (54-138)
Nakahara et al.102 2012 3 2 M, 1 F 11 (8-13) NA NA 3 D 3 knee 3 OS 0 29 (20-36)
van der Heijden et al.20 2014 7 2 M, 5 F 14 (6-18) NA NA 7 D 7 knee 4 AS, 3 OS 4 95 (24-212)
Total 133 57 L, 67 D, 9 
unknown
*  Large joints were defined as all joints proximal to and excluding metatarsophalangeal and metacarpo-
phalangeal joints; large case-series not describing children in detail were not included.
† Language of article was French; included information is based on an English abstract.
‡ Range unavailable.
§ Including adult cases.
|| TGCT cases in digits were excluded.
{ Case number 6, a 2-year-old girl, was excluded according to a delayed time to diagnosis of 38 months.
TGCT = tenosynovial giant cell tumor; M = male; F = female; NA = information not available; S = swelling; 
W = warmth; LROM = limited ROM; P = pain; L = localized TGCT; D = diffuse TGCT; AS = arthroscopic 
synovectomy; OS = open synovectomy; US = unspecified synovectomy; MT = medical treatment; 
WS = wait-and-see treatment; AP = belowknee amputation; RS = radiosynovectomy.
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Table 1   Literature overview on TGCT affecting all joints in children, including at least  
two TGCT cases (1990-2016, English language)*
Study Year Number Sex Mean age 
(years; range)
Symptoms 
before 
diagnosis
Mean duration 
of symptoms 
(months; range)
TGCT type Joint Primary  
surgeries
Recurrent  
disease
Mean follow-up  
(months; range)
Givon et al.90 1991 2 1 M, 1 F 7 (7-7) S, W, LROM 60 (both patients) 1 L, 1 D 2 knee 1 AS, 1 US 0 24 (12-36)
Rosenberg et al.†91 2001 2 2 M 12 (10-14) S NA 1 L, 1 D 2 knee 1 OS, 1 US NA NA
Neubauer et al.|| 92 2007 5 3 M, 2 F 12 (8-15) S,P 10 (2-24) 5 unknown 4 knee, 1 ankle 5 AS 1 36 (12-84)
Gholve et al.|| 89 2007 11 6 M, 5 F 12 (7-16) S, P 10 (1-24) 11 L 2 knee, 3 ankle, 4 foot, 
1 hand, 1 wrist
11 OS 0 54 (15-130)
Pannier et al.† 93 2008 6 2 M, 4 F 12‡ NA NA 2 L, 4 D 5 knee, 1 ankle 5 US, 1 MT 2 58‡
Baroni et al.88 2010 9 4 M, 5 F 11 (7-15)¶ S, P, LROM 18 (2-48) 4 L, 5 D 9 knee 4 AS, 5 OS 0 82 (46-143)
Current 2017 57 24 M, 33 F 14 (4-18) S, P, LROM 16 (1-72) 28 L, 29 D 32 knee, 11 ankle,  
5 foot, 4 hip, 2 hand,  
2 other, 1 wrist 
9 AS, 47 OS,  
1 WS
23 55 (0-260)
Also adult cases included
Abdul-Karim et al.94 1992 2 2 M 10 (10-10) S, P NA 2 D 1 foot, 1 ankle 1 US, 1 AP 0 132 (108-156)
de Visser et al.19 1999 5 4 M, 1 F 16 (12-18) NA NA 5 D 4 knee, 1 ankle 4 US, 1 RS 5 residual disease 30 (21-75)
Perka et al.95 2000 2 2 F 12 (8-16) S, P, LROM 12‡ 2 L 2 knee 2 US 0 NA
Somerhausen and Fletcher96 2000 4 3 M, 1 F 14 (3-18) S 7 (6-8) 4 D 1 knee, 1 foot,  
1 buttock, 1 thigh
4 US 0/1 NA 44.5 (0-114)
Gibbons et al.97 2002 3 1 M, 2 F 11 (8-15) S 28 (6-96)§ 3 L 3 foot 3 US 0 NA
Bisbinas et al.98 2004 5 5 F 14 (12-15) S 2‡ 5 L 5 ankle 5 OS 0 46 (12-150)
Brien et al.99 2004 3 1 M, 2 F 13 (12-15) S, P 7 (1-24)§ 3 D 2 foot, 1 ankle 3 US 2 NA
Sharma et al.100 2006 4 2 M, 2 F 14 (8-17) S, P 2‡ 4 unknown 4 ankle 4 US 0 37.5 (19-65)
Sharma et al.101 2007 3 2 M, 1 F 17 (16-18) S, P 5 (2-9) 3 D 3 knee 3 OS 1 96 (54-138)
Nakahara et al.102 2012 3 2 M, 1 F 11 (8-13) NA NA 3 D 3 knee 3 OS 0 29 (20-36)
van der Heijden et al.20 2014 7 2 M, 5 F 14 (6-18) NA NA 7 D 7 knee 4 AS, 3 OS 4 95 (24-212)
Total 133 57 L, 67 D, 9 
unknown
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between 1990 and 2016. Search terms and MeSH headings were “tenosynovial 
giant cell”, “diffuse type giant cell”, “giant cell tumors”, “PVNS”, “pigmented 
villonodular synovitis”, and “synovitis, pigmented villonodular” combined with 
“infant”, “child”, “neonat”, “pediatric”, “paediatric”, “toddler”, “teen”, “teenager”, 
“juvenile”, “adolescent”, “girl”, and “boy”. A total of 619 articles were identified in 
PubMed, EMBASE, and Cochrane library. All titles and abstracts were screened by 
two independent reviewers (MJLM, DU) including case series with at least two 
TGCT pediatric patients and published in English. Case series without detailed 
data on children were excluded, resulting in a data set of 17 heterogeneous, 
mostly small case series of two to six patients (Table 1). The largest study included 
11 patients with localized TGCT of large joints89. 
 The Dutch pediatric incidence rate was extracted from the nationwide TGCT 
incidence study by including patients < 18 years of age.18 Standardized incidence 
rates were obtained by using the direct method, applying age-specific incidence 
rates in each 1-year age group to the WHO standard population (http://seer.cancer.
gov). This study by Mastboom et al.18 was a registry-based study and eligible 
patients with TGCT were clinically verified.
 Patients without histologically proven TGCT were not included.
 From our national bone and soft tissue tumor data registry (PALGA), a clinical 
data set was derived, including 57 patients < 18 years with (histologically proven) 
TGCT in large joints, treated between 1995 and 2015, in one of the four tertiary 
sarcoma centers in The Netherlands. Clinical, biologic, and imaging data on TGCT 
type, sex, localization, age at diagnosis, symptoms before diagnosis, treatment(s), 
recurrence(s), and follow-up were collected.
 A combined retrospective database of two tertiary oncology centers (Leiden 
University Medical Center and Radboud University Medical Center) in The Netherlands 
has recorded all patients with TGCT since 1990 (455 patients). TGCT data on children 
were compared with TGCT data on 423 adults (32 children within this database 
were excluded from the adult group).
 Statistical analyses, for our clinical data set, were pre-dominantly descriptive. 
Chi-square test was used to compare children and adults on TGCT type, sex (male 
versus female), localization (knee versus other large joints [hip, ankle, and foot]), 
symptoms before diagnosis (pain, swelling, and loss of function: yes versus no), 
first treatment (arthroscopic resection versus open resection), recurrent disease 
(no recurrence versus recurrence), and follow-up status. Independent t-test was 
used to compare median duration of symptoms and median time to follow-up. 
All reported p values were two-tailed. Statistical significance level was defined at 
p < 0.05. The recurrence-free survival curve was assessed with Kaplan-Meier methods.
 This study was approved by the institutional review board from the Leiden 
University Medical Center (medical ethical approved protocol P13.029). Data capturing 
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and analyses were performed at Leiden University Medical Center. SPSS Version 23 
(Chicago, IL, USA) was used for analyses.
Results
Our systematic review identified 17 case series involving 76 children (39 female) 
with TGCT, 29 localized, 38 diffuse, and nine unknown type (table 1). The pediatric 
group ranged from 3 to 18 years of age. The knee was most frequently affected 
(44 [58%]). Swelling, pain, and limited ROM were described symptoms before 
diagnosis (mean duration, 15 months). The majority of patients were primarily 
treated with synovectomy, either arthroscopic or open. Recurrent disease was 
described in 10 patients (13%). Only five pediatric studies described function or 
quality of life after treatment. Patients with (multiple) recurrences experienced 
impaired function and quality of life, according to van der Heijden et al.20 Five 
children with diffuse TGCT, described by de Visser et al.19, had fair to excellent 
results on the Musculoskeletal Tumor Society (MSTS) score after surgical treatment 
(MSTS by Enneking). Gholve et al.89 described 11 children with surgically treated 
localized TGCT without disabling joint function according to a telephone 
questionnaire survey. Seven surgically treated children, described by Baroni et al.88, 
recovered full ROM and two patients showed impaired joint movement with 
occasional mild to moderate pain in four children with localized and five children 
with diffuse type. Nakahara et al.102 showed three children with diffuse disease of 
the knee with almost maximum Knee Society Scores and improved post-operative 
ROM of at least 0° to 145°.
 The standardized pediatric TGCT incidence rate of large joints was 2.42 and 
1.09 per million person-years in localized and diffuse types, respectively18. 
Between 2009 and 2013, 53 children with localized TGCT (excluding digits) and 
24 children with diffuse TGCT were diagnosed in The Netherlands. This resulted 
in a Dutch incidence rate of 2.86 per million person-years for localized TGCT 
(excluding  digits) and 1.30  per million person-years for diffuse TGCT; this was 
converted to standardized incidence rates (table, supplemental digital content 1). 
In both localized and diffuse types, the knee was most commonly affected (figure 3).
 Clinical data of TGCT in children from the four Dutch tertiary sarcoma 
centers seemed similar to those observed in the combined two Dutch retrospective 
adult databases (table 2). Fifty-seven children (median age at diagnosis, 16 years; 
range, 4-18 years) with TGCT of large joints were identified (table 2). Symptoms 
before diagnosis were swelling, pain, and limited ROM with a median duration of 
12 months (range, 1-72 months). These symptoms and the diagnostic delay seemed 
similar to those observed in adults (table 2). Children showed a localized diffuse 
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ratio of one to one; the knee was predominantly affected (13 of 28 [46%] localized, 
19 of 29 [66%] diffuse) and there was a predilection for females (15 of 28 [54%] 
localized, 18 of 29 [62%] diffuse). In 423 adults, the localized: diffuse ratio was 
1:1.6; the knee was predominantly affected (121 of 172 [70%] localized, 189 of 251 
[75%] diffuse) with a predilection for females (107 of 172 [62%] localized, 142 of 251 
[57%] diffuse).
 Recurrence-free survival curves were not different with the numbers available 
between children and adults at the four involved tumor centers (figure 4). The 2.5-year 
recurrence-free survival, after surgical treatment, in pediatric patients compared 
with adults was 85% (95% confidence interval [CI], 67%-100%) versus 89% (95% CI, 
83%-96%; p = 0.527) in localized and 53% (95% CI, 35%-79%) versus 56% (95% CI, 
49%-64%; p = 0.691) in diffuse type, respectively. In the four involved sarcoma 
centers, most children and adults alike were primarily surgically treated by open 
Figure 3  Skeleton showing TGCT localization in children extracted from a Dutch incidence 
study, excluding digits.103
In diffuse TGCT, one patient was classified as “other”; he was treated for TGCT in his vertebral column.
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resection: localized TGCT in 25 of 28 children (89%) were thus treated compared 
with 142 of 172 adults (85%; p = 0.486); for diffuse TGCT in children, the proportion 
was 22 of 29 (76%) compared with 188 of 251 in adults (75%; p = 0.289). Recurrence 
risk in children and adults was likewise not different with the numbers available: 
two of 28 (7%) compared with 22 of 172 (13%; p = 0.365) in localized type and 11 of 
29 (38%) compared with 119 of 251 (47%; p = 0.921) in diffuse type, respectively.
Figure 4  Local recurrence-free survival curve of localized and diffuse TGCT (Kaplan-Meier), 
excluding digits. 
Time zero is the time of the primary surgery. All patients were surgically treated; patients treated with 
wait-and-see treatment are excluded. In the adult graph, two patients died and were censored at the time 
of death if recurrence had not occurred.
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Discussion
TGCT is most commonly seen in adults in the third and fourth decades of life, but 
this study confirms that it also affects pediatric patients. The pediatric incidence 
rate for both localized and diffuse types suggests that it is rare, but we believe it is 
still common enough to include in the differential diagnosis of both children and 
adults with nonspecific symptoms like swelling, pain, and limited ROM. We found 
no differences with the numbers available between children and adults in terms 
of presenting symptoms, treatments used in the few available case series, and 
 recurrence-free survival rates. In the era of personalized medicine, future research 
should define the most effective treatment for TGCT, with its various clinical 
scenarios, both in children and adults.
 There are some limitations to this study. In our systematic review, many case 
series included data from children with TGCT in embedded studies that also 
contained adults’ data. When data on children were not separately described, these 
children were not included in the overview (Table 1). The determined incidence 
rate is a conservative estimate, because our search was based on the nationwide 
network and registry of histo- and cytopathology in The Netherlands.85 Patients 
with TGCT without a biopsy or treatment were not represented in this pathology- 
based cohort. By standardizing incidence rates, they could be extra -polated to 
other populations. However, generalizability of the standardized incidence rate 
depends on the age-specific population structure of the country compared with 
the WHO population. Included patients had histologically proven TGCT by a 
dedicated musculoskeletal pathologist (UF, HB, AS, JB). However, patients were not 
centrally reviewed for this study. Neither functional outcome nor quality of life 
was evaluated. For TGCT treatment, only surgical treatment was evaluated. Future, 
comparative studies on treatments should determine what should be done for 
patients (children and adults) with TGCT. Although surgery is the mainstay, other 
treatments are used, and future research needs to define what the best approaches 
are for the various clinical scenarios in which this disease presents. In our patients, 
children with the localized type frequently lacked longer term follow-up, mainly 
as a result of absence of clinical symptoms (17 censored in the first 2.5 years; figure 4). 
Smaller patient numbers with the diffuse type sometimes lacked longer follow-up 
(nine censored in the first 2.5 years).
 TGCT does not seem to be an adults-only disease and should be considered in 
the differential diagnosis in children with (chronic) mono-articular joint effusion. 
Our systematic review identified mainly small, heterogeneous TGCT case series in 
children. Future studies might consider including children with TGCT to allow for 
optimization of the treatment protocol in both children and adults.
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The standardized pediatric TGCT incidence rate of large joints was 2.42 and 1.09 
per million person-years compared with an overall incidence rate of 10.2 and 
4.1 per million person-years in localized and diffuse types, respectively.18 To date, 
the incidence rate for chronic mono-arthritis in children and adolescents is 
unknown. Savolainen et al.104 calculated an incidence rate of 64 per 100,000 for 
all types of arthritis in children (< 16 years) in a defined population in Finland. 
Although TGCT in children probably accounts for only a small percentage of all 
types of arthritis, it should still be considered in the differential diagnosis.
Symptoms in children seemed similar to those in adults (Table 1). Nonspecific 
symptoms accompanied by pain and diffuse joint swelling with thickening of the 
synovial capsule and/or joint effusion resulted in limited movement in approximately 
half of the patients. Studies in adults add mechanical symptoms, instability, and 
stiffness.37,105
 A systematic review (without age limitations) in 201337 reported average 
recurrence rates for localized TGCT in the knee after open resection (4%) and after 
arthroscopic resection (6%) in contrast to the diffuse type after open resection 
(14%) and after arthroscopic resection (40%) at a mean follow-up of 108 months. 
Patel et al.105 presented 214 patients with knee TGCT of all ages with a recurrence 
rate of 9% in 100 localized patients and 48% in 114 patients with diffuse TGCT after 
a mean follow-up of 25 months (range, 1-168 months). Palmerini et al.38 reported 
294 patients with TGCT of all ages in all joints with a local failure rate of 14% in 
localized and 36% in diffuse type after a median follow-up of 4.4 years (range, 1-20 
years). The sole primary disease or patients with a first relapse were included. 
The current pediatric case-series showed comparable recurrence rates of 7% in 
localized and 39% in diffuse type after a mean follow-up of 55 months (range, 
7- 350 months).
 TGCT is a rare condition in adults and it is even less common in children. 
Nonspecific symptoms often contribute to a delay in establishing a diagnosis. 
TGCT should be considered in chronic mono-arthritis both in adults and in 
children. Recurrent disease after surgical treatment of this orphan disease seems 
comparable between children and adults. With targeted therapies now being 
developed16, future research should define the most effective treatment strategies 
for this heterogeneous disease.
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Abstract
Current development of novel systemic agents requires identification and monitoring 
of extensive Tenosynovial Giant Cell Tumours (TGCT). This study defines TGCT 
extension on MR imaging to classify severity. 
 In part one, six MR parameters were defined by field-experts to assess disease 
extension on MR images: type of TGCT, articular involvement, cartilage-covered 
bone invasion, and involvement of muscular/tendinous tissue, ligaments or neuro - 
vascular structures. Inter- and intra-rater agreement were calculated using 118 
TGCT MR scans. In part two, the previously defined MR parameters were evaluated 
in 174 consecutive, not previously used, MR-scans. TGCT severity classification was 
established based on highest to lowest Hazard Ratios (HR) on first recurrence.
 In part one, all MR parameters showed good inter- and intra-rater agreement 
(Kappa≥0.66). In part two, cartilage-covered bone invasion and neurovascular 
involvement were rarely appreciated (<13%) and therefore excluded for additional 
analyses. Univariate analyses for recurrent disease yielded positive associations for 
type of TGCT HR12.84(95%CI4.60–35.81), articular involvement HR6.00(95%CI2.14–
16.80), muscular/tendinous tissue involvement HR3.50(95%CI1.75–7.01) and ligament -
involvement HR4.59(95%CI2.23–9.46). With these, a TGCT severity classification 
was constructed with four distinct severity-stages. Recurrence free survival at 
4 years (log rank p<0.0001) was 94% in mild localized (n56, 1 recurrence), 88% in 
severe localized (n31, 3 recurrences), 59% in moderate diffuse (n32, 12 recurrences) 
and 36% in severe diffuse (n55, 33 recurrences).
 The proposed TGCT severity classification informs physicians and patients on 
disease extent and risk for recurrence after surgical treatment. Definition of the 
most severe subgroup attributes to a universal identification of eligible patients 
for systemic therapy or trials for novel agents.
524982-L-bw-Verspoor
Processed on: 3-10-2018 PDF page: 63
63
4
TGCT SEVERITY CLASSIFICATION
Introduction
Tenosynovial Giant Cell Tumour (TGCT) affecting large joints is an orphan, mono-
articular, potentially locally aggressive disease with high recurrence rates. 
According to the 2013 WHO classification of tumours of soft tissue and bone, at the 
base of growth pattern, a radiological distinction is made between single nodule 
(localized-TGCT) and multiple lesions (diffuse-TGCT). These types differ in their 
clinical presentation, response to treatment and prognosis, but histologically, 
they seem identical.1,106
 Localized-type TGCT is classified as a circumscribed benign small (between 
0.5 and 4 cm) mass.1,18 Standard treatment of choice is excision. Subsequently, 
overall reported recurrence rates are relatively low: 0–6%.37 On the contrary, 
diffuse-type TGCT, previously named Pigmented Villonodular Synovitis (PVNS), 
extensively involves the synovial membrane and infiltrates adjacent structures.37,107 
Reported recurrence rates of diffuse-TGCT following open synovectomy are 14% 
up till 67% and after arthroscopic synovectomy 40% up till 92%.37 Recurrent or residual 
disease, frequently requiring multiple, sometimes mutilating operations, may result 
in total joint arthroplasties, morbidity and loss of quality of life.20,42,43,80,108  With 
this large variety in disease presentation and recurrence rates, a more omprehensive 
and out- come-based classification is asked for. The emerging era of systemic targeted 
and multimodality therapies (available in trial settings) increases the need for a method 
to select eligible patients in order to create com- parable patient cohorts.61,62,65
 In diagnosing and treating TGCT, magnetic resonance (MR) imaging is the 
most distinctive imaging technique.30-32,60,109 MR imaging reveals conspicuous 
nodular (localized-type) or villous proliferation of synovium (diffuse-type). 
However, current literature lacks specific MR discriminating features to describe or 
quantify tumour extent in relation to clinical outcome. Uniform MR descriptions 
are of utmost importance for clinical and research purposes. Therefore this study 
aims to sub-classify tumour severity especially in diffuse-type TGCT. First, a group 
of radiologists and orthopaedic surgeons identified and defined potentially 
distinguishing parameters. Second, these MR parameters were applied on a different 
study-population to establish TGCT severity subgroups.
Methods
Part I: Identification and evaluation of TGCT specific MR parameters.
Using case discussions in expert meetings with two dedicated musculoskeletal 
radiologists and three oncological orthopaedic surgeons, six MR parameters were 
selected in relation to anatomical or surgical landmarks. These parameters were 
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1 type of TGCT (based on 2013 WHO classification1), 2 articular involvement, 
3 cartilage-covered bone invasion, 4 involvement of muscular/tendinous tissue, 
5 involvement of ligaments and 6 involvement of neurovascular structures (figure 1, 
appendix).
Figure 1  Definition of six TGCT specific MR parameters 
TGCT-type
a.  Localized-type on a sagittal PD-weighted FSE MR image of a 49 year old female patient. Localized-TGCT 
is defined according to WHO as a well circumscribed nodular lesion at synovial lining of bursa, joint 
or tendon sheath.
b.  Diffuse-type on a sagittal PD-weighted FSE MR image of a 24 year old male patient. Diffuse-TGCT is defined 
as a multinodular lesion involving a larger part or multiple compartments of the synovial lining. 
Articular involvement
c.  Intra-articular well circumscribed lesion on posterior cruciate ligament on a PD-weighted FSE MR 
image of a 18 year old female patient. Intra-articular involvement is defined as TGCT involvement 
inside synovial lining of joint.
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To evaluate usability and reproducibility, 118 MR scans of TGCT patients, treated at 
the Leiden University Medical Center (LUMC), were randomly retrieved (MM). 
The six MR parameters were evaluated in a heterogeneous group of TGCT cases as 
scans included cases of various large joints (knee (79; 67%), ankle (13; 11%), foot 
(10; 9%)), severity subtypes and treatment phases. MR scans were conducted using 
a 1.5 or 3.0 T unit Philips (Best, The Netherlands) Ingenia MR with dedicated coils. 
Standard musculoskeletal scan-protocol included: T1-and T2-weighted fast spin 
echo, T1-weighted fat-suppressed post Gd-chelate contrast and optionally T2* gradient- 
echo sequences in two planes (transversal and either sagittal or coronal). To assess 
inter- and intra-rater agreement, all MR scans were evaluated by one dedicated 
musculoskeletal radiologist (DH) and by two dedicated orthopaedic surgeons (RW, 
MS). MR evaluation was blinded to patient characteristics.
 Inter-rater agreement and accompanying 95% confidence interval (95% CI) 
between three physicians was calculated for all 118 cases by Fleiss-Kappa (dichotomous 
outcomes in all parameters, except for articular involvement with three outcomes). 
To evaluate intra-rater agreement with the accompanying 95% CI (linear weighted 
kappa), 36 randomly chosen MR scans (31%) were again evaluated three months 
after initial evaluation by the senior orthopaedic surgeon (MS).
d.  Extra-articular involvement, along gastrocnemius muscle insertion, on a sagittal T1-weighted FSE MR 
image of a 33 year old male patient. Extra-articular involvement is defined as TGCT involvement 
outside synovial lining of the joint.
e.  Both intra- and extra-articular involvement on a sagittal T1-weighted fat-suppressed MR image after 
intravenous administration of gadolinium of a 63 year old female patient with TGCT. Extensive 
tumour growth anterior and posterior.
Cartilage-covered bone invasion
f.  Cartilage covered bone invasion on a sagittal T1-weighted FSE MR image of a 59 year old male patient. 
Square presents cartilage covered bone, defined as clear invasion of bone through cartilage; not only 
touch cartilage. Circle presents not-cartilage covered bone invasion.
Muscular/tendinous tissue involvement
g.  Muscular/tendinous tissue involvement, anterior vastus medialis muscle and posterior hamstrings 
tendon, on a sagittal T1-weighted fat-suppressed MR image after intravenous administration of gadolinium 
of a 63 year old female patient with TGCT. Muscular/tendinous tissue is defined as involvement of 
muscular/tendinous tissue or >180 degrees encagement of tendon/muscle.
Ligament involvement
h.  Cruciate ligament enhancement on a sagittal T1-weighted fat-suppressed MR image after intravenous 
administration of gadolinium of a 64 year old male patient. Ligament involvement is defined as 
involvement of ligament or >180 degrees encagement of ligament.
Neurovascular structures involvement
i.  Popliteal artery encagement on an axial PD-weighted FSE MR image of a 62 year old female patient, 
referred to a tertiary sarcoma center with extensive TGCT. Neurovascular involvement is defined as 
> 180 degrees encagement of the artery or nerve.
FSE, Fast Spin Echo; PD, Proton Density
Figure e & g is the same female patient.
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Part II: Application of TGCT MR parameters.
None of the MR scans in part I were used in part II. The combined TGCT-database 
of two sarcoma centres in The Netherlands (LUMC and Radboud University Medical 
Center (RUMC)) was used to include consecutive MR scans conducted between 
2005 and 2015 (n = 283). MR scan inclusion criteria were: pre-treatment MR scan of 
histologically proven TGCT of large joints, conducted in two planes (transversal 
and either sagittal or coronal), and open resection as primary treatment in one of 
the two participating centers. Large joints were defined as all joints proximal to 
and excluding metatarsophalangeal and metacarpophalangeal joints. When TGCT 
affected the knee, one diagnostic arthroscopy prior to open resection was allowed, 
since tumour extent would not be affected. Open synovectomy was defied as gross 
total resection of disease, either one- or two-staged, without adjuvant therapy. 
174/283 Patients met the inclusion criteria (figure 2). Median follow-up was 36 (IQR 
21–60) months, maximum follow-up 12 years after primary surgery.
The senior author (MS) evaluated the six defined MR parameters (part I) on these 
pre-treatment scans (77 LUMC, 97 RUMC). MR evaluation was blinded to patient 
characteristics and clinical outcome. Patient and tumour characteristics were 
gathered: gender, localization (affected joint), age at time of the MR scan, date of 
open synovectomy, first local recurrence and date of first recurrence (on MR 
imaging), and date of last follow-up. Median follow-up was calculated from date of 
primary surgery to date of last clinical follow-up, including interquartile range 
(IQR). Recurrence free survival was calculated from date of surgery to recurrent 
disease or last contact.
 As outcome, first recurrence was defined as new disease presence after syno - 
vectomy or growing residual disease (diagnosed on follow-up MR scan). Proposed 
risk factors were gender, localization (knee versus other joints) and age at the time 
Figure 2   Inclusion flowchart part II TGCT severity classification.
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of the MR scan (below or above 40 years). Hazard ratios (HRs) and their corresponding 
95% CI were estimated for risk factors and MR parameters (part I) by univariate 
and multivariate Cox regression analyses to estimate the relation on recurrent 
disease. Since estimating HR is unreliable for rarely present MR parameters, only 
parameters with an adequate number of presence (minimum of 20%) were used for 
additional analyses. Recurrence free survival close to median time of follow-up 
was calculated by Kaplan Meier analyses and log rank test. Time zero was defined 
as date of primary open synovectomy.
 At the base of HRs with positive associations of risk factors and MR parameters 
on first recurrences, the TGCT severity classification was established. The TGCT 
subgroup flow chart started with the MR parameter with highest HR, followed by 
descending HRs. Statistical Package for Social Statistics (SPSS) version 23 was used 
for analyses.
Ethical statement
This study was approved by the institutional review board from our institution 
(registration number P13.029). No funding was received.
Results
Part I: Evaluation of TGCT specific MR parameters.
Inter-rater agreements for type of TGCT, articular involvement, cartilage-covered 
bone invasion, and involvement of muscular/tendinous tissue, ligaments or neuro - 
vascular structures were 0.71; 0.68; 0.66; 0.67; 0.75 and 0.73, respectively. Intra-rater 
agreements for these parameters were between 0.72 and 1.00 (table 1). Since inter- 
and intra-rater agreements were good [5] for these six MR features, all parameters 
were considered viable to use for TGCT subgroup analyses.
Part II: Application of TGCT MR parameters.
Out of 174 MR scans, the knee was affected most (122; 70%), followed by the ankle 
(20; 12%) (table 2). In univariate analyses, none of the proposed risk factors were 
associated with recurrent disease (p > 0.37) (table 3) and consequently not used 
for further analyses. Both MR parameters cartilage-covered bone invasion and 
involvement of neurovascular structures were rarely seen on MR images (<13%) 
and in accordance with our exclusion criteria not used for additional analyses. 
In univariate analyses, the remaining four MR parameters were associated with 
recurrent disease (p < 0.002) (Table 3); strongest association was seen in diffuse-type 
compared with localized-type (HR 12.84(95%CI 4.60–35.81)), subsequently intra-and 
extra-articular involvement compared with extra-articular (HR 6.00 (95%CI  2.14–16.80)) 
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and involvement of muscular/tendinous tissue or ligaments compared with no 
involvement (HR 3.50 (95%CI 1.75–7.01), HR 4.59 (95%CI 2.23–9.46), respectively).
 Multivariate analyses for MR parameters did not show individual positive 
association, except for parameter type of TGCT (supplementary material I).
Four TGCT severity subtypes were established using a flowchart that begins with 
the parameters with highest HR (parameter type of TGCT), followed by parameters 
with descending HRs. These four sub-types showed a clinically relevant or 
significant prognostic value for recurrent disease and were classified as: mild 
localized (n56, 1 recurrence), severe localized (n31, 3 recurrences), moderate 
diffuse (n32, 12 recurrences) and severe diffuse (n55, 33 recurrences).
1.  Mild localized contained localized-type, either intra- or extra-articular 
involvement without involvement of muscular/tendinous tissue/ ligaments.
2.  Severe localized included localized-type, either intra- or extra-articular lesions 
and either or both involvement of muscular/tendinous tissue/ligaments.
3.  Moderate diffuse comprised diffuse-type with intra- and/or extra-articular 
disease without and involvement of muscular/tendinous tissue/ligaments.
4.  Severe diffuse was diffuse-type including intra- and extra-articular involvement 
and involvement of at least one of the three structures (muscular/tendinous 
tissue/ligaments) (figure 3).
Recurrence free survival at 4 years (close to median follow-up diffuse-type) for the 
four patient groups according to the new MR sub-types descended from 94% in 
mild localized, to 88% in severe localized, to 59% in moderate diffuse and to 36% 
Figure 3  TGCT severity classification. 
Four severity subtypes: mild localized, severe localized, moderate diffuse and severe diffuse. RFS 4y, 
recurrence free survival at 4 years.
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in the least favorable subtype, severe diffuse. Median time to local recurrence in 
moderate diffuse and severe diffuse subtypes was 29.5 (IQR 14.5–48.0) and 22.0 
(IQR 11.8–33.5) months, respectively. Majority of recurrent disease cases were 
already treated with a re-operation (32/49, 65%). One patient, classified as severe 
diffuse, died of another disease, after four months and was censored at that time. 
Novel MR based TGCT severity and associated Kaplan Meier survival curves presented 
significant difference between the four patient groups (log rank p< 0.0001) and 
additional differentiation compared with solely sub-classifying in localized- and 
diffuse-TGCT (figure 4 and supplementary material II).
Figure 4  TGCT recurrence free survival curve for four TGCT severity subtypes, affecting 
large joints. 
Time zero was date of primary open synovectomy. One patient, classified as severe diffuse died of another 
disease after 4 months and was censored at that time.
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Discussion
This is the first study to define severity subtypes in Tenosynovial Giant Cell 
Tumours (TGCT) based on a combination of four MR imaging parameters. These 
subtypes correlate with a spectrum of disease severity ranging from low to high 
risk of local recurrence after surgical intervention.
Within this present era of systemic targeted and multimodality therapies (available 
in trial settings) in TGCT, standalone surgical resection cannot be regarded the 
gold standard anymore for more severe cases.70 Because of the lack of clear-cut 
boundaries in diffuse-TGCT, complete resection is difficult and at times technically 
impossible or undesirable with joint function preservation and quality of life in 
mind. In patients with locally advanced TGCT or (multiple) recurrence(s), systemic 
therapies targeting the CSF1/CSF1R axis have been investigated; less potent drugs 
as nilotinib and imatinib,15,63 and more specific inhibitors as emactuzumab 
(RG7155), pexidartinib (PLX3397) and cabiralizumab (FPA008). Emactuzumab 
(N=29) had an overall response rate of 86% (two patients with a complete response) 
and a rate of disease control of 96%, including a significant functional and 
symptomatic improvement (median follow up 12 months).15 In a randomized, 
placebo- controlled phase 3 study, pexidartinib showed an improved overall 
response rate by RECIST: 39% in the pexidartinib-group (N=61) and 0% of 
placebo-group (N=59), after median six months follow-up.65 The preliminary 
results with cabiralizumab (N=22) are consistent, with radiographic response and 
improvement in pain and function in five out of 11 patients 28.62 However, long 
term efficacy data have not yet been reported with these newer agents.
 Patient inclusion for these trials is very heterogeneous. A strict patient 
selection is desirable, to accurately evaluate effect of these treatments. At present, 
patient selection for trial inclusion is established by preference of treating 
physician and might differ per center. Defining more aggressive TGCT subtypes 
and including these uniformly defined patients into trials would more adequately 
investigate the effect and toxicities of treatment.71 In this study, we propose to 
include patients defined with ‘severe diffuse’ TGCT subtype. Monitoring the effect 
of systemic therapy would also benefit from clear agreements on parameters.
 Uniform MR descriptions are of utmost importance for clinical and research 
purposes. Thus far, no well-defined tumour parameters exist. Definition of 
unambiguous MR criteria is challenging, because of the rarity of the tumour and 
small number of heterogeneous cases, variety of joints involved, different disease 
severity as well as several treatment modalities.1,75 So far, MR imaging has shown 
to be the best discriminating method to evaluate TGCT.30,110 In our study, six 
objective clinically relevant MR parameters were defined in relation to anatomical 
or surgical landmarks. According to our exclusion criteria for the development of 
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the severity classification, parameters cartilage covered bone invasion and 
neurovascular involvement showed inadequate number of presence and were 
therefore not used. However, in larger case series these two parameters might 
correlate with more aggressive disease and hence a higher recurrence rate.
 To date, no radiology-based TGCT severity classification exists. Subdividing 
between localized- and diffuse-TGCT seems an oversimplification that fails to 
estimate differences in recurrent rates for individual patients. Murphey et al. 
presented an extensive review of different TGCT features on several imaging 
techniques, without relating these features to disease severity, treatment or 
recurrences.30 Van der Heijden et al.20 further sub-classified diffuse-TGCT affecting 
the knee in 30 patients into mild or severe, without linking to recurrent disease. 
Mild diffuse-TGCT was defined as involvement of either anterior or posterior 
compartment of the knee, with the cruciate ligaments as boundary. Severe 
diffuse-TGCT was defined as involvement of both compartments, with or without 
extra-articular extension.20 In contrast to most literature, we selected a 
homogeneously treated patient population to develop four severity subtypes, by 
only including patients initially treated with an open synovectomy.
 In line with most papers, especially papers on trial medication, and based on 
clinical practice, we included all large joints to sub-classify disease severity for 
TGCT. Prior research did not show a (significant) difference in recurrence rates for 
both localized and diffuse disease when comparing the knee with other 
joints.37,38,75,111 A recent TGCT incidence calculation study showed a predominance 
of the knee in 46% in localized- and 64% in diffuse-type (excluding digits)18, in line 
with our overrepresentation of the knee of 70%. In the future, a TGCT severity 
classification focused on the knee would contain more detailed knee-specific MR 
parameters and equal treatment approaches.
 Limitations to this study: primary, the resulting HRs had wide confidence 
intervals, indicating low precision in the estimates. This is likely related to the 
relatively small sample size, given that the patients were divided into several 
groups based on the MR parameters. Secondly, because of the relatively small 
number of recurrences in severity subtypes mild localized (n 1) and severe localized 
(n 3), Hazard Ratios may be unreliable. Therefore, it was not feasible to estimate a 
cox model and to generate a true prediction model. Additionally, localized-TGCT is 
known to have few recurrences and often remains without clinical complaints 
after resection. In both sarcoma centers, patients are therefore discharged from 
follow-up after the first follow-up post-surgery and requested to return again when 
clinical complaints present. In our analyses, 31 localized-type patients were 
censored at date of last clinical follow-up within the first two years in survival 
curve (figure 4). Less often, patients with diffuse-type have also lacked follow-up 
(13 censored first two years). It could be assumed that these patients did not have 
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complaints and recurrent disease. Furthermore, in study part two (establishing 
TGCT subtypes), newest included MR scans originated from 2015. These cases had 
a maximum follow-up of two years. Since it is known that local recurrence might 
develop years after initial surgery1,38,42, in our study a median of 29.5 in moderate 
diffuse and 22.0 months in severe diffuse-TGCT subtypes, underestimation of 
recurrence free survival could be present. Finally, even though quite a large 
number of MR scans (174) were used in development of the severity classification, 
in larger case-series including long follow-up time, it might be possible to 
differentiate further in disease severity and assess additional subtypes.
 To conclude, in reporting TGCT affecting large joints on MR imaging, six 
parameters are helpful in discriminating disease extent. Patients can be accurately 
monitored by using these MR parameters. With respect to recurrence, a combination of 
four MR parameters classifies patients into one of four severity subtypes, presented 
with distinct recurrence free survival rates. In the era of personalized medicine, 
treatment is individualized for each patient depending on the extent of disease. 
Because histopathological prognostic factors are lacking, sub-classification of 
TGCT on MR imaging is a potential tool to stratify future patient prognosis and 
identify candidates for targeted therapies, thereby aiding with the decision in 
daily practice.
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Table 2  TGCT MR scan demographics.
Cases (%) Cases  
localized-TGCT 
(%)
Cases  
diffuse-TGCT  
(%)
Total number of MR scans 174 87 87
Gender
     Female 105 (60) 33 (38) 36 (41)
     Male 69 (40) 54 (62) 51 (59)
Median age at MR scan (IQR) 37 (26-48) years 37 (24-47) years 36 (26-49) years
Localization
     Knee 122 (70) 63 (72) 59 (68)
     Hip 8 (5) 0 (0) 8 (9)
     Ankle 20 (12) 10 (11) 10 (11)
     Foot 9 (5) 5 (6) 4 (5)
     Elbow 6 (3) 4 (5) 2 (2)
     Other 9 (5) 5 (6) 4 (5)
Median follow-up (IQR) 36 (21-60) months 32 (17-56) months 41 (24-63) months
Total number of recurrences
     Recurrent disease 49 (28) 4 (5) 45 (52)
     No recurrent disease 125 (72) 83 (95) 42 (48)
IQR, interquartile range
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Table 3   Risk of recurrence on MR imaging; univariate analyses in proposed  
risk factors and four MR parameters.
n (%) Hazard ratio  
(95% CI)
P
Gender
    Male 69 (40) 1.29 (0.74-2.27) 0.37
    Female 105 (60) 1
Age
    <40 years 91 (52) 1.15 (0.66-2.02) 0.63
     >40 years 83 (48) 1
Localization
     Knee 122 (70) 1.15 (0.63-2.12) 0.65
     Other joint 52 (30) 1
TGCT-type
     Diffuse 87 (50) 12.84 (4.60-35.81) <0.000
     Localized 87 (50) 1
Articular involvement
     Intra-articular 59 (34) 1.11 (0.31-3.95) 0.87
     Intra- and extra-articular 75 (43) 6.00 (2.14-16.80) 0.001
     Extra-articular 40 (23) 1
Muscular/tendinous tissue involvement
     Yes 90 (52) 3.50 (1.75-7.01) <0.000
     No 84 (48) 1
Ligament involvement
     Yes 86 (49) 4.59 (2.23-9.46) <0.000
     No 88 (51) 1
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Supplementary material I   Risk of recurrence on MR imaging, multivariate analyses.
Hazard ratio (95% CI) P
TGCT-type
     Diffuse 7.79 (2.17-28.03) 0.002
     Localized 1
Articular involvement
     Intra-articular 1.86 (0.37-9.46) 0.45
     Intra- and extra-articular 1.20 (0.36-3.99) 0.77
     Extra-articular 1
Muscular/tendinous tissue involvement
     Yes 1.98 (0.70-5.58) 0.20
     No 1
Ligament involvement
     Yes 1.62 (0.71-3.69) 0.26
     No 1
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Supplementary material II  TGCT recurrence free survival curve with four TGCT severity 
subtypes compared with solely sub-classifying by localized- or diffuse-TGCT, affecting large 
joints.
Time zero was date of primary open syno - vectomy. One patient, classified as severe diffuse died of another 
disease after 4 months and was censored at that time.
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Appendix   TGCT MR parameters, affecting large joints, in therapy naïve 
primary TGCT patients
Agreement: 
Involvement of a structure: when signal intensity is changed to TGCT signal intensity, this structure is 
considered to be involved with TGCT and to be scored.
When involvement of a structure is unclear: choose ‘structure involved’ (when in doubt; over-scoring, 
not under-scoring).
MI parameters:
TGCT-type
Localized-type†: well circumscribed nodular lesion at synovial lining of bursa, joint or tendon sheath
Diffuse-type††: multinodular lesion involving a larger part or all of the synovial lining
Articular involvement
Intra-articular$: inside synovial lining of joint
Extra-articular$$: outside synovial lining of joint
Both intra- and extra-articular
Cartilage-covered bone invasion
Yes: clear invasion of bone invading cartilage; not only touch cartilage 
No: no bone invasion or solely bone-usuration or bone invasion not cartilage-covered
Muscular/tendinous tissue involvement*
Yes: involvement of muscular/tendinous tissue or >180 degrees encasement of tendon/muscle
No: no involvement or encasement of tendon/muscle
Ligament involvement**
Yes: involvement of ligament or >180 degrees encasement of ligament
No: no involvement or encasement of ligament
Neurovascular structure involvement#
Yes: encasement >180 degrees of important nerves and/or vessels
No: no encasement of nerves or vessels
†Localized-type: be careful to always classify one nodular lesion as localized-type. Also when one nodular 
lesion is reeved by another structure (it might seem like additional nodules).
††Diffuse-type: be careful to always classify diffuse-type when two or more tendon sheaths or muscles 
are involved. Do not classify these cases as one large nodule.
$Intra-articular: concerning the knee: cruciate ligaments are counted as intra-articular structures as 
the synovial lining of the ligaments should be considered intra-articular.
$$Extra-articular: concerning the knee: Hoffa
* Muscular/tendinous tissue involvement: concerning the knee: also account parameter when solely 
popliteus muscle involvement is present.
**Ligament involvement: TGCT involvement of ligament, in hand or foot: account parameter when 
intra-tarsal/digital ligaments, ankle syndesmose and plantar fascia are involved. TGCT concerning the 
knee with ligament involvement: anterior and/or posterior cruciate ligament, and/or medial/lateral 
collateral ligament.
#Neurovascular involvement: in hand or foot: also digital or sensible nerves
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Abstract
At present, the treatment strategies in patients with localized and diffuse forms of 
pigmented villonodular synovitis have more or less been standardized. However, 
these strategies are not optimal because high recurrence rates persist and studies 
with a sufficient level of evidence are lacking. This systematic review article 
describes all known treatment options for intra-articular pigmented villonodular 
synovitis and their clinical results. Based on this research, we provide guidelines 
to support physicians in making the optimal treatment decisions. Given the rarity 
of the disease, randomized studies are not to be expected, but an international 
registry through existing networks would offer the benefit of getting a better 
insight into the outcome of this disease. Therefore, we propose a basic set of data 
to be investigated and ideally to be reported on in such a registry.
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Introduction
Pigmented villonodular synovitis (PVNS), also known as an intra-articular giant 
cell tumor, is a rare, benign and usually mono-articular lesion, arising from the 
synovial membrane. The lesion was first described in 1852 by the French surgeon 
Chassaignac, but he overstated its biological potential in referring to it as ‘a cancer 
of the tendon sheath’.7 The general accepted clinical description of PVNS was 
published by Jaffe et al. in 1941.2 They reported 20 cases with joint and tendon 
involvement, and proposed a classification by location and histology.2 The 
nomenclature outlined by Granowitz et al.8 and modified by the WHO in 20029 is 
currently the most common one.
 The pathogenesis of PVNS has been discussed for more than a century. 
Neoplastic, inflammatory, traumatic, metabolic and viral pathways were studied, 
but could not be confirmed until recently.8 Studies found PVNS to be a neoplastic 
process with specific genetic changes and a reactive component known as the 
‘paracrine landscape effect’.12,13,29 This new insight may lead to the development 
of treatment strategies, such as targeted therapy.64,68
 PVNS affects adults predominantly between 20–50 years of age, with equal sex 
prevalence. The annual incidence has been estimated at 1.8 cases per million US 
inhabitants.4,5 PVNS refers to articular involvement, which can be subdivided in a 
localized form (L-PVNS), characterized by discrete nodular or pedunculated 
lesions, and a diffuse form (D-PVNS), with involvement of the intra-articular soft 
tissue lining. The localized form rarely recurs after marginal surgical excision. 
The more common diffuse form recurs frequently and may result in a chronic 
disease, hampering normal function of the affected joint. Recurrence rates after 
treatment range from 9 to 46%, depending on the duration of follow-up and the 
joint involved.3,50 Microscopically, the two forms are indistinguishable.35
 Diagnosis of PVNS is often delayed due to the nonspecific nature of its 
symptoms.3,4 At first the diagnosis was solely based on histology. At present, MRI 
is an indispensable tool in making a diagnosis, determining staging and evaluation 
during follow-up31. Despite these improvements in diagnostic options, limited 
progress has been achieved in the treatment of PVNS, particularly the diffuse 
form.36,75 Physicians can choose from a number of treatment options with varying 
effectiveness and morbidity: a surgical synovectomy in an open or arthroscopic 
procedure, radiosynovectomy, external-beam radiotherapy (EBRT) or targeted 
treatments. Other treatments have also been described, such as cryosurgery, 
immunotherapy, arthroplasty, arthrodesis or amputation.3,19,48-59,113
 Currently, no randomized trials comparing different treatment strategies are 
available; the highest level of evidence is level five, based on retrospective case 
series. These case series are difficult to compare because different disease locations, 
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subtypes, and primary and recurrent PVNS are all grouped together to increase 
patient numbers.51,75 Various measurements are also used to assess treatment 
outcome.41,44,51,55,60,114 We have systematically reviewed the original literature on 
PVNS. Based on this research we have formulated treatment guidelines. These 
guidelines can help clinicians in making consistent treatment plans for PVNS 
patients. In the future this would allow case series from different centers to be 
compared and analyzed together, resulting in a higher level of evidence for the 
optimal treatment of PVNS.
Methods
Eligible papers were searched across a range of data sources, and included case 
series and clinical trials. Figure 1 shows a diagram of the search criteria and a 
selection of papers through the review process. 
 Search terms included ‘pigmented villonodularsynovitis’, ‘villonodularsyno-
vitis’, ‘PVNS’, ‘pigmented villo nodular synovitis’, ‘pigmented villonodular teno-
synovitis’, ‘giant cell fibrohemangioma,’ ‘chronic hemorrhagic villous synovitis’, 
‘fibrous xanthoma of synovium’, ‘pigmented villo nodular arthrosynovitis’ and 
‘synovitis and pigmented villonodular’. PVNS of the hands, temporomandibular 
joint and spine, as well as single case reports and review articles, were excluded. 
PubMed, EMBASE and Cochrane databases were searched. To ensure that all 
appropriate references were identified, reference lists of retrieved articles were 
screened, and a general internet search using the above search terms for Google 
was undertaken to uncover any additional publications. No date limit was included. 
Papers were excluded if there was no abstract and/or full text available. All languages 
were included, and, if foreign, were translated.
 The primary search yielded 840 articles. An initial screening of 522 titles and 
abstracts was undertaken after removal of duplicates, and any papers not meeting 
the broad inclusion/exclusion criteria (figure 1) were discarded. Forty-one papers 
reported on more than 20 cases or patients, of which 25 reported on treatment 
strategies. These 25 papers (tables 1 & 2) were read in full text, and data from these 
articles were systematically entered into a Microsoft® Office Access database 
(Microsoft Corporation, WA, USA). Data from each paper was categorized in 
relation to purpose and objectives, methodology, search, and analytical strategies, 
outcome and origins of the studies. In each article patient characteristics, subtype 
and locations of PVNS, number and types of treatments, number and kind of 
recurrences, duration of follow-up and number of patients lost to follow-up, other 
avail- able outcome measurements and treatment complications were scored. We 
attempted to pool and analyze patients from the selected articles. However, after 
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careful studying of all the literature, we were not able to identify patients treated 
in similar ways to make pooling justified. The described case series are too 
heterogeneous and there is a great diversity of patient groups. Furthermore, often 
operation techniques are not described in detail. Most articles do not describe how 
many surgeons performed the operation and how experienced they were. In our 
opinion, pooling data and analyzing it will not strengthen or change the found 
conclusions. To visualize this, we have attached tables (tables 1 & 2) that show this 
diversity of patients and treatments.
 For some treatments, no case series over 20 patients were available. To enable 
completeness for these treatments, smaller series were included.
Diagnosis
Based on clinical symptoms, age and history the diagnosis of PVNS is difficult. 
The disease mimics many other mono-articular pathologies, which makes differ-
entiation a challenge.31,60 L-PVNS can present with locking or clicking sensations 
of the affected joint.4,8 D-PVNS is relatively painless, although it can cause 
discomfort and swelling.3,4 In patients with knee complaints who undergo an 
arthroscopy, PVNS may be diagnosed macroscopically.124
 MRI is an indispensable tool in PVNS, making diagnosis, staging and evaluation 
during clinical follow-up possible31. Hemosiderin deposition occurs in the majority 
of cases, but it is most prominent in the diffuse intra- articular form of the disease.30 
Hemosiderin is a magnetic material, its deposit on proliferative synovial tissue 
results in a spotty low signal or extensive low signal area within the proliferative 
synovial masses on T1- and T2-weighted images, which is best seen on fat-field echo 
sequence MRI images.33 Fat-suppressed sequences obscured the deposit. This is 
highly diagnostic of PVNS. Enhancement of PVNS is common after intravenous 
administration of gadolinium; although the extent of enhancement varies, it is 
often a prominent feature.30 The MRI features of PVNS include extent of synovial 
proliferation, joint effusion, erosion of bone, subchondral cysts, septations, 
cartilaginous defects and, in particular, the deposit of hemosiderin within the 
synovial masses.31,33
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Treatment strategies
Surgical removal
Localized disease
When diagnosed arthroscopically, L-PVNS can be excised immediately and completely 
if the tumor is clearly visible.50,115 However, if the arthroscopist is not able to get an 
impression of the entire process, or if the tumor is difficult to reach, the procedure 
should be converted to an arthrotomy.125 This can be done immediately in the 
same procedure or secondary after final diagnosis and staging with MRI.30,111
 L-PVNS rarely recurs (0–15%) when completely resected.3,5,19,52,54,116 The recurrence 
free survival rates for L-PVNS in large joints, at 1 and 5 years, were 100 and 88%, 
respectively, as reported by Chiari et al.,75 while Sharma and Cheng calculated 
2- and 5-year recurrence free survival rates of 91 and 73%, respectively.36 Both studies 
included only primary cases. Besides recurrence rates, functional outcome (pain, 
swelling, range of motion and joint-specific scores) seemed improved. Byers et al.3 
reported 46% complete relief of symptoms postoperatively, compared with mostly 
‘excellent’ and ‘good’ results in case series over the last three decades.19,52,54,118 
However, most reports on functional outcomes fail to define specific outcome 
measurements and are described in subjective terms. We found no literature on the 
treatment of L-PVNS recurrences, besides a few cases mentioned in larger series.19
Diffuse disease
Unlike localized disease, D-PVNS is a much greater challenge to eradicate.3,57,75 
Despite many attempts to improve treatment strategies, recurrence rates have 
remained high (14–55%) over the last decade,39,41,52,55,75,117,118 with a 5-year 
recurrence- free survival of 27–48% in large joints.36,75
 In D-PVNS, removal of all the diseased tissue often means a complete anterior 
and posterior synovectomy as described by Chin et al. in patients with advanced 
primary and recurrent D-PVNS of the knee.55 Currently, an open surgical synovectomy 
is considered more reliable compared with an arthroscopic synovectomy51,55, 
especially in patients with large popliteal masses or extra-articular involvement114. 
It is technically almost impossible to remove all the pathologic tissue with an 
arthroscopic procedure. Blanco et al. suspects that many arthroscopic surgeons 
treating PVNS actually perform a subtotal (i.e., partial) synovectomy owing to the 
difficulty in visualizing the entire posterior aspect of the joint39. Ogilvie-Harris 
et al. describes complete arthroscopic synovectomies52. However, patients who had 
been selected for this arthroscopic procedure had no major posterior palpable 
masses and only slight or no radiographic degenerative changes.
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Table 1   Pigmented villonodular synovitis subtype, anatomical location, primary or  
recurrent disease with number of patients followed and duration of follow-up,  
in patients described in the selected articles.
Study (year) L-PVNS (n) D-PVNS (n) L- and D-PVNS (n) Primary/ FU (n) Mean FU; months .
     recurrent  (range)
    K H A O T K H A O T K H A O T P R
Blanco et al. (2001) – – – – – 22 – – – 22 – – – – – 22 – 14 33 (26–76) 
Byers et al. (1968) 13 – – 33 46 24 2 5 3 34 37 – – – 80 – – 51 (36–420) 
Chiari et al. (2006) 9 – – 14 23 3 3 3 10 19 12 3 3 24 42 42 – 42 80 (26–294) 
Chin et al. (2002) – – – – – 40 – – – 40 – – – – – – 40 40 60 (20–96) 
de Visser et al. (1999) – – – – 9 – – – – 29 31 3 2 2 38 27 11 34 48 (12–228) 
Dines et al. (2007) 84 – – – 84 – – – – – – – – – – 84 – 26 66 (46–123) 
Flandry et al. (1994) – – – – – 25 – – – 25 – – – – – 19 4 25 58 (20–126) 
Flipo et al. (1994) – – – – – – 58 – – – – – – – – – – 56 34 (12–156) 
Heyd et al. (2010) – – – – 1 – – – – 40 25 3 8 5 – 24 17 39 (6–120) 
Johansson et al. (1982) 7 – – 4 11 24 4 2 3 33 31 4 4 5 44 – – 38 94 (7–192) 
Liu et al. (2009) 22 – – – 22 – – – – – – – – – – 22 – 19 22 (8–28) 
Mankin et al. (2011) – – – – – – – – – – 125 12 48 30 215 – – 205 NR 
Miller et al. (1982) – – – – – – – – – – 18 8 3 7 34 – – 32 NR 
Myers et al. (1980) 10 – – – 10 27 1 2 9 39 – – – – – – – 49 NR 
Ogilvie-Harris et al. (1992) 5 – – – 5 20 – – – 20 29 – – – 29 29 – 25 54 (24–132) 
Ottaviani et al. (2011) 12 – – 2 14 79 – – 29 108 91 7 19 5 122 † † 39 70 (SD: 51.6) 
Pavlica et al. (1997) – – – – 30 – – – – 20 34 1 – 1 50 – – 22 (3–132) 
Pinaroli et al. (2006) – – – – 8 – – – – 20 25 – – 3 28 28 – 28 97 (12–309) 
Rao et al. (1984) 8 – – – 16 6 – – – 7 23 2 2 54 81 – 3 35 D-PVNS: 24 (12–48) 
                   L-PVNS: 43 (5–120)
Rochwerger et al. (1998) 3 – – – 3 19 – – – 19 22 – – – 22 – – 16 60 (24–192) 
Schwartz et al. (1989) – – – – – – – – – – 75 20 2 2 99 58 41 99 162 (14.4–564) 
Sharma et al. (2009) 12 – – – 12 37 – – – 37 49 – – – 49 49  49 74 (12–156) 
Ushijima et al. (1986) – – – – – – – – – – 25 5 13 9 52 – – 52 NR 
Ustinova et al. (1986) – – – – – 18 – – 6 24 – – – – – – 14 24 (6–72) 
Wang et al. (2005) – – – – 14  – – – 14 15 13 – – 28 – – 28 (12–144) 
Total (n) 199 – – 53 308 358 68 12 60 550 695 81 104 147 1013 404 134 – –
Pigmented villonodular synovitis subtypes, anatomical locations, and primary or recurrent disease 
are often pooled in the literature to increase patient numbers.
† 
Both primary and recurrent patients, however, it is unclear how many of each there are.
A: Ankle; D-PVNS: Diffuse pigmented villonodular synovitis; FU: Follow-up; H: Hip; K: Knee; L-PVNS: 
Localized pigmented villonodular synovitis; NR: Not reported; O: Other joints; P: Patients with primary 
pigmented villonodular synovitis; R: Patients with recurrent pigmented villonodular synovitis; SD: Standard 
deviation of the mean; T: Total number of patients.
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Table 1   Pigmented villonodular synovitis subtype, anatomical location, primary or  
recurrent disease with number of patients followed and duration of follow-up,  
in patients described in the selected articles.
Study (year) L-PVNS (n) D-PVNS (n) L- and D-PVNS (n) Primary/ FU (n) Mean FU; months .
     recurrent  (range)
    K H A O T K H A O T K H A O T P R
Blanco et al. (2001) – – – – – 22 – – – 22 – – – – – 22 – 14 33 (26–76) 
Byers et al. (1968) 13 – – 33 46 24 2 5 3 34 37 – – – 80 – – 51 (36–420) 
Chiari et al. (2006) 9 – – 14 23 3 3 3 10 19 12 3 3 24 42 42 – 42 80 (26–294) 
Chin et al. (2002) – – – – – 40 – – – 40 – – – – – – 40 40 60 (20–96) 
de Visser et al. (1999) – – – – 9 – – – – 29 31 3 2 2 38 27 11 34 48 (12–228) 
Dines et al. (2007) 84 – – – 84 – – – – – – – – – – 84 – 26 66 (46–123) 
Flandry et al. (1994) – – – – – 25 – – – 25 – – – – – 19 4 25 58 (20–126) 
Flipo et al. (1994) – – – – – – 58 – – – – – – – – – – 56 34 (12–156) 
Heyd et al. (2010) – – – – 1 – – – – 40 25 3 8 5 – 24 17 39 (6–120) 
Johansson et al. (1982) 7 – – 4 11 24 4 2 3 33 31 4 4 5 44 – – 38 94 (7–192) 
Liu et al. (2009) 22 – – – 22 – – – – – – – – – – 22 – 19 22 (8–28) 
Mankin et al. (2011) – – – – – – – – – – 125 12 48 30 215 – – 205 NR 
Miller et al. (1982) – – – – – – – – – – 18 8 3 7 34 – – 32 NR 
Myers et al. (1980) 10 – – – 10 27 1 2 9 39 – – – – – – – 49 NR 
Ogilvie-Harris et al. (1992) 5 – – – 5 20 – – – 20 29 – – – 29 29 – 25 54 (24–132) 
Ottaviani et al. (2011) 12 – – 2 14 79 – – 29 108 91 7 19 5 122 † † 39 70 (SD: 51.6) 
Pavlica et al. (1997) – – – – 30 – – – – 20 34 1 – 1 50 – – 22 (3–132) 
Pinaroli et al. (2006) – – – – 8 – – – – 20 25 – – 3 28 28 – 28 97 (12–309) 
Rao et al. (1984) 8 – – – 16 6 – – – 7 23 2 2 54 81 – 3 35 D-PVNS: 24 (12–48) 
                   L-PVNS: 43 (5–120)
Rochwerger et al. (1998) 3 – – – 3 19 – – – 19 22 – – – 22 – – 16 60 (24–192) 
Schwartz et al. (1989) – – – – – – – – – – 75 20 2 2 99 58 41 99 162 (14.4–564) 
Sharma et al. (2009) 12 – – – 12 37 – – – 37 49 – – – 49 49  49 74 (12–156) 
Ushijima et al. (1986) – – – – – – – – – – 25 5 13 9 52 – – 52 NR 
Ustinova et al. (1986) – – – – – 18 – – 6 24 – – – – – – 14 24 (6–72) 
Wang et al. (2005) – – – – 14  – – – 14 15 13 – – 28 – – 28 (12–144) 
Total (n) 199 – – 53 308 358 68 12 60 550 695 81 104 147 1013 404 134 – –
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Table 2   Various treatments or combination of treatments that pigmented  
villonodular synovitis patients received with available recurrence rates,  
described in the 25 selected articles.
Study (year) L-PVNS D-PVNS L- and D-PVNS 
 AE E A RR AS OS E Des/  EBR IS A X RR  AS OS E Des/ EBR IS A X RR    
    (%)    Amp     (%)      Amp      (%) 
    
     
 
Blanco et al. (2001) – – – – K: 22† – – – K: 22† – – – 14  – – – – – – – – – 
Byers et al. (1968) – 13 – 15 – 16† 9 4 2† – – 1† 46  – – – – – – – – <50 
Chiari et al. (2006) – 27 – ‡ – 5† 12 – – – 2 2† ‡  –  – – – – – – – 24 
Chin et al. (2002) – – – – – 40† – – 5† 30† – – 18  – – – – – – – – – 
de Visser et al. (1999) – 9 – 0.1 – 6 18 – – 4 1 – 34§  – – – – – – – – – 
Dines et al. (2007) 12 14 – 0 – – – – – – – – –  – – – – – – – – – 
Flandry et al. (1994) – – – – – 24 1 – – – – – 8  – – – – – – – – – 
Flipo et al. (1994) – – – – – – – – – – – – –  – 21† 9 – 1 14† 13 17† 14 
Heyd et al. (2010) – – – – – – – – – – – – –  – 41† – – 41† – – – 4.9 
Johansson et al. (1982) – 11 – 0 – 29 – – – – 4 – K: 33  – – – – – – – – – 
             H: 50
Liu et al. (2009) 22 – – 0 – – – – – – – – –  – – – – – – – – – 
Mankin et al. (2011) – – – – – – – – – – – – –  – – 173 11 3 – 17 1 1.4 
Miller et al. (1982) – – – – – – – – – – – – –  – – 34 – – – ¶ – 0 
Myers et al. (1980) – 8 – NR – 12† 18 – 3† – – – 18  – – – – – – – – 6 
                       K: 21
Ogilvie-Harris et al. (1992) – 5 – 0 11 – 9 – – – – – 30#  – – – – – – – – – 
Ottaviani et al. (2011) – – – 26 – 73† – – – 73† – – K: 30††  K: 54† K: 33† – – – K: 50† – – K: 55 
             O: 9††  O: 17† O: 14†    O: 23†   O: 26
Shows the various different treatments pigmented villonodular synovitis patients received with their 
effect on recurrence rates. Notably, descriptions of recurrence rates are based on clinical, imaging or 
pathological confi med diagnosis.
†  Some patients had a combination of these treatments.
‡  Chiari et al. [17]: 100% recurrence-free survival for L-PVNS at 1 year and 88% at 5 years; and 80% 
recurrence-free survival for D-PVNS at 1 year and 27% at 5 years. Sharma et al. [16]: 91% recurrence-
free survival for L-PVNS at 2 years and 73% at 5 years; and 70% recurrence-free survival for D-PVNS at 
2 years and 48% at 5 years.
§  Residual or recurrent disease.
¶  Joint replacement as necessary, no number or percentage mentioned.
#  9% RR for complete synovectomy and 56% for partial synovectomy.
††  Primary cases.
‡‡  Excisions, of which five were complete synovectomies and one was a menisectomy.
§§  Included all treatments of recurrent disease.
¶¶  Cumulative recurrence: 7% at 1 year, 15% at 5 years, 27% at 10 years, 31% at 15 years and 35% at 25 years.
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Table 2   Various treatments or combination of treatments that pigmented  
villonodular synovitis patients received with available recurrence rates,  
described in the 25 selected articles.
Study (year) L-PVNS D-PVNS L- and D-PVNS 
 AE E A RR AS OS E Des/  EBR IS A X RR  AS OS E Des/ EBR IS A X RR    
    (%)    Amp     (%)      Amp      (%) 
    
     
 
Blanco et al. (2001) – – – – K: 22† – – – K: 22† – – – 14  – – – – – – – – – 
Byers et al. (1968) – 13 – 15 – 16† 9 4 2† – – 1† 46  – – – – – – – – <50 
Chiari et al. (2006) – 27 – ‡ – 5† 12 – – – 2 2† ‡  –  – – – – – – – 24 
Chin et al. (2002) – – – – – 40† – – 5† 30† – – 18  – – – – – – – – – 
de Visser et al. (1999) – 9 – 0.1 – 6 18 – – 4 1 – 34§  – – – – – – – – – 
Dines et al. (2007) 12 14 – 0 – – – – – – – – –  – – – – – – – – – 
Flandry et al. (1994) – – – – – 24 1 – – – – – 8  – – – – – – – – – 
Flipo et al. (1994) – – – – – – – – – – – – –  – 21† 9 – 1 14† 13 17† 14 
Heyd et al. (2010) – – – – – – – – – – – – –  – 41† – – 41† – – – 4.9 
Johansson et al. (1982) – 11 – 0 – 29 – – – – 4 – K: 33  – – – – – – – – – 
             H: 50
Liu et al. (2009) 22 – – 0 – – – – – – – – –  – – – – – – – – – 
Mankin et al. (2011) – – – – – – – – – – – – –  – – 173 11 3 – 17 1 1.4 
Miller et al. (1982) – – – – – – – – – – – – –  – – 34 – – – ¶ – 0 
Myers et al. (1980) – 8 – NR – 12† 18 – 3† – – – 18  – – – – – – – – 6 
                       K: 21
Ogilvie-Harris et al. (1992) – 5 – 0 11 – 9 – – – – – 30#  – – – – – – – – – 
Ottaviani et al. (2011) – – – 26 – 73† – – – 73† – – K: 30††  K: 54† K: 33† – – – K: 50† – – K: 55 
             O: 9††  O: 17† O: 14†    O: 23†   O: 26
A: Arthroplasty; AE: Arthroscopic excision; AS: Arthroscopic synovectomy; D-PVNS: Diffuse pigmented 
villonodular synovitis; Des/Amp: Arthrodesis or amputation; E: Marginal excision, partial synovectomy 
(anterior or posterior) or subtotal synovectomy; EBR: External-beam radiotherapy; H: Hip; IS: Isotopes 
synoviorthesis; K: Knee; L-PVNS: Localized pigmented villonodular synovitis; O: Other joints; Op: Open 
surgical excision;
OS: Open complete surgical synovectomy or combined arthrotomy with arthroscopy; RR: Recurrence rate; 
X: Other treatments such as bone curettage, cup prosthesis, chemotherapy, menisectomy, bone impaction 
grafting, no treatment or unknown treatment.
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The open synovectomy can be performed in one or two stages. To our knowledge, 
there is no literature that underlines the advantage of either a one- or a two-stage 
procedure. The two-stage procedure, with a few weeks rehabilitation between the 
anterior and posterior approach, may have the advantage of reducing wound surface 
and, therefore, functional impairment. Authors arguing for an open synovectomy 
state that this approach leads to longer hospital stays, longer rehabilitation periods 
and higher chances of postoperative stiffness that may require manipulation.51-53 
Although acceptable rates of recurrences in arthroscopic knee procedures were 
described, this was not verified by MRI, and was only based on clinical 
symptoms.52,53,56 Recurrence rates up to 60% have been reported.36,52,55,56 
Theoretically, there is the risk of joint seeding and portal contamination during 
arthroscopic procedures126, but experienced arthroscopists report recurrence rates 
of 9–20%53, which is comparable to open procedures.51,55 However, the level of 
‘experience’ needed for these results and arthroscopic techniques are not specified.
 A third option is to combine the open and arthroscopic procedures.127 An 
arthroscopic approach offers excellent visualization of the anterior compartment, 
as well as the medial and lateral recesses. Combining this with an open posterior 
approach reduces the wound surface, which may result in better functional 
outcome and a similar risk of residual disease or relapse. Sharma et al. described 
that recurrence was highest in patients with diffuse disease who were treated 
with anterior arthroscopic surgery only, emphasizing the importance of eliminating 
posterior disease in D-PVNS as well as improving disease-free survival.36
Arthroplasty
Total joint arthroplasty is frequently used in the treatment of severe primary 
PVNS, persistent recurrent PVNS or secondary osteoarthritis caused by 
PVNS.50,111,114 Previously, patients with PVNS of the hip were observed until total 
joint arthroplasty became necessary. This is no longer recommended, since early 
complete synovectomy of the hip can postpone the need for an arthroplasty. 
Luxation of the femoral head, to achieve a complete synovectomy, is not advisable. 
It can cause avascular necrosis by interruption of the vascular supply to the 
femoral head. Total hip arthroplasty can be necessary when the bone is excessively 
affected by erosions.58,59 Studies show a potential lower recurrence rate after 
complete synovectomy combined with total hip replacement than after complete 
synovectomy only.50,111 An extensive exposure of the joint, as achieved in joint 
replacements, ensures complete debridement of the synovial membrane. In the 
knee this can be obtained by excision of the posterior cruciate ligament.128 Hamlin 
et al.129 described 14 D-PVNS patients, 11 of which had active disease and were 
treated with total synovectomy and total knee arthroplasty.128 Three polycentric 
and 11 condylar prostheses were used. Of the condylar implants, nine were inserted 
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with cement, one with hybrid fixation (the femoral component was inserted 
without cement and the tibial component with cement) and one without cement. 
Ten patients had an intact, well-functioning prosthesis at an average follow-up 
evaluation of 10.6 years (range: 3.6–20.1). Of the four failures, three had aseptic 
loosening requiring revision. There were two recurrences of PVNS, one eventually 
requiring an above the knee amputation. To our knowledge, there is no evidence 
on how often patients need a joint replacement after synovectomies. Some authors 
mention arthroplasty for a few patients (table 2). However, they mostly do not 
clarify if this was required for extensive disease or secondary osteoarthritis caused 
by progressive disease or multiple treatments.
 Thus, a prosthesis can provide a painless, well-functioning extremity in a 
patient who would otherwise have had complaints of stiffness and pain.129 Since 
the incidence of post-operative complications of prostheses surgery has decreased 
remarkably, this treatment has been applied more frequently.3,59 Prosthesis 
surgery can be used as a primary modality to treat PVNS-induced osteoarthritis, or 
in conjunction with synovectomy in severe or persistent recurrent PVNS to achieve 
radical disease removal.
Additional treatments
Complete resection of D-PVNS is almost never possible. Therefore, additional 
treatments may be useful to reduce functional impairment of joints, residual 
disease and recurrences. These additional treatments can be used directly as 
initial adjuvant treatment with the intention of reducing the risk of recurrence, 
or only applied when recurrences occur as another treatment option. Various 
additional treatments have been described.
Cryosurgery
Cryosurgery, in the form of liquid nitrogen spray, is widely used as an adjuvant 
treatment in various tumors.130 Mohler and Kessler treated three D-PVNS patients 
through open synovectomy plus cryosurgery, two with recurrent and one with 
arthroscopically unresectable disease.49 All non-cartilaginous surfaces were treated 
with cryosurgery. There were no complications or morbidity from the cryosurgical 
procedure and patients had excellent functional recovery. After 14, 30 and 31 months 
there were no clinical symptoms of recurrence.
 Described complications of cryosurgery in the treatment of benign and low- 
grade malignant bone tumors are: infections (4%) caused by tissue necrosis; damage 
to the articular (cartilage) surface; temporarily nerve palsy; and, sporadically, a gas 
embolism.131
524982-L-bw-Verspoor
Processed on: 3-10-2018 PDF page: 96
96
CHAPTER 5
The effectiveness of cryosurgery in the treatment of primary severe or recurrent 
PVNS, has not currently been tested. So, if applied this should be performed in the 
setting of a clinical trial, by an experienced surgeon.
External-beam radiotherapy
Differences of opinion exist on the role of EBRT in the treatment of PVNS. It seems 
to be reserved for treatment of extensive extra-articular involvement of the disease 
near vital structures such as the neurovascular bundle, residual disease after 
complete synovectomy and persistent recurrent disease.39,40 Blanco et al. described 
22 patients with primary D-PVNS who received an anterior arthroscopic 
synovectomy followed, 2 weeks later, by EBRT.39 Nineteen patients (86%) had 
excellent or good results after an average follow-up of 33 months (range: 26–76), 
with three (14%) clinical recurrences. Ustinova et al. treated 24 D-PVNS patients 
with adjuvant EBRT after incomplete surgical disease removal.118 Of these, 18 
patients had D-PVNS affecting the knee joint and six of these had bone involvement. 
The surgeons performed a complete synovectomy followed by EBRT within 3–4 
weeks. After a follow-up ranging from 0.5–6 years, complete recovery convalescence 
was noted in 23 patients and occupational rehabilitation was achieved in 21 
patients. These data indicate a high efficacy of surgical removal combined with 
EBRT. A multicenter study by Heyd et al. presented 41 cases, 24 primary cases and 
17 recurrences.120 All 41 followed patients received surgical synovectomy plus 
EBRT. Excellent and good results were achieved in 34 patients (87%), with a 
recurrence rate of 5% during a 0.5–10-year follow-up period. During the last 
decade, other smaller case series confirmed the positive results of adjuvant EBRT 
with regards to local recurrence and functional outcome of PVNS40,128. Currently, 
total doses in the range of 30–36 Gy are recommended.47 To our knowledge, there 
is no clinical trial available regarding the optimal time frame for EBRT after 
surgery. The abovementioned studies used 2–4 weeks.39,118
 Reported complications associated with EBRT are skin reactions, poor wound 
healing, joint stiffness, sarcomatous transformation, femoral fractures and 
impotence.3,120 Owing to these complications, EBRT should not be used as a 
primary treatment, but only for symptomatic residual and recurrent PVNS. 
However, one needs to be reserved when recommending EBRT for this benign 
condition, especially in young patients.
Radiosynovectomy
Radiosynovectomy (isotopic synoviorthesis) has been a focus of discussion for 
years. It is mostly used as an adjuvant treatment after surgical synovectomy, but 
no large series have been published in which it is systematically compared with 
surgery alone or with other adjuvant therapies. Chin et al. treated 40 patients with 
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primary and recurrent D-PVNS of the knee.55 All were treated by open surgical 
synovectomy. Thirty patients received additional intra-articular radiation synovectomy 
with use of 11 GBq of dysprosium-165 in combination with 20 mg triamcinolone 
hexacetonide to decrease the swelling that is commonly associated with this 
procedure. Five patients received additional EBRT of 35 Gy in single fractions each 
day over a 15-day period. The overall recurrence rate, detected by MRI, was seven 
out of 40 patients (18%), during the 5-year follow-up. The reason why some people 
received radiosynovectomy and others received no additional treatment or EBRT 
was not stated. Owing to the lack of randomization and the small number of 
patients in the group that had received no adjuvant treatment or EBRT, no fair 
comparison is possible. In the authors’ opinion, complete resection of all PVNS 
tissue is the key factor in preventing recurrences. The largest case series on radio-
synovectomy is a single-center report of Ottaviani et al. describing 108 cases of 
D-PVNS and 14 of L-PVNS.41 In their center, all patients who were not treated 
elsewhere before (n = 73) were treated by open synovectomy with additional radio-
synovectomy (knees with 185 MBq of yttrium-90; hips and ankles with 111 and 
74 MBq of rhenium-186, respectively). They encountered no serious complications and 
only mild febrile reactions. Relapse rates of these patients were 15 out of 50 (30%) 
for knees and two out of 23 (9%) for other locations, after a mean follow-up period 
of 4.6 years. The remaining patients, who had relapsed after treatment elsewhere, 
received only surgery. A direct comparison between these two groups was not 
performed because relapsed patients are at higher risk for another relapse.41 A few 
smaller studies (ten patients or less) reported recurrence rates of 0–17% after 
surgery and adjuvant yttrium-90 radiosynovectomy using higher doses (555–925 
MBq).46,132
 Other small case series (five to ten cases per series) reported on PVNS that 
recurred after surgery, and was subsequently treated only by radiosynovectomy. In 
these patients, who were at a higher risk of another relapse, success percentages of 
approximately 50% were described.19,133,134
 Severe complications, such as radionecrosis requiring plastic surgery and 
chronic severe pain have incidentally been described, particularly in ankles with 
limited soft tissue coverage135. Osteonecrosis and intra-articular infections have 
been described following radiosynoviorthesis in osteoarthritis and arthroplasty.136 
Theoretically, radiosynovectomy may carry a risk of radiation-induced malignancy, 
but this has never been reported. Furthermore, in theory it has the disadvantage 
of not covering extra-articular disease. In general, the side effects are mild, especially 
if radiosynovectomies are performed by an experienced team and necessary 
precautions are taken.41
 A study investigating the efficacy and articular effects of radiosynovectomy in 
patients with persistent arthritis of the knee showed that radiosynovectomy with 
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yttrium-90 combined with triamcinolone hexacetonide was no more effective 
than triamcinolone hexacetonide alone.137 Furthermore, harmful effects on 
human cartilage and bone following radiation synovectomy with yttrium-90 were 
reported, both in vivo and in vitro.138,139 Owing to these findings, we discourage 
the use of radiosynovectomy for PVNS treatment, or if continued it should be in 
the setting of a proper randomized trial.
Immunotherapy
Some research uses anti-TNF-α as a local or general treatment in patients with 
relapsing PVNS, with relatively good results.29,48,140 Kroot reported a patient with 
recurrent PVNS of the knee, which clinically improved after TNF-α blockade.48 In 
addition, a marked reduction in macrophages and TNF-α expression in the 
synovium was  found. Fiocco et al. reported two patients with recurrent disease of 
the knee who benefited from the TNF- α blocker etanercept.141 Knee function and 
disease activity improved, which was confirmed by regression of knee joint 
synovial proliferation. The use of anti-TNF-α is supported by the fact that 
macrophages and proinflammatory cytokines, such as TNF-α are present in the 
synovium of patients with PVNS.142 This treatment is possibly an option in patients 
who relapse frequently, but it is not validated. Furthermore, this may be replaced 
by upcoming results of targeted therapy (see ‘Targeted therapy’ section).
Targeted therapy
The search for the pathogenesis of PVNS has led to the development of new 
treatment options, such as targeted therapy.68 PVNS is a benign neoplastic process 
with specific genetic alterations.12,13 A specific t(1;2) translocation, involving the 
COL6A3 gene (on chromosome 2q35) and the M-CSF gene (also known as CSF1, on 
chromosome 1p13), is present in a fraction of tumor cells in PVNS/tenosynovial 
giant cell tumors (TGCTs).143 This fusion gene, t(1p13;2q35), encodes for a fusion 
protein, which attracts non-neoplastic cells expressing M-CSFR, though a 
‘paracrine landscape’ effect.12,13 It is hypothesized that CSF inhibitors, such as 
imatinib, may disrupt this paracrine land- scape effect found responsible for PVNS/
TGCT growth.12,13,144
 Imatinib has been reported to block M-CSFR activation at therapeutic 
concentrations.145 Rapid relapse at discontinuation, and a secondary response 
obtained after imatinib reintroduction was reported in gastrointestinal stromal 
tumors.146 The same effect was described after treatment of two cases of PVNS with 
imatinib, one in an elbow143 and one in a hip147. PVNS relapsed after interruption of 
treatment, and when imatinib was reintroduced a second remission was observed.143 
Cassier et al. described the largest retrospective study of 29 imatinib-treated PVNS/
TGCT patients.64 Most patients (20 out of 29; 69%) had undergone previous surgery. 
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Four of the nine remaining patients received imatinib mesylate as neoadjuvant 
therapy before they underwent surgical excision. Cassier et al. do not differentiate 
their results for the two disease entities. Overall, one (4%) patient was in complete 
remission, four (15%) were in partial remission and 20 (74%) patients had stable 
disease. Remarkably, two (8%) patients had metastatic disease, and both progressed. 
In two (8%) patients, evaluation was not possible due to discontinuation of treatment 
due to early side effects (febrile neutropenia and grade 3 edema). Although these 
findings are promising, there are disadvantages to imatinib treatment: it has to be 
given chronically, since probably PVNS recurs after discontinuation, and it is not 
without side effects. These mainly include hematologic and gastrointestinal 
toxicity.148 Another disadvantage is that prolonged exposure may cause new 
mutations, which  are imatinib  resistant.149 Theoretically, this may lead to more 
aggressive PVNS subgroups or worse, secondary malignant tumors.
 In the abovementioned study by Cassier et al., over half the patients (17; 59%) 
discontinued imatinib treatment due to side effects during the mean 10.8-month 
follow-up (range: 3.0–42.9).64 This percentage is much higher than observed in 
metastatic gastrointestinal stromal tumors treated with imatinib. At present, the 
results of an international study with nilotinib are awaited. Of note, neither 
imatinib nor nilotinib are specific CSF1R inhibitors.
 Another important clinical issue is the goal of CSF inhibition treatment in 
PVNS. Is it a merely palliative treatment or is meant for bridging until surgery or 
radiation therapy? Does it induce long-term complete remission and what is the 
ideal duration of treatment?
 At this moment, CSF1R inhibitors should be preserved for patients with 
unresectable disease or multiple recurrences that produce clinical and functional 
impairment.
Follow-up
MRI has been shown to be an effective tool for detection of D-PVNS tissue 
preoperatively and for monitoring patients postoperatively.60,113 MRI is highly 
sensitive, but less specific for detecting residual PVNS postoperatively, owing to 
the confounding presence of surgical changes within the knee. Chin et al. advised 
a postoperative MRI after 3 and 6 months, then annually (it was not specified for 
how many years).55 However, 3 months after surgical treatment early postoperative 
changes may still be present. We recommend a MRI, 6 months postoperatively, as 
a baseline scan to observe changes when symptoms arise. This can be after a long 
period of time, as PVNS can recur after many asymptomatic years. No evidence 
exists that an annual MRI is contributory in the absence of clinical symptoms.
 Each treatment increases the risk of functional impairment and secondary 
osteoarthritis in addition to all abovementioned complications.3,4,19,39,51,54,55,75,117 
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The socio-economic consequences of the multiple operations and adjuvant 
treatments for PVNS are seldom described; Ustinova et al. described some patients 
that could not continue their work owing to the consequences of D-PVNS.118
 Several groups have been looking for predictive markers for possible PVNS 
relapse150,151, but none have yet been found. However, in a small number of 
long-term follow-up studies evaluating the different types and locations of PVNS, 
more recurrences were seen in the diffuse form, in large joints and in prior 
incomplete synovial excisions.3-5,75
 Using joint-specific scores, Enneking et al.152 and Chiari et al.75 showed that 
prevention of recurrence does not automatically equate to a successful clinical 
outcome. de Visser et al. evaluated the functional aspects of treatment of PVNS and 
found excellent or good results despite 34% residual and recurrent disease.19 
Consequently, PVNS research should focus more on the effects of the disease and 
treatments on joint function.
 Longer-term follow-up studies would not only increase our understanding of 
the biological behavior of PVNS, but would also enable us to evaluate the potential 
development of secondary osteoarthritis.116 It could provide more knowledge on 
the lifespan of prostheses after complete synovectomy. Furthermore, we should 
pay greater attention to the impact of PVNS on patients’ occupational and social 
lives. PVNS can be highly debilitating and, thus, can have a major impact on 
quality of life. More knowledge of these aspects can contribute greatly to patient 
counseling.
Literature limitations
Our literature search on PVNS treatment options yielded mostly retrospective case 
series. However, instead of clarifying, they provided new uncertainties. First, since 
PVNS rarely occurs, the major subgroups, localized and diffuse are often merged 
(table 1)4,35,44,50,74,121-123. It has been known for decades that these two entities 
behave different biologically.2 Second, the anatomic site of PVNS can have a 
significant influence on its clinical behavior.2,8,59 According to Chung and Janes, 
bone invasion is more likely to occur in joints without large synovial recesses to 
accommodate expanding synovial masses, such as the hip.58 Furthermore, owing 
to the deeper location the diagnosis may be delayed. Schwartz et al. found higher 
recurrence rates in affected knees compared with any other locations.50 
Nevertheless, subtypes and locations are combined in outcome measurements to 
increase patient numbers (table 1).3,19,44,50,75,120 Third, the diversity in treatment 
options is enormous (table 2). In most case series, more than three different 
treatment strategies are described.3,19,44,50,54,75,117 In this way, the already mixed 
patient groups are too small to draw conclusions from. Fourth, patient groups 
consist of newly diagnosed patients and patients already treated elsewhere (table 
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1).5,19,41,50,51 Some studies focus on this topic and describe the treatments patients 
received before arrival in their center,19,50,51,55 and others do not report the 
composition of their patient groups at all.3,44 It leads to bias in outcome 
measurements, such as overall recurrence rates, which becomes incorrectly high 
compared with case series with solely primary cases. Schwartz et al. described this 
manipulation as referral bias, mostly present in patient populations from tertiary 
centers.50 Their study showed that patients with previous surgery had more 
recurrences than those who did not (p < 0.01). The patients with previous 
procedures had unusual cases of PVNS: their prior operations may have affected 
recurrence in some way, perhaps by biologically aggressive characteristics or 
locations less amenable to eradicate surgically.
 Besides the abovementioned difficulties, other issues should be highlighted. 
What is the best way to describe treatment outcome? Studies used recurrence 
rates, recurrence-free survival percentages, numbers of secondary osteoarthritis 
and rate of complications, while some only used broad outcome terms such as 
good, excellent, fair and poor. Unfortunately, the largest case series (>20 patients) 
all use different outcome measures or are incomplete in their descriptions (figure 1).
 Some studies accept clinical symptoms and radiographs to detect recurrent 
disease3,5 and others insist on MRI or even histological con- formation before 
designating a relapse. Only a few differentiate between residual disease and 
recurrences.19,117 Again, a decision needs to be made whether clinical symptoms 
are enough proof, or if MRI and histological conformation are required. What 
treatment implications do residual or recurrent disease on MRI without clinical 
symptoms have? Should additional treatment occur, or is ‘wait and see’ sufficient? 
Further research needs to provide these answers. In addition, clear differentiation 
between real recurrent disease and additional operations for other reasons is 
significant. Not all operations in one joint indicate recurrent PVNS. Frequently, it 
is secondary osteoarthritis requiring arthroplasty or stiffness needing manipulation 
under anesthesia.
 Finally, follow-up time is usually short; especially knowing PVNS can recur 
after many years.59 Due to the retrospective character of these studies, data are 
missing and a high number of patients are lost to follow-up.
 We emphasize the weakness of the current study, because it is based on the 
only available literature, which has the above described limitations. However, by 
pointing out these limitations, future studies may be able to gather stronger 
evidence on PVNS.
524982-L-bw-Verspoor
Processed on: 3-10-2018 PDF page: 102
102
CHAPTER 5
Guidelines
The following guidelines are summarized in figure 2. After diagnosis by histology 
and/or MRI, correct classification (localized or diffuse) determines the best 
individualized treatments. PVNS behaves differently in various locations. The 
limited available literature describes mostly treatment results on knees and hips. 
These guidelines are, therefore, most reliable for these joints, but in our opinion 
applicable to all joints. In primary L-PVNS, arthroscopic excision is sufficient. 
Open excision should be preserved for difficult excisable L-PVNS lesions. For 
recurrent L-PVNS the results of excision are unknown. Due to the good results of 
primary surgery116, we recommend re-excision for symptomatic recurrent disease.
 D-PVNS is clearly more difficult to treat with higher recurrent rates and 
various treatment options sparse in evidence of efficiency. The treatment of choice 
is surgical synovectomy. According to the extent of the process, the involved 
anatomical structures, and the experience of the surgeon, an open or an 
arthroscopic approach needs to be considered. The main goal of treatment is the 
removal of all abnormal synovial tissue, thereby taking away the source of 
symptoms, and reducing joint destruction and recurrences. Based on present 
knowledge and technical operative possibilities, complete arthroscopic removal of 
D-PVNS tissue should be reserved for patients with limited, intra-articular disease 
and an experienced arthroscopist. When it is uncertain whether all the diseased 
tissue has been removed, or there is disappointing visibility, the closed procedure 
should be converted to an open procedure. In patients with extra-articular 
involvement or large popliteal masses, an arthroscopic approach is contra- 
indicated, but can be combined with an open approach.52,56,57,113 Importantly, 
these patients should be referred to centers with expertise in this disease from the 
time of diagnosis. Adjuvant treatment is applied in cases of residual disease. In 
case of recurrent disease, the patient will require rescue therapy or second- or 
third-line treatment.
 If there is residual disease after surgical excision adjuvant treatment needs 
consideration. The strongest available evidence on treatment effects favor EBRT. 
All other adjuvant treatments; cryosurgery, radiosynovectomy and immunotherapy, 
lack evidence on treatment effects and outcome caused by the abovementioned 
literature limitations. Targeted therapy with the tyrosine kinase inhibitor, 
imatinib, has shown promising results in some patients, but this treatment is still 
in an experimental phase and imatinib is not believed to be as effective as 
CSF1R-directed treatment. Additionally, it is unclear which patients benefit, how 
long they should be treated and whether side effects of this and other tyrosine 
kinase inhibitors may hamper long-lasting treatment of this in general benign 
disease.
 Arthroplasty is preserved for severe primary or recurrent PVNS where removal 
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of menisci, collateral and cruciate ligaments is needed to achieve excision of all 
pathologic tissue. In most of these cases bone erosion and degenerative joint 
disease is present. Here, arthroplasty facilitates a functional joint. The kind of 
prosthesis best applied, a regular prosthesis or megaprosthesis used for tumor 
surgery, depends on the extension of tissue removal.
 Clearly, all adjuvant treatments should be given in a trial to generate stronger 
evidence for future guidelines. These trials should be limited to one or two treatments 
to gather enough evidence on efficacy, but also on complications, side effects, joint 
function and quality of life (box 1). The decision concerning diagnostics, treatment 
and follow-up should ideally be made in a multi-disciplinary team of people who 
have expertise in this peculiar and rare disease.
Conclusion & future perspective
An international registry should be started in which group registries could enter 
their data. This would enable the start of future protocols based on greater patient 
numbers. It should answer questions about the percentage of patients with 
residual, recurrent or degenerative disease based on clinical, imaging or 
pathological data. Centralization of treatments for PVNS patients will lead to less 
morbidity and a decrease in residual and recurrent disease. It will improve the 
quality and quantity of treatments. For example, future arthroscopic techniques, 
along with greater experience, will allow greater and more complete access to in-
tra-articular pathologic tissue. As in all technical procedures, there is a definite 
learning curve to a complete arthroscopic synovectomy. We may become able to 
excise more severe PVNSs arthroscopically.
 Arthroplasty as a treatment of PVNS should be studied further, including the 
risk of prosthesis loosening caused by persistent or recurrent disease. Furthermore, 
the significance of cryosurgery, EBRT, radiosynovectomy, immunotherapy and 
targeted therapy in the treatment of PVNS should be elucidated. Indications for 
each therapy must be clarified, including their optimal regimes. The discovery of 
an aggressive biological subgroup would be helpful in decisions about the need for 
additional treatments, for example, a specific patient group experiencing favorable 
effects with targeted therapy.
 More knowledge should become apparent about the impact of PVNS on 
patient’s quality of life, influenced by the disease itself or by multiple received 
treatments. This will not only optimize care, but it will also improve patient 
education and guidance.
 Despite the benign character, PVNS patients’ lives are often severely affected 
in their quality due to the long course of the disease, the multiple surgeries, 
residual- or post-surgical complaints and secondary osteoarthritis. Although the 
two forms, L-PVNS and D-PVNS, are almost identical histologically, elimination of 
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D-PVNS is much more challenging. Various different treatment options have been 
proposed and implemented, however, due to the low incidence of the disease, 
randomized clinical trials are lacking and treatment efficacies are hard to 
compare. Analyses and comparisons of different case studies are difficult and may 
lead to inaccurate conclusions. Nevertheless, we have now established treatment 
guidelines based on a systematic analysis of the literature to improve future 
comparability and aggregation capabilities of study results from different centers. 
The gold standard of treating D-PVNS is complete surgical synovectomy. Other 
therapeutic options, preserved for severe primary and recurrent disease, are 
treatments with additional cryosurgery, arthroplasty or adjuvant EBRT. In case of 
relapsed disease radiosynovectomy, immunotherapy with TNF-α blockers or 
CSF1R-directed targeted therapy, preferably in the context of a well-designed 
clinical trial, are proposed. These trials would ideally be initiated internationally 
in order to reach a significant number of patients in a short period of time. This 
has already been the case in the first studies with nilotinib [101,102]. Outside 
clinical trials it would be interesting to make use of networks, such as the World 
Sarcoma Network, to create a registry in which international outcome data can be 
linked to each other [103]. This will generate data that will certainly improve the 
outcome of this rare and disabling disease.
Websites:
[101] ClinicalTrials.gov. Nilotinib in Patients With Relapsed or Metastatic Pigmented 
Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell 
Tumor. http://clinicaltrials.gov/ct2/show/ NCT01207492
[102] ClinicalTrials.gov. Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ 
Tenosynovial Giant Cell Tumour (PVNS/TGCT). http://clinicaltrials.gov/ct2/show/NCT01261 
429?recr=Open&cntry3=EU%3AGB&phase=1&lup_s=04%2F19%2F2012&lup_d=360
[103] World Sarcoma Network. www.worldsarcomanetwork.com/
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Box 1  Key points for analyzing case series.
Diagnosis through MRI and/or histology
• Differentiate in all analyses
 – PVNS (intra-articular) from tenosynovial giant cell tumor (extra-articular)
 – Localized PVNS from diffuse PVNS
 – Anatomical locations
 – Primary from recurrent PVNS
 – Accidental PVNS (e.g., during prostheses surgery)
Treatment
• Localized PVNS
 – Excision/nodulectomy
 – Arthroscopic or open surgery
• Diffuse PVNS
 – Number and nature of treatments in which (tertiary) center
 – Surgical synovectomy
  –  Complete or partial
  –  Open or arthroscopic
 – Prostheses
 – Additive treatments
  –  Cryosurgery
  –  Radiosynovectomy
  –  External-beam radiotherapy
  –  Immunotherapy
  –  Protein kinase inhibitor
 – Time to first recurrence
 – Number of manipulations
 – Number and kind of treatments elsewhere
Follow-up
• Mean overall follow-up: date of diagnosis to date of last follow-up
•  Mean follow-up: date of first operation in tertiary hospital (index operation) to date of 
last follow-up
• Number of overall recurrences
• Number of recurrences in tertiary hospitals
• Number of nonrecurrence operations (e.g., prostheses for secondary osteoarthritis)
• Nature of relapse: MRI, clinical symptoms, histological proven
• Recurrence-free survival (1 ,5 ,10 or 15 years)
•  Pre- and post-operative joint function score (Knee Society Score, Western Ontario and 
McMaster Universities Arthritis Index, Harris Hip Score)
• Number and nature of complications
• Quality of life (RAND-36 and CIS20r)
• Number of patients lost to follow-up with reasons (explanation)
CIS20r: Checklist Individual Strength; RAND-36: RAND 36-item Health Survey; PVNS: 
Pigmented villonodular synovitis.
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Executive summary
Background
•  Limited progress has been achieved in the treatment of pigmented villonodular 
synovitis (PVNS), particularly the diffuse form.
•  Currently, the highest level of evidence on treatment outcomes is level five, based on 
retrospective case series.
Diagnosis
•  MRI is an indispensable tool in diagnosing, staging and evaluating in clinical follow-up.
Treatment strategies
•  Surgical removal
 –  Localized PVNS can be excised immediately and completely if the tumor is clearly 
visible on arthroscopy. If one is unable to get an impression of the entire localized 
PVNS process, or if the tumor is difficult to reach, the procedure should be 
converted to an arthrotomy.
 –  In diffuse PVNS, surgical removal of all diseased tissue often means a complete 
anterior and posterior synovectomy.
 –  According to the extent of the process, the involved anatomical structures and 
the experience of the surgeon, an open or an arthroscopic approach needs to be 
considered.
 –  Complete arthroscopic removal of diffuse PVNS tissue should be reserved for 
patients with limited, intra-articular disease and an experienced  arthroscopist.
 –  If there is extra-articular involvement or large popliteal masses an arthroscopic 
approach is contraindicated, but can be combined with an open approach.
•  Arthroplasty
 –  Total joint arthroplasty is used in the treatment of severe primary PVNS, persistent 
recurrent PVNS or secondary osteoarthritis caused by PVNS.
Additional treatments
•  Cryosurgery
 –  Cryosurgery should be preserved for severe primary and recurrent disease in a 
study.
•  External-beam radiotherapy
 –  External-beam radiotherapy should be reserved for treatment of extra-articular 
involvement, residual disease after complete synovectomy and persistent recurrent 
disease.
•  Radiosynovectomy
 –  The use of radiosynovectomy for PVNS treatment should be discouraged, or if 
continued, should be used in the setting of a proper randomized trial.
•  Immunotherapy
 –  In the case of PVNS relapse, immunotherapy with TNF-α blockers can be 
considered, preferably in the context of a clinical trial.
•  Targeted therapy
 –  Currently, CSF1R inhibitors should be preserved for patients with unresectable 
disease or multiple recurrences that produce clinical and functional impairment.
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Follow-up
•  An MRI 6 months postoperatively can be useful as a baseline scan to observe changes 
when symptoms arise.
•  Each treatment increases the risk of functional impairment and secondary 
osteoarthritis.
•  Prevention of recurrence does not automatically equate to a successful clinical 
outcome.
Literature limitations
•  The highest level of evidence is level five, based on retrospective case series.
•  Case series are difficult to compare because different disease locations, subtypes, 
primary and recurrent PVNS are grouped to increase patient numbers.
•  Various measurements are used in case series to assess treatment outcomes.
•  Case series have a relatively short follow-up time.
•  Case series differ in or lack description of recurrent or residual disease.
Future  perspective
•  In the future, predictive markers for possible PVNS relapse could be developed.
•  Centralization of care would improve PVNS outcomes.
•  More knowledge of the lifespan of prostheses after complete synovectomy would also 
be useful.
•  The impact of PVNS on patients’ occupational and social lives should be studied, because 
PVNS can be highly debilitating and, thus, have a major impact on quality of life.
•  An international registry would enable the start of future protocols based on greater 
patient numbers in a short period of time.
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Abstract
Tenosynovial giant cell tumors (t-GCTs) can behave aggressively locally and affect 
joint function and quality of life. The role of arthroplasty in the treatment of t-GCT 
is uncertain. We report the results of arthroplasty in t-GCT patients.
 t-GCT patients (12 knee, 5 hip) received an arthroplasty between 1985 and 
2015. Indication for arthroplasty, recurrences, complications, quality of life, and 
functional scores were evaluated after a mean follow-up time of 5.5 (0.2–15) years.
 2 patients had recurrent disease. 2 other patients had implant loosening. 
Functional scores showed poor results in almost half of the knee patients. 4 of the 
hip patients scored excellent and 1 scored fair. Quality of life was reduced in 1 or 
more subscales for 2 hip patients and for 5 knee patients.
 In t-GCT patients with extensive disease or osteoarthritis, joint arthroplasty is 
an additional treatment option. However, recurrences, implant loosening, and 
other com- plications do occur, even after several years.
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Introduction
Tenosynovial giant cell tumors (t-GCTs) are benign proliferative growths of the 
synovial membrane.1 The approximate annual incidence in the USA is 1.8 patients 
per million inhabitants.4 T-GCT mainly affects adults between 20 and 50 years of 
age, with the same prevalence in both sexes. There is a predilection for weight- 
bearing extremities, the knee and the hip being the most commonly involved.42
 The clinical presentation is non-specific, with mild discomfort, stiffness, 
effusion, or progressive pain. Based on the clinical and radiological presentation, 
2 subtypes of t-GCT have been identified, localized t-GCT (Lt-GCT) and diffuse 
t-GCT (Dt-GCT).30,42
 Treatment strategies are based on removal of all pathological tissue. In primary, 
limited disease, a surgical synovectomy is often sufficient.76 However, for extensive 
or recurrent disease, complete surgical synovectomy can be a technical challenge. 
Recurrence rates have been reported to be between 0% and 15% for Lt-GCT and 
between 9% and 46% for Dt-GCT, depending on the duration of follow-up and on 
the joint involved.42,75,116
 A variety of treatment modalities in addition to surgical resection of t-GCT 
have been used to achieve cure, such as external beam radiation therapy, radiation 
synovectomy, cryosurgery, immune or targeted therapy, and joint arthroplasty. 
However, little is known about the actual effect of these additional treatments.76
 The surgical removal of t-GCT combined with arthroplasty has been described 
previously in patients with extensive disease, and in patients with destructive 
joint changes caused by the disease itself or by the multiple treatments patients 
received.129 The goal of this treatment is to achieve a disease-free, well-functioning 
joint.153 In addition, patients with osteoarthritis-like symptoms in whom t-GCT 
was an incidental finding during arthroplasty have been described.59
 This retrospective study was conducted to analyze the results of arthroplasty 
in patients with t-GCT. More specifically, we examined the indications, number of 
recurrences, complications, quality of life, and joint function in relation to t-GCT 
subtype and the joint affected.
Patients and methods
For this retrospective study, we identified 141 t-GCT patients in our patient 
databases (1985–2015). 48 patients were classified as Lt-GCT and 93 as Dt-GCT. 17 of 
these patients (5 Lt-GCT and 12 Dt-GCT) received an arthroplasty (tables 1 and 2).
 Clinical, pathological, radiological, treatment, and follow-up information were 
assessed by 2 independent reviewers (FGMV and AS). Any disagreements were 
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resolved by consensus with a third reviewer (HWBS). Recurrences, treatment 
complications, functional scores, and quality of life (QoL) were documented 
according to t-GCT subtype and location. During the regular hospital visits, QoL 
questionnaires were used and function scores were taken.
 QoL was evaluated by using the Dutch translation of a generic QoL instrument, 
the 36-item Short Form health survey (SF-36)154 and the 20-item Checklist 
Individual Strength (CIS20r) questionnaire.155 14 patients participated, and the 
other 3 patients were lost to follow-up. 1 patient did not complete all the questions 
in the CIS20r questionnaire, so it could not be used.
 Scoring systems used to evaluate function were the standardized Western 
Ontario and McMaster Universities osteoarthritis index (WOMAC)156, the Knee 
Society score (KSS)157, and the Harris hip score (HHS)158. The data were extracted 
from database records. We managed to collect function scores from all but 1 
patient.
Ethics
The study protocol (2012/555) was assessed by our institutional review board (the 
research ethics committee of the Radboud University Nijmegen Medical Centre) 
and was carried out in the Netherlands in accordance with the applicable rules 
concerning the review of research ethics committees.
Results
Hip
5 patients received a hip arthroplasty. 4 had Dt-GCT and 1 had Lt-GCT. 2 were 
women aged 20 and 25 years and 3 were men aged 36, 44, and 49 years. The 
indication for total hip arthroplasty (THA) was extensive disease (n = 3) and 
secondary osteoarthritis (n = 1). In the fifth patient, Lt-GCT was an incidental 
finding. The mean overall follow-up after arthroplasty was 8.6 (7–15) years (table 1).
 3 primary patients received their arthroplasty within 1.5 years of diagnosis 
(table 1). 1 patient with recurrent disease had a surgical synovectomy followed by 
an unsuccessful yttrium radiosynovectomy elsewhere. 4 years after diagnosis, this 
patient was treated at our tertiary center using a 3-stageprocedure. During almost 
15 years of follow-up, no recurrences or complications occurred (tables 1 and 2).
 Another patient who was initially treated using a 3-stage procedure for 
extensive disease (table 2) first had an anterior luxation immediately after THA 
with acetabular bone impaction grafting, followed by a cup revision after a trauma 
5 years later (without any evidence of recurrent disease), and finally had 
histologically proven recurrent disease 4 years after that. This recurrent disease 
524982-L-bw-Verspoor
Processed on: 3-10-2018 PDF page: 115
115
6
ARTHROPLASTY
was treated with a synovectomy, additional cryosurgery, and removal of osteosynthesis 
material that had been placed during the initial THA (table 2).
Quality of life
An SF-36 score was obtained for 4 of the 5 patients, on average 10 (6–15) years after 
arthroplasty. 2 patients scored low (> 1 SD below the means for the general 
population155) on Vitality and General health perception and 1 of these 2 patients 
also scored low on Physical functioning, Social functioning, Role limitations due 
to physical problems, General mental health, and Bodily pain (table 3, see 
Supplementary data).
 CIS20r was obtained for 4 patients, on average 10 (6–15) years after arthroplasty. 
Compared to healthy individuals155, 1 patient scored high (> 1 SD above healthy 
individual means) on all 4 domains: Fatigue, Concentration, Motivation, and 
Physical activity (table 4, see supplementary data).
Function scores
A Harris hip score was obtained for all 5 THA patients, on average 6.8 (4–13) years 
after arthroplasty. 4 patients scored excellent (90–99) and 1 patient scored fair (77) 
(Table 5, see Supplementary data).
Knee
12 patients, 4 with Lt-GCT and 8 with Dt-GCT, received a knee arthroplasty, 6 
women (mean age 58 (48–63) years) and 6 men (mean age 54 (33–73) years). 
Indications for arthroplasty were extensive disease (n = 6), secondary osteoarthritis 
(n = 3), and an incidental finding (n = 3) (Tables 1 and 2). The mean overall follow-up 
period after arthroplasty was 5.5 (0.2–13) years (Table 1).
 Patient 7 (Lt-GCT) received a total knee arthroplasty (TKA) for osteoarthritis 
almost 7 years after diagnosis of t-GCT. Rehabilitation was complicated by stiffness, 
which was treated by manipulation under anesthesia. 2 other patients with 
osteoarthritis received a TKA, 8 and 38 years after diagnosis of Dt-GCT.
 The 6 patients who were treated for extensive disease received an arthroplasty 
on average 9 (1.6–17) years after diagnosis (Table 1). These patients had 0–4 
recurrences before arthroplasty and 1 recurrence diagnosed by ultrasound after 
TKA with so far no intervention. 2 patients suffered postoperative complications 
after TKA. 1 patient had neuropathic pain, which was treated with surgical 
neurolysis (figure 1). Another patient experienced stiffness, which was treated by 
manipulation under anesthesia. This last patient also developed medial tibial 
component loosening 6 years after arthroplasty, followed by revision surgery. No 
recurrent disease, polyethylene wear, or infection was found.
524982-L-bw-Verspoor
Processed on: 3-10-2018 PDF page: 116
116
CHAPTER 6
Quality of life
SF-36 was obtained for 10 patients, on average 4.6 (0.2–11) years after arthroplasty. 
5 patients scored low (> 1 SD below the means for the general population) on 
General health perception; 4 on Physical functioning, Role limitations due to 
physical problems, Vitality, and Health change; 3 on Social functioning, General 
mental health, and Bodily pain; and 2 on Role limitations due to emotional 
problems (table 3, see supplementary data).
 CIS20r was obtained for 9 of the patients, on average 4.6 (0.2–11) years after 
arthroplasty. Compared to healthy individuals155, 2 patients scored high (> 1 SD above 
Table 1   Details of t-GCT patients treated with arthroplasty: demographics, indications,  
recurrences and time of follow up
ID Gender Age at 
diagnosis
(yrs)
Type
t-GCT
Side FU (yrs)
prior to
arthroplasty
N
previous
recurrence(s)
Indication
for 
arthroplasty
Age at
prosthesis 
(yrs)
Implant FU (yrs)
after
arthroplasty
N Recurrence(s)
after
arthroplasty
Knee
5 F 55 Diffuse L 7.5 4 Extended disease 62 TKA 5.9 1 On ultrasound
7 F 41 Localized L 6.8 0 Osteoarthritis 48 TKA 3.3 0
22 F 61 Localized L 0 0 Incidental 61 PF 8.3 0
32 F 44 Diffuse R 8.4 2 Extended disease 52 TKA 0.2 0
40 M 38 Diffuse L 17.4 2 Extended disease 56 TKA 3.5 0
44 F 60 Diffuse L 1.6 0 Extended disease 62 TKA 5.3 0
56 F 47 Diffuse R 16.2 1 Extended disease 63 TKA 5.4 0
69 M 62 Localized R 0 0 Incidental 62 TKA 12.9 0
75 M 28 Diffuse R 8.1 1 Osteoarthritis 36 PF 10.8 0
105 M 73 Localized L 0 0 Incidental 73 HP 6.3 0
120 M 24 Diffuse R 37.9 1 Osteoarthritis 62 TKA 2.3 0
132 M 30 Diffuse R 3.2 3 Extended disease 33 TKA 2.1 0
Hip
1 M 44 Diffuse R 0.5 1 Extended disease 44 THA 10.7 1 Histological confirmed
3 M 34 Diffuse R 1.5 1 Extended disease 36 THA 8.4 0
34 V 24 Diffuse R 0.7 1 Osteoarthritis 25 THA 7.0 0
92 M 49 Localized R 0 0 Incidental 49 THA 10.7 0
115 V 16 Diffuse R 4.3 2 Extended disease 20 THA 14.6 0
TKA= total knee arthroplasty, PF= patella femoral arthroplasty, HP= hemi arthroplasty knee, THA= total 
hip arthroplasty. 
The follow-up prior to arthroplasty was defined as the period between first pathologic conformation of 
diagnosis and arthroplasty. The follow up after arthroplasty was defined as the period between 
arthroplasty and most recent patient contact. Time to recurrence after arthroplasty was calculated as 
the time from joint arthroplasty until histological proven recurrent disease, or highly susceptive 
recurrent disease on ultrasound.
524982-L-bw-Verspoor
Processed on: 3-10-2018 PDF page: 117
117
6
ARTHROPLASTY
the means for healthy individuals) in all 4 domains, i.e. Fatigue, Concentration, 
Motivation, and Physical activity, and 1 patient scored high on the Motivation and 
Physical domains (table 4, see supplementary data).
Function scores 
WOMAC156 and KSS157 were obtained for all but 1 patient, at an average of 3.7 
(0.2–11) years after arthroplasty. According to the standardized WOMAC sum 
scores (0–100), higher values indicate less pain, less stiffness, or better physical 
functioning.159 2 knee patients scored below 50 on all subscales. 3 other knee 
patients had less than 70 in the total score; in particular, they had low scores on 
the Stiffness and Physical functioning subscales. On the KSS Object knee score, 7 
patients had excellent results (80–100), 1 had good results (70–79), and 3 had poor 
results (< 60). On the KSS Function knee score, 6 patients had excellent results 
(80–100) and the other 5 patients had poor results (< 60), as with the low WOMAC 
scores in these 5 patients (table 6, see supplementary data). 
Table 1   Details of t-GCT patients treated with arthroplasty: demographics, indications,  
recurrences and time of follow up
ID Gender Age at 
diagnosis
(yrs)
Type
t-GCT
Side FU (yrs)
prior to
arthroplasty
N
previous
recurrence(s)
Indication
for 
arthroplasty
Age at
prosthesis 
(yrs)
Implant FU (yrs)
after
arthroplasty
N Recurrence(s)
after
arthroplasty
Knee
5 F 55 Diffuse L 7.5 4 Extended disease 62 TKA 5.9 1 On ultrasound
7 F 41 Localized L 6.8 0 Osteoarthritis 48 TKA 3.3 0
22 F 61 Localized L 0 0 Incidental 61 PF 8.3 0
32 F 44 Diffuse R 8.4 2 Extended disease 52 TKA 0.2 0
40 M 38 Diffuse L 17.4 2 Extended disease 56 TKA 3.5 0
44 F 60 Diffuse L 1.6 0 Extended disease 62 TKA 5.3 0
56 F 47 Diffuse R 16.2 1 Extended disease 63 TKA 5.4 0
69 M 62 Localized R 0 0 Incidental 62 TKA 12.9 0
75 M 28 Diffuse R 8.1 1 Osteoarthritis 36 PF 10.8 0
105 M 73 Localized L 0 0 Incidental 73 HP 6.3 0
120 M 24 Diffuse R 37.9 1 Osteoarthritis 62 TKA 2.3 0
132 M 30 Diffuse R 3.2 3 Extended disease 33 TKA 2.1 0
Hip
1 M 44 Diffuse R 0.5 1 Extended disease 44 THA 10.7 1 Histological confirmed
3 M 34 Diffuse R 1.5 1 Extended disease 36 THA 8.4 0
34 V 24 Diffuse R 0.7 1 Osteoarthritis 25 THA 7.0 0
92 M 49 Localized R 0 0 Incidental 49 THA 10.7 0
115 V 16 Diffuse R 4.3 2 Extended disease 20 THA 14.6 0
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Table 2   All treatments t-GCT patients received before and after arthroplasty,  
including complications and implant information.
Treatments Implant information
ID Center 1e 2e 3e 4e 5e Implant Type of implant
Knee
5 Referred SEa + ME SE Two stage SE + Cryo + RT TKA PS, PFC, cemented PFC ® SIGMA ® 
TC3 Knee System - DePuy Synthes
7 Primary Nodulectomy Arthrotomy* Arthroscopy* TKAc, * MUA* PS, cemented PFC ® SIGMA ®
TC3 Knee System - DePuy Synthes
22 Primary Patella fracture  OSM PFi PF, cemented Smith & Nephew
pat-mod III long femoral
32 Primary 2-stage SE SE +TKA neurolyse* PS, PFC, cemented PFC ® SIGMA ®
TC3 Knee System - DePuy Synthes
40 Referred SE SE 2-stage + Cryo
+ TKA
PS, cemented PFC ® SIGMA ®
TC3 Knee System - DePuy Synthes
44 Primary SE + TKAc MUA* Revision tibia* CR, cemented PFC ® SIGMA ®
TC3 Knee System - DePuy Synthes 
With extended stem tibia (3cm)
56 Primary SE SE + TKA PS, PFC, cemented PFC ® SIGMA ®
TC3 Knee System - DePuy Synthes
69 Referred TKAi CR, PFC, cemented Genesis II prosthesis
75 Referred Yttrium 2-stage PF* PF, cemented Smith & Nephew
pat-mod III long femoral
105 Referred TKAi HP, cemented Oxford
120 Primary SE Yttrium TKA* PS, PFC, cemented PFC ® SIGMA ®
TC3 Knee System - DePuy Synthes
132 Referred SE SE SE + Yttrium Imatinib no response SE + TKA PS, PFC, cemented Nexgen
Hip
1 Primary 3-stage + Cryo + 
THAh with acetabular BIG 
Cup revision*j SE + Cryo
+ remove OSM
THA, BIG, cemented Exeter stem, contemporary cup,
bone allograft, mesh, Kreutzschale
3 Referred SE with luxation THA THA, cemented Exeter stem, contemporary cup
34 Primary SE THA* THA, BIG, cemented Exeter stem, contemporary cup,
bone allograft
92 Referred THAi THA, cemented Exeter stem, contemporary cup
115 Referred SE Yttrium 3-stage + Cryo
+ THA
THA, uncemented Link screw in cup MP ® reconstruction 
prosthesis
SE= surgical synovectomy, ME= partial meniscectomy, OSM= osteosynthesis material,  TKA= total knee 
arthroplasty (i= incidental finding), PF= patella femoral arthroplasty, HP= hemi arthroplasty knee, THA= 
total hip arthroplasty *= treatment not for recurrent disease, 2-stage= an anterior synovectomy followed 
by a posterior synovectomy 4-6 weeks later, 3-stage= a complete synovectomy followed by a second look 
with excision of residual disease and arthroplasty in a 3rd procedure, Cryo= per operative additional 
cryosurgery, BIG= Bone impaction grafting, Yttrium= radiosynovectomy with Yttrium, MUA= manipulation 
of the knee under anesthesia, RT= external beam radiation therapy, PS = posterior stabilized, PFC= patella 
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Table 2   All treatments t-GCT patients received before and after arthroplasty,  
including complications and implant information.
Treatments Implant information
ID Center 1e 2e 3e 4e 5e Implant Type of implant
Knee
5 Referred SEa + ME SE Two stage SE + Cryo + RT TKA PS, PFC, cemented PFC ® SIGMA ® 
TC3 Knee System - DePuy Synthes
7 Primary Nodulectomy Arthrotomy* Arthroscopy* TKAc, * MUA* PS, cemented PFC ® SIGMA ®
TC3 Knee System - DePuy Synthes
22 Primary Patella fracture  OSM PFi PF, cemented Smith & Nephew
pat-mod III long femoral
32 Primary 2-stage SE SE +TKA neurolyse* PS, PFC, cemented PFC ® SIGMA ®
TC3 Knee System - DePuy Synthes
40 Referred SE SE 2-stage + Cryo
+ TKA
PS, cemented PFC ® SIGMA ®
TC3 Knee System - DePuy Synthes
44 Primary SE + TKAc MUA* Revision tibia* CR, cemented PFC ® SIGMA ®
TC3 Knee System - DePuy Synthes 
With extended stem tibia (3cm)
56 Primary SE SE + TKA PS, PFC, cemented PFC ® SIGMA ®
TC3 Knee System - DePuy Synthes
69 Referred TKAi CR, PFC, cemented Genesis II prosthesis
75 Referred Yttrium 2-stage PF* PF, cemented Smith & Nephew
pat-mod III long femoral
105 Referred TKAi HP, cemented Oxford
120 Primary SE Yttrium TKA* PS, PFC, cemented PFC ® SIGMA ®
TC3 Knee System - DePuy Synthes
132 Referred SE SE SE + Yttrium Imatinib no response SE + TKA PS, PFC, cemented Nexgen
Hip
1 Primary 3-stage + Cryo + 
THAh with acetabular BIG 
Cup revision*j SE + Cryo
+ remove OSM
THA, BIG, cemented Exeter stem, contemporary cup,
bone allograft, mesh, Kreutzschale
3 Referred SE with luxation THA THA, cemented Exeter stem, contemporary cup
34 Primary SE THA* THA, BIG, cemented Exeter stem, contemporary cup,
bone allograft
92 Referred THAi THA, cemented Exeter stem, contemporary cup
115 Referred SE Yttrium 3-stage + Cryo
+ THA
THA, uncemented Link screw in cup MP ® reconstruction 
prosthesis
femoral component, CR= Cruciate retaining. Perioperative complications included; delayed wound 
healinga, stiffnessc, neurolysise, hip luxationh, traumatic cup displacementj.
Primary patients received all treatments at our institution; referred patients had their initial treatment(s) 
elsewhere. A three stage procedure in hip joint patients implies a complete synovectomy, followed by a 
second look with excision of residual disease and arthroplasty in a third planned procedure. For the knee 
a two stage procedure starts with an anterior synovectomy, followed by a posterior synovectomy four to 
six weeks later.
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Discussion
Indications
In this study, t-GCT patients with extensive disease and/or degenerative joint disease 
following treatment(s) were eligible for arthroplasty. Also, there were patients 
who were preoperatively assumed to have osteoarthritis which (during operation) 
turned out to be t-GCT. Other authors have found similar indications for arthroplasty 
in t-GCT patients.30,160,161 Furthermore, unusual cases of t-GCT first presenting 
after TKA have been described.160,162
 In general, patients with t-GCT in the hip received their arthroplasty over 20 
years earlier than patients with t-GCT of the knee. An explanation for this age 
difference might be that lesions involving the hip joint are associated with a 
higher incidence of bony erosion and cyst formation compared to those involving 
the knee. Some investigators have hypothesized that the smaller intra-articular 
space in the hip does not allow the tumor to expand without causing increased 
pressure on the femoral and acetabular cartilage.76 
 THA has been performed in young patients, with good results. However, 
the authors of a long-term follow-up evaluation of THA advised caution with this 
procedure in younger patients because of high failure rates.163
Figure 1  Gradient-echo-based MRI image from a patient with recurrent t-GCT (right knee). 
There was very low signal intensity corresponding to hemosiderin depositions anterior to the lateral 
meniscus, extending to the infrapatellar fat pad. Furthermore, there was a hemosiderin deposition in 
the recessus lateralis posterior to the lateral femoral condyle. These localizations corresponded to 
recurrent Dt-GCT, which was confirmed by surgical removal.
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Recurrences
2 recurrences were found in our patient group; both of these Dt-GCT patients were 
treated for extensive disease. The recurrence after THA was histologically proven. 
The recurrence after knee arthroplasty was diagnosed and followed on ultrasound. 
There have been case reports of recurrent t-GCT being diagnosed with arthroscopy 
or during revision arthroplasty.162 However, with the improved visualization of 
periprosthetic soft tissues on MRI, diagnosis of recurrent t-GCT after total joint 
arthroplasty should no longer be a difficulty.164
 Gitelis et al.165 reported on 28 patients in whom synovectomy was combined 
with hip arthroplasty (15 cup arthroplasties, 10 THAs, and 3 hemiarthroplasties—1 
of which was subsequently converted to a THA). The average follow-up time was 3.6 
years, with 1 recurrence.
 In our study, the 2 recurrences occurred 6 and 9 years after arthroplasty, 
indicating that the number of recurrences may increase further with longer 
follow-up times. These 2 patients with recurrent disease had a staged procedure 
before arthroplasty. In hip arthroplasty, clearance of diseased tissue was done 
before implantation, to minimize the chance of recurrent disease. However, 1 of 
the 2 hip patients who underwent a staged procedure showed recurrent disease. 
A meta-analysis of t-GCT in hips showed a recurrence rate of 4% with surgical 
synovectomy and total joint arthroplasty as compared to a rate of 28–50% after 
treatment with surgical synovectomy alone. The indication for additional 
arthroplasty depended on the extent of disease and on cartilage damage.59
 With extensive Dt-GCT, extra-articular lesions are often encountered, e.g. in 
the head of one of the gastrocnemius muscles (figure 2). In these cases, all 
pathological tissue should be removed before joint arthroplasty, to reduce the risk 
of residual and/or recurrent disease. To ensure removal of all pathological tissue, 
before arthroplasty a staged procedure should be considered in these diffi-
cult-to-cure patients.
Complications
We had 2 cases of aseptic loosening 5 and 6 years after arthroplasty, but not recurrent 
disease. Hamlin et al.129 (1998) described 18 patients who underwent TKA, 14 with 
Dt-GCT and 4 with Lt-GCT. There were 3 cases of aseptic loosening, 1 of them with 
recurrent disease. Another patient with recurrent disease needed an above-the-knee 
amputation.
 Other complications, such as stiffness requiring manipulation and neuropathic 
pain requiring neurolysis, have been reported in patients undergoing arthroplasty.166 
However, this patient group is possibly more prone to develop these kinds of 
complications from limited joint function preoperatively, due to the disease itself 
or to previously received treatments.42
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Quality of life
In 5 patients, we found reduced QoL scores compared to the general population.154 
Recently, 2 other publications had QoL scores for t-GCT patients20,42 but these 
scores were not reported for t-GCT patients treated with arthroplasty.
Joint function
We found reduced joint function after arthroplasty in 5 of the 12 t-GCT knee 
patients, mainly due to stiffness (table 6, see supplementary data). It has been 
reported that preoperative joint function is a predictor of postoperative TKA 
function.167 In general, reduced preoperative joint function in t-GCT patients is 
related to disease severity or the often multiple treatments in the past.75 Similar 
results have been reported for postoperative hip function.168 However, 4 out of 5 of 
our hip arthroplasty patients had excellent Harris hip scores. Gitelis et al.165 
reported that after an average follow-up of 5 years, 24 of 28 patients treated with 
primary hip arthroplasty had satisfactory results and 4 had poor results. The poor 
results were due to mechanical failure of the implants.165 
 Our hip arthroplasty patients had better function scores than our knee patients, 
which might be explained by their younger age and shorter course of disease. 
Taking disease-induced loss of joint function into consideration, joint function 
outcomes may be better with earlier joint arthroplasty. It may also reduce the 
chances of recurrent t-GCT, as the disease is less extensive and therefore easier to 
eradicate. However, early joint arthroplasty might result in higher revision rates.
Figure 2  Gradient-echo-based MRI image from a patient with recurrent t-GCT (left knee). 
There was very low signal intensity corresponding to hemosiderin depositions, particularly in the posterior 
compartment of the joint and in the popliteal fossa. There was also osseous destruction.
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Limitations
The retrospective character of this study, the small number of patients, the 
different indications for arthroplasty, and the different implants used should not 
go unnoticed. It is difficult to perform a prospective study with adequate patient 
numbers, because of the low incidence of t-GCT and the years of delay before local 
recurrence may occur. Complete information regarding subtypes, location, 
arthroplasty, and other treatments was available, including long-term follow-up. 
Because of this, the information could possibly be used in future (meta-)analyses to 
obtain evidence regarding arthroplasty in the treatment of t-GCT. Furthermore, 
patients with localized t-GCT as an incidental finding should be differentiated 
from those with diffuse recurrent and extensive t-GCT, as localized disease 
behaves less aggressively.
 It should also be noticed that QoL and function scores were taken at variable 
points after arthroplasty. To our knowledge, this is the first study to report QoL 
measures in t-GCT patients who underwent arthroplasty. QoL is important in a 
disease as disabling as t-GCT. Further studies should investigate whether or not the 
reduced QoL in this specific patient group is a consequence of the disease itself, of 
the arthroplasty, of the (multiple) treatment(s) received, or of other factors, such as 
comorbidities or issues not related to disease.
 In summary, in t-GCT patients with extensive disease or osteoarthritis, arthroplasty 
is an additional treatment option after surgical synovectomy. However, recurrences, 
implant loosening, and other complications do occur, even after years of follow-up.
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Table 4   Quality of life in CIS20r scores at the last follow up, for t-GCT patients  
after arthroplasty.
Follow-up
(yrs) after
arthroplasty
CIS20r
ID Fatigue Concentration Motivation Physical  Total
Knee
5 4.0 8 5 4 3 20
7 NA NA NA NA NA NA
22 NA NA NA NA NA NA
32 0.2 27 12 13 21 73
40 7.8 21 8 4 10 43
44 4.4 18 5 21 11 55
56 5.4 9 5 4 5 23
69 4.0 9 5 4 4 22
75 10.8 50 30 23 17 120
105 NA NA NA NA NA NA
120 2.3 33 21 13 13 80
132 2.1 17 11 4 3 35
Hip
1 10.2 18 10 8 9 45
3 6.3 16 5 5 4 30
34 7.0 12 5 4 7 28
92 NA NA NA NA NA NA
115 14.6 45 19 18 18 100
Healthy individuals 
mean (SD)
17.3 (10.1) 9.5 (5.0) 7.9 (4.1) 6.6 (4.5) 41.5 (19.8)
CIS20r= 20-item Checklist Individual Strength questionnaire, NA= not available. High scores (>1SD above 
healthy individual means) indicate a high level of fatigue, a high level of concentration problems, low 
motivation and a low level of physical activity.
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Table 5   Joint function in HHSs for t-GCT patients after hip prosthesis implantation.
Follow-up in years Harris Hip Score
ID after arthroplasty implantation Total
1 7.9 90
3 6.3 95
34 4 95
92 9.9 99
115 12.5 77
In the Harris Hip Score (HHS), activities of daily living and gait account for 47 points, pain for 44, joint 
movement for 5 and absence of deformity for 4 in a total of 100. Harris defined 90 to 100 points as 
excellent, 80 to 90 as good, 70 to 80 as fair and below 70 as poor.
Table 6   Joint function in WOMAC and KSS scores for t-GCT patients after knee arthroplasty. 
Follow-up
(yrs)
WOMAC KSS
ID FU post Pain Stiffness Physical Total Object Function Total
5 4.0 75 75 76.5 76.0 87 80 167
7 1.7 65 62.5 85.3 79.2 84 90 174
22 0.5 70 75 69.1 69.8 71 55 126
32 0.2 70 50 57.4 59.4 53 40 93
40 6.8 95 100 98.5 97.9 94 100 194
44 5.3 75 50 66.2 66.7 88 40 128
56 3.0 100 100 88.2 91.7 93 80 173
69 4.0 85 75 88.2 86.5 84 90 174
75 10.8 30 0 22.1 21.9 53 50 103
105 NA NA NA NA NA NA NA NA
120 2.3 45 37.5 47.1 45.8 53 50 103
132 2.1 95 75 95.6 93.8 94 100 194
NA= not available, WOMAC= standardized Western Ontario and McMaster Universities Osteoarthritis 
Index, KSS=Knee Society Score. In the standardized WOMAC (0-100) sum scores, higher values indicate 
less pain, stiffness or better physical functioning. On the KSS scores were defined excellent (80-100), good 
(70-79), fair (60-69) or poor (<60).
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Abstract
Tenosynovial giant cell tumors (TGCT) emerge from the synovium and can behave 
aggressively. Surgical resection is the standard treatment. However, up to half of 
the patients with diffuse-type show recurrences. Several additional treatments 
have been applied to reduce recurrences, none of these treatments was proven to 
be superior to surgical resection solely. This article describes the results of 
additional cryosurgery to surgical resection.
 We retrospectively evaluated 141 TGCT patients, between 1999 and 2007. 
Twelve patients had additional cryosurgery. The knee (n=8), hip (n=2), ankle (n=1) 
and elbow (n=1) were affected. Primary outcome variables were treatment indications, 
recurrences and complications.
 Indications for additional cryosurgery were extended disease, bone involvement 
and surgical key locations difficult get disease free. Five patients had recurrent 
disease, all of which had prior treatments. None of the primary treated patients 
had recurrent disease. One patient had a deep infection. 
 Cryosurgery may serve as an additional treatment for diffuse TCGT in selected 
cases. However, because of the small number of patients and the heterogeneous 
group we could not prove an advantage of additional cryosurgery over surgical 
resection only. Cryosurgery should be considered for further evaluation in a 
prospective study. If there is any effect it would be helpful, especially in patients 
with multiple TGCT recurrences. 
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Introduction
The tenosynovial giant cell tumor (TGCT), formerly known as pigmented 
villonodular synovitis (PVNS), is a rare proliferative disorder originating from the 
synovial membrane. Its annual incidence is described as 1.8 per million US 
citizens.4 TGCT has a neoplastic origin, with a reactive component based on 
specific genetic changes.9,12 Although TGCT can behave locally aggressive, it is 
considered a benign disorder.9 Two subtypes have been described, 1), the less 
aggressive, localized form (LTGCT), which usually is a single nodular lesion, and 2) 
the diffuse form (DTGCT), which usually affects the whole joint and frequently 
recurs (14-55%).41,76 The knee (75%) is the most frequently affected joint, followed 
by the hip, ankle, elbow and other synovial joints.9 
 The recommended treatment for TGCT is surgical resection of all affected 
tissue.76 Incomplete resection or multiple treatments can result in functional 
impairment.11 With extended or recurrent disease, several additional treatments 
(e.g. External Beam Radiotherapy (EBRT), radiosynovectomy, immune and targeted 
therapy) have been applied to reduce recurrence rates.76 None of these treatments 
was proven to be superior to surgical resection on its own, which makes aggressive, 
persistently recurrent TGCT difficult to cure.76
 Cryosurgery, in the form of liquid nitrogen spray, is widely used as an additional 
treatment for various bone tumors.131 In order to try to reduce recurrence rates, we 
started using cryosurgery as an additive treatment to surgical resection of TGCT in 
selected cases. Mohler and Kessler49 reported on the successful treatment of three 
TGCT patients through surgical synovectomy combined with cryosurgery. To the 
best of our knowledge, there are no other publications that describe cryosurgery as 
an additive treatment to surgical resection, in the treatment of TGCT.
 We retrospectively evaluated TGCT patients treated with cryosurgery in 
addition to surgical synovectomy, with respect to the indication for additional 
treatment(s), the number of recurrences and complications.
Materials and methods
We retrospectively searched pathologic and radiologic reports in the hospital 
database with the keywords ‘pigmented villonodular synovitis’, ‘local tenosynovitis’, 
and ‘giant-cell tumor of the tendon sheath’. Between 1985 and 2014, 141 TGCT 
patients were identified; 48 (34%) with localized and 93 (66%) with diffuse disease. 
According to operative reports, cryosurgery was used in 12 patients, between 1999 
and 2007. Clinical, pathological, radiological, treatment and follow up information 
was obtained from medical records. The study protocol (CMO2015-1915) was 
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assessed by our institutional review board (the research ethics committee of the 
Radboud University Nijmegen Medical Centre) and was carried out in the Netherlands 
in accordance with the applicable rules concerning the review of research ethics 
committees and informed consent.
 There was no protocol for the use of additional cryosurgery. All patients with 
extended or recurrent disease were discussed in a multidisciplinary team (medical 
oncology, radiotherapy, surgical oncology, orthopedic surgical oncology). However, 
eventually it was the surgeon’s call for each individual case whether or not to use 
cryosurgery. In the 12 patients that received additional cryosurgery the knee (n=8), 
hip (n=2), ankle (n=1) and elbow (n=1) were affected. All diagnoses were histologically 
confirmed. One patient (elbow) had localized disease; all other patients had diffuse 
disease. The mean age at the time of cryosurgery was 39 (range 21-61) years. All 
patient characteristics are listed in table 1. 
 Cryosurgery was used in addition to a surgical synovectomy. After complete 
removal of the affected tissue, the non-cartilaginous surface of the joint (synovium, 
joint capsule, bone) was treated with three cycles of liquid nitrogen spray. All frozen 
tissue got to at least -50°C. Spontaneous thawing warmed the tissue up to 20°C. 
After three cycles of rapid cooling and spontaneous thawing the entire wound was 
lavaged with sodium hyponitrate to prevent seeding of tumor cells. A healthy 
circulation (no use of a tourniquet) is important to protect neurovascular 
structures and the skin.131,169 To our knowledge there is no literature available yet 
on costs of cryosurgical treatment. However, we would estimate a maximal extra 
surgical time of 15 minutes (i.e. three times 5 minutes, quick freeze and slow 
thawing). The materials needed for cryosurgery are a little container and 
temperature sensors. Liquid nitrogen costs 10 euro cents a liter and we use less 
than a liter for one patient. Details of all received treatments are listened in table 1.
 Between 1985 and 2014 our follow up protocol has changed from an intensive 
follow up with 3 monthly visits, including a MRI every 6 months, to only a single 
clinical follow up visit 3 months postoperatively with additional visits when 
clinical symptoms appear, a ‘wait and see policy’. 
 Outcomes were the indications for additional cryosurgery, recurrent disease 
and complications. To be able to formulate indications for cryosurgery we scored 
extra-articular disease, large expansion (described in operative reports as; 
extensive or bulky disease or when two or more compartments of the knee were 
involved), bone involvement and involvement of the cruciate ligaments. Local 
recurrent disease was defined as histological proven recurrent disease.
 Descriptive statistics were used to summarize the data. No further analyses 
were performed because of the small number and diversity of patients.
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Results
Of the 141 identified TGCT patients, 12 patients received additional cryosurgery. 
In the 129 patients without additional cryosurgery, 82 had diffuse disease. 
Fourteen of these patients had no treatment at our tertiary center. In 68 patients 
treated at our center the knee (n=59), hip (n=3), ankle (n=5) and elbow (n=1) were 
affected. Three patients were lost to follow up. The mean time from first treatment 
to follow up was 10 (range 0.6-41) years.
Indications for cryosurgery
In the 12 cryosurgical patients, five had primary disease and seven had prior 
treatments (1-3 previous treatments). The mean time from diagnose to cryosurgical 
treatment was 4.5 (range 0.5-6.3) years. In 10 out of 12 patients, the entire intra-ar-
ticular space was affected with extension in surrounding structures, such as bone, 
ligaments, fat and muscle tissue. All were diffuse type TGCT. Seven of these 
patients had extra-articular disease. The cruciate ligaments of the knee were 
involved in 6 out of 8 patients. In 7 out of 12 patients (n=4 knees, n=2 hips, n=1 
ankle) there was bone involvement. Bone involvement and extended disease were 
reported to be indications for additional cryosurgery to surgical synovectomy. 
 In one patient with localized disease of the elbow, we retrospectively did not 
find the considerations for additional cryosurgery. Probably the surgeon wanted to 
minimize the chance on recurrent disease in this location.
 In patients with DTGCT of the knee (n=59), 19 patients had extra articular 
disease, 4 patients had bone involvement, 52 patients had intracondylar involvement 
and 55 had extended disease or a combination of two, three or all four of these 
features. All five ankles had extended disease with extra-articular involvement, 
and one of these patients also had bony involvement.
Recurrences
The mean follow up after cryosurgery was 7.7 (range 5.5-14.9) years. Five patients 
with the diffuse subtype developed recurrent disease after cryosurgery, at a mean 
time of 2.8 (range 0.7-9.0) years. All recurrences were diagnosed on MRI, which was 
performed when clinical symptoms of any kind in or nearby the affected joint 
presented. Four were also histologically confirmed.  None of these five patients had 
primary disease, they already had recurrent disease at the time of cryosurgical 
therapy. One patient with recurrent disease  received EBRT following initial 
cryosurgery. Another patient received a total hip arthroplasty (THA) during the 
same surgical procedure.
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Three out of five patients with recurrent disease after cryosurgery developed a 
second or even third recurrence. Treatments following these recurrences are listed 
in table 2.
 All four recurrences in patients with TGCT of the knee occurred within 2 years 
(9-22 months) after treatment. These patients had extended disease with involvement 
of the cruciate ligaments. In two patients with recurrent disease there was extra- 
articular disease and in one there was bone involvement. In the four knee patients 
without recurrences (of whom three were primary treated and one was treated 
with additional EBRT following cryosurgery), three had extended disease with 
bone involvement. 
 In the two patients with TGCT of the hip, one recurrence occurred nine years 
after cryosurgery. It was the third recurrence since onset of disease. At the time of 
cryosurgery, the acetabulum was affected by TGCT. Both patients also received a 
total hip arthroplasty for joint destruction by extended disease combined with 
secondary osteoarthritis. In both ankle and elbow, no recurrences were seen.
In patients with diffuse type disease whom did not receive additional cryosurgery 
30 (44%) had recurrent disease. The mean time to first recurrence was 4.7 (range 
0.7-27) years. All referred knee patients (n=26) had recurrent disease. Nine (34.6%) 
of these patients developed another recurrence after treatment at our center in 1.7 
(range 0.7-4.4) years. In primary treated knee patients 16 (55%) had recurrent 
disease in 6.4 (range 1-27) years.
 Twenty seven patients (40%) had extra-articular disease, 6 (9%) had bone 
involvement, 52 (77%) had involvement of the cruciate ligaments and in 64 (94%) 
patients there was extended disease or a combination of two, three or all four of 
these features. For example, in the 27 patients with extra-articular disease 6 had 
bone involvement, 18 had affected cruciate ligaments and all 27 had extended 
disease. Eighteen of these patients had recurrent disease in 7 (0.8-17) years follow 
up. The time to first recurrence was 1.9 (0.7-4.1) years. And 11 recurrences appeared 
after treatment at our center. All 6 patients with bone involvement had extra-artic-
ular disease and extended disease, including 4 patients with affected cruciate 
ligaments. Five of these patients had recurrent disease in 11 (2-17) years follow up. 
The time to first recurrence was 1.8 (1.2-3.2) years. Three recurrences appeared 
after treatment at our center.
 Of five patients with TGCT in the ankle 4 had recurrent disease, two of which 
were primary treated patients. The mean time until first recurrence was 2.7 
(1.2-4.1) years.
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Complications 
Two complications were reported in the cryosurgical group (table 2): A hip dis- 
location direct after arthroplasty, which was closed reduced. And a deep infection of 
the knee, three months after surgery, which was treated with surgical debridement 
and antibiotics.
Discussion
TGCT is difficult to cure; in particular, the diffuse subtype frequently recurs. The 
treatment of first choice is surgical resection of all affected tissue. However, with 
extended and/ or extra-articular disease, bone involvement or disease at key 
locations inside the joint (ACL, PCL and collateral ligaments), resection of all 
affected tissue can be difficult to achieve. Various treatments (e.g. radiosynovecto-
my, EBRT, immune or targeted treatment) have been used, without the desired 
results.76 We retrospectively evaluated the effect of additional cryosurgery in the 
treatment of TGCT.
 We found indications of cryosurgery in addition to surgical resection for 
TGCT, were the presence of extended, extra-articular disease, affected bone or 
locations surgically difficult to get disease free, such as the cruciate ligaments. 
Furthermore, no recurrent disease was observed in patients primary treated with 
surgical synovectomy combined with cryosurgery. In patients known with 
recurrent disease additional cryosurgery was not effective.
 Various indications were described for additional therapies in the treatment 
of TGCT.76 The indications found for cryosurgery were similar to those considered 
for EBRT, except for patients with involvement of the neurovascular bundle. 
Cryosurgery is contraindicated in these patients. Effectiveness of radiosynovecto-
my in the treatment of TGCT is not proven and does not cover the extra-articular 
space.41 Therefore, it is not indicated in patients with extended disease. 
Immunotherapy is not validated yet for the treatment of TGCT, however it has 
been applied in patients with extended disease.20,135 For the use of targeted 
therapy in the treatment of TGCT, only small case studies and one retrospective 
cohort (29 patients) are published so far.12,143,147,170 Due to the rapid relapse after 
discontinuation and severe side effects of targeted therapy, these treatments are 
only recommended for patients with surgical unresectable disease or multiple 
recurrences that produce clinical and functional impairment.170 Other systemic 
treatments are individually available in trial-settings.70
 Additional cryosurgery was not used after 2007 for different reasons: less 
extreme TGCT cases were presented the last years. The surgeon who often used 
cryosurgery for TGCT retired. Others preferred a more throughout resection of 
524982-L-bw-Verspoor
Processed on: 3-10-2018 PDF page: 138
138
CHAPTER 7
affected tissue. There were definitely no adverse effects of cryosurgery that made 
us stop using it.
 The number of recurrences in DTGCT with or without the use of cryosurgery 
were similar, respectively 45% after 2.8 years and 44% after 4.7 years. However, 
retrospectively it is difficult to determine if the patients in the cryosurgical group 
had worse disease compared to the other patients. In the cryosurgical group there 
was 90% extended disease, 64% extra-articular disease, 64% bone involvement and 
in 88% the cruciate ligaments were involved. The others had 94% extended disease, 
40% extra-articular disease, 6% bone involvement and in 77% involvement of the 
cruciate ligaments.
 In both groups there was a great difference in recurrences between referred 
patients versus primary treated patients. There were five (71%) recurrences after 
cryosurgery, in patients with prior treatments. Two out of seven patients with 
bone involvement had recurrent disease. None of the primary treated TGCT 
patients had recurrences after surgical synovectomy with cryosurgery. In the 
patients not treated with cryosurgery all referred knee patients showed recurrent 
disease of which 35% had recurrent disease after treatment at our center. There 
were 55% recurrences in the primary treated knee patients. 
 Mohler et al49  described the use of cryosurgery in addition to surgical 
synovectomy in three patients (25-31 years of age) with TGCT of the knee. Two of 
these patients were diagnosed with recurrent disease. Cryosurgery was used 
during their third treatment. The other patient had primary disease. Two patients 
had extended disease. But, no details of bone involvement or involvement of the 
cruciate ligaments were described. No recurrent disease was found after 14-31 
months follow up. However, TGCT recurrences are described up to 14 years later.171
 Although cryosurgery is uncommon in the treatment of TGCT, it has been 
described for orthopedic oncologic diseases.131 Reported complications as a result 
of cryosurgery are post-operative fractures (5-30%), infections (4%), transient nerve 
palsies and gas-embolisms (0.3%).131 Also, damage to surrounding structures, such 
as the epiphysis and cartilage, have been described. In case of  TGCT, the chance on 
fractures will be negligible though the intra-articular location. However, for this 
reason there might be an increased risk on damage to the joint cartilage. 
Furthermore, in TGCT the cartilage is often already damaged due to the disease 
itself, or to the multiple prior treatments. None of these complications were found 
in this study. However, one patient with recurrent disease after cryosurgery 
received a total knee arthroplasty for secondary osteoarthritis. Also, a 
post-operative dislocation of the hip and a deep infection of the knee three months 
after surgery occurred. These could be general complications after surgery; 
however, increased risk on infections have been described for cryosurgery.131
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Limitations
It is very difficult to produce a large volume study on treatment effects in a rare 
disease such as TGCT. For the subgroup of patients with extended disease, this is 
even more difficult. Therefore the study is limited by its retrospective character 
and the small number of patients. However, detailed information on received 
treatments was available and carefully described. Furthermore, some patients had 
other additional treatments next to cryosurgery, such as EBRT or arthroplasty 
what could have influenced our results. However, this was seen in both patient 
groups with and without recurrent disease. Despite these limitations, this article 
provides cautious insight for a possible role of cryosurgery in the treatment of 
TGCT. A prospective study with clear indications should follow to show if there is 
a role for cryosurgery in a subgroup of TGCT patients.
 We conclude, cryosurgery may serve as an additional treatment for diffuse 
TCGT in selected cases. However, because of the small number of patients and the 
heterogeneous group we could not prove an advantage of additional cryosurgery 
over surgical resection only. Cryosurgery is a cheap, easy and relative harmless 
technique that should be considered for further evaluation in a prospective study 
with a sufficiently large number of patients, clear indications and a proper control 
group. If there is any effect it would be helpful, especially in patients with multiple 
TGCT recurrences. 
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Abstract
Tenosynovial giant cell tumors (TGCT), are rare colony stimulating factor-1(CSF-1)-
driven proliferative disorders affecting joints. Diffuse-type TGCT often causes 
significant morbidity due to local recurrences necessitating multiple surgeries. 
Imatinib mesylate (IM) blocks CSF-1 receptor. This study investigated the long term 
effects of IM in TGCT.
 We conducted an international multi-institutional retrospective study to 
assess the activity of IM: data was collected anonymously from individual patients 
with locally advanced, recurrent or metastatic TGCT.
 Sixty-two patients from 12 institutions across Europe, Australia and the 
United States were identified. Thirty-nine patients were female (63%), median age 
at treatment start was 45 (range 20-80) years, with a median time from diagnose to 
treatment of 3.5 (range 0-38,2) years. Median follow-up after treatment start was 52 
(IQR 18-83) months. Four patients with metastatic TGCT progressed rapidly on IM 
and were excluded for further analyses. Seventeen of 58 evaluable patients 
achieved CR or PR. One- and five-year progression-free survival rates were 71% and 
48%, respectively. Thirty-eight (66%) patients discontinued IM after a median of 7 
(range 1-80) months. Reported adverse events in 45 (78%) patients were among 
other edema (48%) and fatigue (50%), mostly grade 1-2 (89%). Five patients 
experienced grade 3-4 toxicities.
 This study confirms, with additional follow-up, the efficacy of IM in TGCT. In 
responding cases we confirmed prolonged IM activity on TGCT symptoms even 
after discontinuation, but with high rates of treatment interruption and additional 
treatments.
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Introduction
Tenosynovial giant-cell tumor (TGCT), historically known as pigmented 
villonodular synovitis (PVNS), is a rare, at times locally aggressive neoplasm 
affecting the joints or tendon sheaths in young adults. It is most common around 
large joints such as the knees, ankles and hips.41,42 Known subtypes are localized 
and diffuse TGCT. The localized subtype comprises a single nodule and has a 
favorable course while the diffuse subtype involves the synovial lining as well as 
surrounding structures and is associated with a significant risk of recurrence 
(>50% depending on follow up times), despite being a benign neoplasm.1,42,68 
Metastatic forms have been described, but seem to occur very rarely.172,173
 Surgical resection is the primary treatment for both subtypes. However, 
diffuse TGCT is difficult to remove completely and often requires a total 
synovectomy, or at time a joint replacement, or rarely even amputation.41-43 In 
patients with extensive and/or recurrent TGCT, other available treatment 
modalities include radiation synovectomy46, external beam radiation therapy47, 
and cryosurgery.174 Their therapeutic value has only been assessed in retrospective, 
in most cases single center series and their long term side effects and complications 
are poorly described.76
 Recurrent TGCT is rarely lethal, but frequently becomes a debilitating chronic 
illness with substantial morbidity to the joints and quality of life impairment, 
caused by the disease itself and the multiple treatments.20,42
 In TGCT, a neoplastic clone constitutes a subpopulation (2-16%)12 of cells that 
overexpress colony-stimulating factor-1 (CSF-1). A t(1;2) translocation that links the 
CSF1 gene on chromosome 1p13 to the COL6A3 gene on chromosome 2q35 has been 
described and is believed to be responsible for the overproduction of CSF1 by 
neoplastic cells.12,13 Inhibition of CSF1/CSF-1 receptor (CSF-1R) signaling has shown 
efficacy in the treatment of locally advanced and recurrent diffuse TGCT.15,64,66
 Imatinib mesylate (IM) inhibits the CSF-1R kinase among other kinases.64 
We have previously reported on the efficacy of IM in TGCT. In the present study we 
provide long term follow-up on these initial patients and data on 33 additional 
consecutive patients.
Methods
This retrospective study was conducted at 12 referral centers across Europe (9 
institutions), the United States of America (2 institutions), and Australia (1 
institution). The file of all patients with locally advanced, recurrent or metastatic 
TGCT, treated with IM were reviewed. Patients information were extracted from 
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individual patients’ files at each institution by the local investigators and was 
provided in an anonymous form for final analyses. Histopathologic examination 
was performed at center of origin by pathologists with extensive experience in 
mesenchymal tumors. Response was measured using version 1.0 of Response 
Evaluation Criteria in Solid Tumors (RECIST). Data were described using 
percentages for qualitative variables and medians with ranges for continuous 
variables. Patients were not treated on a research protocol. They provided informed 
consent to treatment with a ‘off-label’ medical treatment, and treatment decision 
was left to the treating physician.  This retrospective analysis was approved by the 
Ethics Committee in Lyon (Committee for the Protection of Individuals, Sud-Est IV, 
Lyon, France – L10-153 dated 9 December 2010).
 Survival was plotted using the Kaplan-Meier method. Progression-free survival 
(PFS) was calculated from the date IM was started to the date of disease progression 
or death. The time to treatment failure (TTF) was calculated from the date IM was 
started to the date it was stopped because of toxicity, disease progression, or death, 
whichever occurred first. For patients with a surgical resection or other additional 
therapy after treatment with IM, PFS and TTF were censored at the time of surgery. 
Disease specific survival was calculated from the date IM was started to the date of 
death due to TGCT. Symptomatic response was defined as improvement of pain 
and/or joint function in patients who had symptoms at baseline. All statistical 
analyses were performed using R version 3.4.0 (R Foundation, Vienna, Austria).
Results
Patients
A total of 62 patients with histopathologically proven TGCT treated with imatinib 
were identified, their main characteristics are described in Table 1. Briefly, median 
age at diagnosis was 39 (IQR 31-53) years and 45 (IQR 36-56) years at start of 
treatment with IM, the majority of patients were female (N=39, 63%), and the knee 
(N=35, 56%) was the most commonly affected joint (Table 1). At start of IM treatment, 
three (5%) patients had biopsy proven metastatic disease, 15 (24%) locally advanced 
disease and 44 (71%) locally recurrent disease. Among patients with prior 
operations for TGCT (n=47), the median number of prior operations was 2 (range 
1-9), and the time since the last operation was 23 (range 1-192) months. Median 
follow up of all patients was 52 (IQR 18-83) months.
Treatment efficacy
Sixty-one patients received 400 mg and one patient received 600 mg IM daily. The 
3 patients with metastatic disease at treatment start progressed rapidly on IM and 
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were excluded from further analysis. One other patient with metastatic disease 
after multiple surgical treatments and IM, was excluded for further analyses too, 
leaving 58 patients for the rest of the analysis.
 Median duration of IM treatment was 9 (IQR 5-27) months. At last follow-up, 
the majority of patients (n=38; 66%) had discontinued treatment. Seventy-seven 
Table 1  Descriptive of diffuse-type TGCT patients receiving imatinib mesylate treatment.
Patients N (%)
Total 62 (100)
Median age at diagnosis (IQR), yrs. 39 (31-53)
Median time from diagnosis to start IM (IQR), yrs. 3.5 (1-8)
Sex
Male 23 (37)
Female 39 (63)
Tumor location
Knee 35 (56)
Ankle 11 (18)
Hip 6 (10)
Foot 4 (6)
Shoulder 1 (2)
Elbow 1 (2)
Head and Neck 2 (3)
Wrist 2 (3)
Surgery before start IM
None 15 (24)
1-2 24 (39)
3-4 13 (21)
>4 10 (16)
Median N of surgeries (range) 2 (1-9)
Median time since last surgery (range), mo. 23 (1-192)
Disease status
Locally advanced 20 (32)
Recurrence after surgery 39 (63)*
Metastatic disease 3 (5)
Abbreviations: TGCT= Tenosynovial Giant Cell tumor, IM= imatinib mesylate, N= Number of patients, 
mo=months, yrs= years. *One of the locally recurrent patients progressed to metastatic disease.
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percent (95% CI 67-89), 41% (95% CI 29-57) and 36% (95% CI 25-52) of patients were 
still on IM after 6-, 12- and 24-months, respectively (figure 1). The treatment 
failure-rate was 82% (95% CI 71-95) after 12 months.
 Response could not be assessed in 3 patients, two of which were lost to 
follow-up and one who discontinued early due to febrile neutropenia, leaving 55 
patients with locally advanced or locally recurrent TGCT assessable for response. 
Seventeen patients (31%; 95% CI 19-43) had a RECIST-defined response, including 2 
(3%) patients with a complete response. The median time to best response was 6 
(range 1-23) months.
 Forty of 51 patients (78%) reported symptom improvement (table 2), including 
14 of 15 patients with radiological response (CR or PR). Among patients with 
radiological SD, 22 of 30 patients (73%), for whom data was available, had symptom 
improvement. 
 The 1-, 2- and 5-years overall PFS, metastatic patients (N=4) excluded, was 71% 
(95% CI 60-85), 60% (95% CI 48-75) and 48% (95% CI 36-65) respectively, (figure 2).
Figure 1  Duration of imatinib mesylate treatment and progression free survival of this 
treatment in patients with locally advanced or recurrent diffuse-type TGCT.
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Follow-up
Overall 38/58 patients (66%), metastatic patients (N=4) excluded, eventually 
discontinued IM after a median of 7.0 (range 1-80 months). the most common 
reason for treatment discontinuation was patient decision to stop (n=14, which 
possibly reflect low grade chronic toxicity), followed by planned surgery (n=10), 
toxicity (n=7), physician’s decision (n=5) and progression (n=1). One patient 
discontinued IM because of the diagnosis of another tumor requiring therapy. 
Among the 27 patients who discontinued treatment for reasons other than surgery 
or progression, progression (either radiological progression or requirement for 
another line of therapy – i.e. surgery, other medical therapy or radiotherapy) 
eventually occurred 17 patients after a median of 12 (range 4-84) months, while 10 
patients never progressed (nor required additional therapy) after a median 
follow-up to 78 (range 1-109) months, suggesting that IM was able to provide 
prolonged symptomatic relief at least in a proportion of patients.
Table 2   Summary of imatinib mesylate efficacy in patients with locally advanced or recurrent 
diffuse-type TGCT.
Parameter Patients N (%)
RECIST best response*
Complete remission 2 (4)
Partial response 15 (27)
Stable disease 36 (65)
Progressive disease 2 (4)
Overall response rate 17 (31)
Rate of disease control 53 (96)
Symptomatic response 40 (78)**
Median IM treatment duration (IQR), mo. 9.3 (5-26)
Median PFS (IQR), mo. 18 (8-55)
Abbreviations: TGCT= Tenosynovial Giant Cell tumour, IM= imatinib mesylate, N= Number of patients, 
mo=months, yrs= years, IQR= inter quartile range.
Overall response rate includes complete remission and partial response; Rate of disease control includes 
complete remission, partial response and stable disease; Symptomatic response was indicated as present 
or not (40/51=78%). Metastatic patients (n=4) were excluded.
*N=3 RECIST best response not available; **N=9  symptomatic response not available.
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Safety
Forty-five of 58 patients (78%), metastatic patients (N=4) excluded, reported at least 
one adverse event with IM. The most common adverse events were edema (N=28, 
48%), fatigue (N=29, 50%), nausea (N=21, 34%) and skin rash/dermatitis (N=7, 12%), 
mostly grade 1-2 (89%). Additional grade 1-2 complaints were diarrhea, reflux, 
auditory hallucinations, conjunctivitis, sexual impairment, asthenia, alopecia, 
cramps and dyspnea. Five (11%) patients had grade 3-4 toxicities, including 
neutropenia, acute hepatitis, facial edema, skin toxicity and fatigue (table 3).
Figure 2  Response and follow up of imatinib mesylate in patients with locally advanced or 
recurrent diffuse-type TGCT.
NED= No evidence of disease, AWD= Alive with disease.
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Discussion
To our knowledge, this retrospective study provides the largest case series, with 
long follow-up, of patients with locally advanced, recurrent or metastatic 
diffuse-type TGCT treated with IM. We confirmed that IM has activity in TGCT 
with an overall response rate of 31% in patients with locally advanced/recurrent 
TGCT. Interestingly all patients with metastatic TGCT progressed on IM, suggesting 
that metastatic TGCT is either a different disease or loses its dependency on the 
CSF1/CSF1R axis during malignant transformation. The main issue, is the drop-off 
rate, with more than half of the patients discontinuing therapy within a year of 
therapy (59%; 95% CI 29-57), in most cases for unclear reasons (patients decision, 
physician’s decision) suggesting an unfavorable efficacy/toxicity balance. Eleven 
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Table 3   Main toxicities associated with imatinib mesylate and reasons for discontinuation, 
metastatic patients excluded.
Patients N (%)
Variable All grades Grade 3-4
Edema/ fluid retention 28 (48) 1 (2)
Fatigue 29 (50) 1 (2)
Nausea 20 (34)
Skin rash/ dermatitis 7 (12) 2 (3)
Other* 15 (26) 3 (5)
Treatment status
Continued on IM 20 (34)
Stopped IM 38 (66)
Reason for stopping
Progression 1 (2)
Toxicity 7 (12)
Surgery 10 (17)
Patient choice 14 (24)
Physician decision 5 (9)
Other tumor 1 (2)
IM= imatinib mesylate, N= Number of patients. Forty-five (78%) patients reported at least one adverse 
event with IM. *Other grade 1-2 complaints were diarrhea, reflux, auditory hallucinations, conjunctivitis, 
sexual impairment, asthenia, alopecia, cramps and dyspnea. Five (11%) patients had grade 3-4 toxicities, 
including neutropenia, acute hepatitis, auditory hallucinations.
Figure 1. Duration of imatinib mesylate treatment and progression free survival of this treatment in 
patients with locally advanced or recurrent diffuse-type TGCT.
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percent of patients reported grade 3-4 toxicities, which is consistent with the rates 
reported with IM for adjuvant gastrointestinal stromal tumors (GIST) or chronic 
myeloid leukemia (CML).175-178
 To date, surgical resection remains the treatment of choice for diffuse-type 
TGCT, but is associated with high recurrence rates and multiple additional 
surgeries.76 It is challenging to balance between increased morbidity of multiples 
or invasive surgeries,20,77 alternative therapeutic options, and daily symptoms of 
the tumor. A more aggressive resection or other multimodality treatments, such 
as external beam radiation therapy, radiosynovectomy and cryosurgery, may 
adversely affect joint function, quality of life and development of osteoarthrosis, 
which, given the young age group, are relevant factors.38,42 This would justify a 
less invasive approach, using systemic therapy, provided those are associated with 
tumor shrinkage and, most importantly, symptomatic improvements.16
 In the present study, age, localization and gender distribution were consistent 
with the literature.18,38,174 The extent of disease in our patient group is emphasized 
by an disease specific survival of 90% including four metastatic patients and 49% 
of patients had three or more surgeries before start IM. Similar to previous 
case-series, we calculated a 1- and 5-years PFS of 71% and 48%, metastatic patients 
excluded, respectively.18,38,174 Because of heterogeneity of patients and a variety of 
treatments, it is debatable to compare these numbers.
 The overall response rate appears higher compared to nilotinib (6% (95% CI 
unknown), a different tyrosine kinase inhibitor, with similar potency against 
CSF1R.179 Our overall response rate (31% (95% CI 19-43, metastatic patients (N=4) 
excluded) was consistent with our previous report on the short term results of IM 
(19% (95% CI 4-34) with similar disease control rate (96% versus 93%).64 In the 
present study, 38 (66%) patients discontinued IM; 14 (37%) without subsequent 
treatment, of which ten patients had stable disease at final follow up. Thirteen 
(62%) patients eventually progressed, after discontinuing IM for toxicity or 
non-specific medical reason (N=21, 55%). Both stable and progressive patients can 
be a result of discontinuing IM treatment or the natural course of disease.
 Newer, more specific inhibitors of CSF1R, currently only available in 
trial-setting such as emactuzumab (RG7155)61, pexidartinib (PLX3397),66 and 
cabiralizumab62 (FPA008, Five-Prime), have shown promising clinical activity on 
similar groups of diffuse TGCT patients in prospective clinical studies with more 
formal criteria and timelines for response assessment than this retrospective 
series. Emactuzumab (N=29)15 had an overall response rate of 86% (two patients 
with a complete response) and a rate of disease control of 96%, including a 
significant functional and symptomatic improvement (median follow up 12 
months). Pexidartinib showed (N=23)66 an overall response rate of 52% (all patients 
had a partial response) and a rate of disease control of 83%. Responses were 
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associated with an improved joint function (median duration of response exceeded 
eight months). The preliminary results with cabiralizumab (N=22) are consistent, 
with radiographic response and improvement in pain and function in five out of 
11 patients.62 However, long term efficacy data have not yet been reported with 
these newer agents.
 Virtually all patients treated with IM for either CML or GISTs, experience148 at 
least one mild or moderate adverse effect (grade 1-2). Toxicities of IM are determined 
by the disease stage and the doses used, advanced disease and higher doses result 
in more frequent and severe toxicities. Most side effects occur early in the course 
of treatment and tend to decrease in frequency and intensity in time.148 We 
consider a 10-15% rate of grade 3-4 toxicities in a generally benign but locally 
aggressive disease, such as diffuse TGCT, too high. Only 22% of patients did not 
experience any side effects.
 Although target anti-cancer therapies are described as ‘well tolerated’, the 
perception of tolerability may vary in the context of a, most often, benign 
condition. Understanding, monitoring and managing the side effects will be 
important to optimize systemic therapy for patients with TGCT.
 Discontinuation of treatment due to toxicities was seen for IM (this series), 
emactuzumab66 and pexidartinib15 in 12%, 20% and 9% patients, respectively. 
TGCT patients might be less willing to cope with adverse event-related and 
study-related procedures. Here, we report prolonged clinical benefit and 
symptomatic relief, even after discontinuation of treatment. A similarly persistent 
effect was observed was also observed with monoclonal antibodies and more 
specific CSF1R tyrosine kinase inhibitors this.16 This suggest that intermittent 
treatment administration may be an option to improve long term tolerability.
 The place of systemic treatment in a benign, locally aggressive disease, such as 
TGCT, and how to optimally deliver this treatment, remains unclear. More 
specifically, the role of CSF1R inhibitors in the peri-operative setting still needs to 
be explored: the number of patients who underwent operation after IM in our 
series is too low to draw any conclusions. Despite limitations related to its 
retrospective nature, this study adds to the knowledge of targeting the CSF-1/
CSF-1R pathway in patients with TGCT. An optimal treatment strategy should be 
developed for the patient group that benefits most from systemic therapy. The 
combination of a short period of treatment and the durable effect after discontin-
uation, should be pursued. It is challenging to maintain compliance for years, 
especially with, even “minor”, toxicities, in the context of a non-life-threatening 
disease.
 A limitation of all, including this, clinical TGCT studies is the lack of a control 
group and the absence of specific and validated patient-reported outcome measures 
to document treatment-induced symptomatic, functional and economic (back to 
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work) improvement.15 Quality of life and functional forms should be implemented. 
These measures are critical endpoints in demonstrating clinical relevance and 
impact of treatments for benign diseases in which death is not a relevant outcome 
variable.72 Clinical benefit necessitates objective measures to correlate with tumor 
reduction.
Conclusion
Identification of a biologic aggressive subgroup of diffuse TGCT, at risk of increased 
surgical morbidity or recurrent disease, should aid to decide which patients 
benefit most of systemic treatments. With the advent of more potent CSF-1R 
inhibitors, such as emactuzumab, pexidartinib and cabiralizumab, the role of IM 
in extensive TGCT might weaken, but may be balanced by the favorable safety 
profile of IM. Availability of these new compounds, both in terms of registration 
and reimbursement, will ultimately define the prescribed drug in daily practice.
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Abstract
Tenosynovial giant cell tumours (TGCTs) are benign lesions affecting synovial 
joints. The classified subtypes are localized and diffuse. They seldom occur in the 
temporomandibular joint (TMJ). The aim of this study is to report on three new 
cases and to review the literature. 
 One patient had surgical debulking with adjuvant external beam radiation 
therapy (EBRT). After 1 year of follow-up, no evidence of disease was presented. 
The second patient was misdiagnosed and treated with denosumab. Debulking 
with adjuvant EBRT followed. Ten months postoperatively, no disease progression 
was seen. The third patient received systemic nilotinib and remained stable for 
over 5 years. 
 The literature review included 106 cases of which 95 had diffuse subtype. 
Most patients, had surgical excision. Thirteen (14%) patients received adjuvant 
EBRT. Eleven (14%) recurrences were identified. After 1-, 5- and 10-years of follow-up, 
an overall progression-free survival (PFS) of 99% (95% confidence interval (CI) 
0.96–1), 80% (95% CI 0.68–0.94), 67% (95% CI 0.51–0.90) was calculated, respectively. 
Treatments for diffuse-TGCT-TMJ should be individualized depending on age, 
severity of symptoms, extent of disease and progression, expected mutilation of 
surgical interference, and current systemic treatment options. In stable disease 
a ‘wait and see’policy, is a viable option. Additional treatments should be reserved 
for symptomatic, irresectable tumours or residual disease after surgical treatment 
with persistent complaints.
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Introduction
Tenosynovial giant cell tumours (TGCTs), formerly known as pigmented 
villonodular synovitis (PVNS), are benign lesions that can affect any synovial 
joint.1,2 It is most common in large weight-bearing joints such as the knee, hip and 
ankle.18 However rare, it does occur in the temporomandibular joint (TMJ) where 
it is even less common compared to malignancies such as sarcomas or metastases.73
 TGCTs can be classified into localized and diffuse subtypes, which differ in 
clinical features and behavior.1 Since 1973180, over 100 TGCT cases with TMJ 
involvement have been reported.181,182 Patients initially present with an indolent 
course of a painless pre-auricular swelling, that may become symptomatic with 
limited mouth opening or trismus as the tumour increases in size.183 The duration 
of symptoms prior to diagnosis is on average, 11.5 months. Age at presentation is 
most common in the late 30s to 40s.184
 On magnetic resonance (MR) imaging, an enlarged mass extending away from 
the joint with hemosiderin deposition, is typical for TGCTs.185 This hemosiderin 
deposition can be depicted as ‘blooming’ on gradient echo or prominent hypointens 
on T1- and T2-weighted sequences.
 Computed tomography (CT) can reveal areas of lytic bone erosion and sclerosis. 
Furthermore, it clearly defines the extent of the tumour, which is the focal areas 
of hyperdensity within the soft-tissue mass.
 Both types of TGCTs are microscopically identical with a heterogeneous 
accumulation of both, neoplastic and non-neoplastic cells. The neoplastic cells 
overexpress colony stimulating factor 1 (CSF1) as a result of a translocation fusing 
CSF1 (at 1p11-13) to COL6A3 (at 2q35) that probably attracts the secondary 
non-neoplastic population of mainly histiocytes. This reactive component is 
known as the ‘paracrine landscape effect’.12,13
 Most reports of TMJ involvement describe the diffuse form, which can be 
locally aggressive with bone destruction and invasion of contiguous structures. In 
large joints, high recurrence rates over 50% are shown, depending on time 
followed.42 In contrast, for TMJ recurrence rates of 15% with at least 1 year of 
follow-up were reported. However, in a limited cohort of seven cases, the rate of 
recurrence at 5 years was 29%.182
 Management of TGCTs entails a complete synovectomy to remove all pathologic 
tissue. When complete removal is considered mutilating, additional treatments 
might be an alternative; external beam radiation therapy (EBRT), radiation 
synovectomy, cryosurgery, total joint arthroplasty and immune or targeted 
therapy. However, the effect of these treatments is unknown, caused by rarity of 
the disease and heterogeneity of the patients.76
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The aim of this study is to report on our experience of three TGCT-TMJ cases and 
review the relevant literature.
Case reports
Patient 1
A 20-year-old female patient had a progressive, pre-auricular, painful swelling 
and hearing loss, on the left side. She had complaints of headaches and nausea. 
Examination confirmed a painful pre-auricular solid-elastic, partially fluctuating 
swelling of 5 cm in diameter. On computed tomography (CT) and MR imaging 
(figure 1A), a large solid multilobular mass in the infratemporal fossa was detected 
with extension into the temporal bone showing destructive and lytic growth. The 
solid components were remarkably low in signal intensity on T1- and T2-weighted 
MR images, without bone matrix. An increased pressure on the temporal lobe was 
seen. No malignant characteristics were shown.
A CT wired biopsy was performed from the solid osseous expansile temporal part 
of the tumour. It showed a benign mesenchymal lesion with giant cells. Differential 
diagnostic, a chondroblastoma with secondary aneurysmal bone cyst, or a diffuse 
type of TGCT were considered.
Figure 1  MR images of a 20-year-old female with TGCT-TMJ on the left (patient 1).
(A) Preoperative MR images demonstrating a large solid multilobular mass in the infratemporal fossa 
with extension into the left temporal bone. An increased pressure on the temporal lobe was seen. 
No malignant characteristics were shown. (B) MR images 1 year after surgical TGCT-TMJ resection. 
There is minimal residual coloring around the TMJ, indicating scar tissue or reactive, without visible 
hemosiderine deposits.
A B
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Three months after initial visit, the lesion extending from the TMJ involving the 
skull base and intracranial extension (extradural), was surgically removed. The 
tumour showed a multilobular yellow, rust-brown aspect with pigmentation. The 
adjacent dura remained intact. The skull base, the lateral os zygomaticus and the 
medial part of the temporal bone were eroded. A titanium mesh was implanted in 
the temporal bone defect. The musculus temporalis was positioned in the TMJ.
 Because of the adjacent internal carotid artery, residual tumour and visible 
pigmentation remained. Definitive pathology report confirmed an irradical 
resection of a diffuse type of TGCT. The patient received adjuvant external beam 
radiationtherapy (11 weeks after surgery a total dose of 45 Gy in 1.8-Gy fractions), 
considering the irradical resection, in combination with the high risk of damage 
to vital structures. Attributed to the EBRT, the patient had transient complaints of 
fatigue, an itchy scalp, and local temporal hair loss. After 1 year of follow-up there 
was no evidence of progressive disease (figure 1B).
Patient 2
A 54-year-old male had a progressive pre-auricular swelling and hearing loss on the 
right side, since 3 years. Examination showed trismus. The solid-elastic pre-auricular 
swelling with a diameter of 5 cm was attached to the bony layer (figure 2A).
Figure 2   Preoperative clinical photo of a 54-year-old male with TGCT-TMJ  
on the right side (patient 2).
(A) A progressive pre-auricular swelling since 3 years. The solid-elastic pre-auricular swelling with a 
diameter of 5 cm was attached to the bony layer. (B) Preoperative contrast enhanced T1-weighted MR 
images show an extensive lesion in the TMJ with involvement of the temporal bone, an intact mandibular 
condyle and intracranial expansion including invasion of the temporal lobe. Mastoid breakthrough with 
destruction of the tegmen tympani, obstruction of the Eustachian tube and post-obstructive oto-inflam-
matory changes are presented.
A B
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CT and MR imaging (Figure 2B) showed an extensive lesion in the TMJ with 
involvement of the temporal bone, an intact mandibular condyle and intracranial 
expansion including invasion of the temporal lobe. Mastoid breakthrough with 
destruction of the tegmen tympani, obstruction of the Eustachian tube and 
post-obstructive oto-inflammatory changes were presented. Initially, TGCT was 
considered. However, open biopsies showed a giant cell lesion of bone histopathology 
suggesting a giant cell granuloma of bone (figure 3).
 Denosumab186, a RANKL (receptor activator of nuclear factor kappa-B ligand) 
inhibitor that inhibits formation and function of osteoclasts, was started for giant 
cell granuloma of bone (not for the final diagnosis: TGCT). After half a year there 
was increased bone formation and pain symptoms disappeared. Calcium and 
vitamin D3 were started to prevent a hypocalcemia.
 After 15 months of stable disease, additional biopsies were taken to evaluate 
the effect of Denosumab186. Histopathologic examination showed vital giant cell 
lesion with fibrosis and necrosis. After 18 months of Denosumab treatment, the 
pre-auricular swelling increased concomitant with a persisting trismus. Operative 
debulking was performed. Trepanation and excision of the arcus zygomaticus 
were essential and macroscopic residual disease remained.
 Histopathologic evaluation confirmed diffuse type TGCT. Additional postoperative 
EBRT (25 × 1.8 Gy) was necessary according to the tight resection margins. 
Denosumab treatment, given for a false diagnosis, was stopped.
 Besides temporary dryness of his right eye and mild erythema of the skin 
following EBRT, no other complaints were presented. Currently, 10months post-
operatively, auditory perception on the right side is absent. The patient describes a 
decreasing pre-auricular painless swelling. His mouth opening is within normal 
ranges (38 mm).
Patient 3
A 27-year-old female presented with a painful TMJ on the left side and a decreased 
mouth opening, since 4 years. At maximum mouth opening slight deviation to the 
left was observed. Palpation of the ipsilateral TMJ was painful.
 CT and MR imaging showed a space occupying intra-articular lesion on the 
TMJ with a diameter of 3.1 cm. Tumour involvement of the parafaryngeal space 
and both pterygoid muscles was presented. Laterally, the lesion affected the 
masseter muscle, the dorsal part of the zygomatic arch and the temporalis muscle. 
Medially, the tumour reached the oval foramen, which itself was not involved. 
Imaging and clinical presentation presumed either synovial chondromatosis or 
TGCT. Histopathologic examination, from a CT-guided cytological biopsy, confirmed 
TGCT diagnosis.
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A primary surgical resection was considered mutilating and nilotinib showed 
effects in some patients (overall response rate nilotinib (6% (95% CI unknown)).179 
Therefore, the proposed treatment regime was 1 year nilotinib, a BCR-ABL tyrosine 
kinase inhibitor,16 to reduce tumour size and to allow a more limited surgical 
resection. Side effects of nilotinib were hair loss, including eyebrows, and a rash. 
Multidisciplinary consultations discussed several treatment options: continuation 
of medical treatment, surgical resection or a ‘wait and see’ policy.
 After 1 year of nilotinib treatment, surgery was reconsidered. Balancing 
between daily complaints and the mutilating aspect of surgery, a ‘wait and 
see’ policy was chosen. The patient was followed every 6 months, over 5 years. 
Consecutive MR imagines showed stable disease. Occasionally, the patient has 
complaints of a stabbing sensation, earache and limited mouth opening.
Discussion
Presentation of TGCT-TMJ is extremely rare. It was first described by Lapayowker 
et al.180 in 1973, followed by over 100 additional cases. There are two subtypes. 
The localized subtype, which involves only part of the synovium, showing a 
pedunculated well circumscribed nodule. And the diffuse subtype, that involves a 
large part or whole of the synovial membrane and often adjacent structures.1 
Distinction between subtypes is important, because diffuse lesions are more 
locally aggressive and recur more frequently.42
Figure 3   Hematoxylin and eosin stain on tumour specimen demonstrating  
TGCT-TMJ (patient 2). 
(A) Hematoxylin and eosin stained slides show sheets of monomorphic mononuclear cells of small or 
intermediate size with round to oval nuclei. Scattered around are multinucleated osteoclast-like giant 
cells. Focally, deposition of iron is presented (brown colored), in a hemorrhagic background. (B) Including 
prominent iron deposition and focal bone formation in the intraosseous part.
A B
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We reviewed 106 TGCT-TMJ cases (appendix 1); 103 selected patients of 70 retrieved 
articles from PubMed, including their reference lists and the current described 
three patients (appendix 1, table 1). Males (n = 62) and females (n = 43) were 
represented. There was an equal side distribution (left n = 44, right n = 43, NA n = 
8). Ages ranged from 8 to 85 (median 45) years. Ninety-five patients had diffuse 
subtype, 10 localized subtype and in one case TGCT-subtype was not reported. All 
except two patients were treated with surgical resection. Thirteen (14%) patients 
received adjuvant EBRT for extended or residual disease. One patient had no 
treatment for advancing age and extended disease.
 Patients present with a pre-auricular pain(less) mass, enlarging in time. 
Additional described symptoms as tinnitus, trismus, limited mouth opening, 
clicking and hearing loss depend on tumour extension and involvement of 
adjacent structures.187,188
 The differential diagnosis of a pre-auricular swelling is extensive, including 
synovial cyst, ganglion, degenerative arthritis, synovial chondromatosis, mandibular 
osteoma, salivary gland tumours, chondrosarcoma, calcium pyrophosphate 
dehydrate deposition disease, rheumatoid arthritis, hemangioma, hemorrhage, 
osteoblastoma, aneurysmal bone cyst, brown tumour of hyperparathyroidism. 
Romanach et al.188 described only 13% of TGCT-TMJ to be included in differential 
diagnosis prior to treatment. In 9% a malignant or metastatic tumour was 
proposed. Patient 2 was initially misdiagnosed with a giant cell granuloma of 
bone due to its bone-centered appearance. Nevertheless TGCT usually presents as a 
joint-centered lesion.189 The following treatment (Denosumab) delayed diagnosis 
for 18months, in accordance with the average diagnostic delay described in 
literature (11.4 (±12) months).184
 Clinical diagnosis of TGCTs is challenging. MR imaging in the right setting is 
pathognomic for the diagnosis, presenting a specific finding of low to intermediate 
signal in both T1- and T2-weighted images. The MR imaging low signal intensity 
areas of TGCT are best seen in T2-weighted images and are attributed to a 
paramagnetic effect produced by the reaction with high quantity hemosiderin. 
Hemosiderin causes the low signal intensity in MR imaging, known as the 
‘blooming effect’.30,190 A CT scan shows extension of the lesion as well as bone 
destruction. When in doubt, diagnosis can be confirmed by a (open) biopsy.
 Fine needle aspiration (FNA) cytology is often not sufficient to confirm TGCT 
diagnosis. This procedure frequently needs to be repeated several times, and diagnosis 
could remain inconclusive. However, it can be usually helpful in differentiating 
benign from malignant lesions. FNA shows mononuclear cells, multinucleated 
giant cells and histiocytes containing hemosiderin pigments.191
 The treatment strategy for TGCTs should be influenced by the nature and 
clinical behavior of the lesion. Surgical removal of localized disease is relatively 
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easy. Still, in the knee recurrences up to 22% within 5 years were described.42 To 
our knowledge, no recurrent disease has been reported for localized TGCT-TMJ.
 Diffuse TGCT behaves naturally more aggressively compared to localized TGCT. 
Within the TMJ, 33% intra-cranial extension and/or middle ear involvement182 and in 
70.4% bone destruction is present.184 The standard treatment for large joints is a 
partial or complete synovectomy, including parts of involved bones or surrounding 
tissue. TGCT-TMJ management includes mainly surgical excision, mostly with 
 reconstructions that vary from no replacement, free costochondral or other bone 
grafts, metal condyle, total joint replacement to free vascular graft replacement 
options (most commonly the fibula).192 Eisig et al.193 recommended a wide excision. 
However, in TGCT-TMJ this is usually not feasible while adjacent to vital structures.
 In patient 3, surgical resection was considered but refrained, given the risk of 
more treatment morbidity compared to the complaints of the benign disease itself. 
Reported complications after surgical resection were temporary or persistent 
mandibular deviation, tinnitus, facial paralysis, limited jaw movement, external 
auditory canal narrowing, hearing loss, liquor leakage and a scar.194
 With extensive disease or disease in difficult attainable sites, adjuvant treatment(s) 
have been applied. However, none of these treatments proved to reduce recurrent 
rates.76 Two of our current TMJ patients received postoperative radiotherapy for 
residual disease. In their relatively short follow-up, no recurrences/progression 
appeared. However, as described they experienced transient adverse effects. Joshi 
et al,195 described grade 1/2 acute toxicities of radiation during treatment, 
including dysgeus, nausea, dermatitis and alopecia, which resolved. They conclude 
there could be a role for EBRT in extensive infiltrative tumours or positive margins. 
Chronic otitis media or hearing loss may occur following surgical resection with 
additional EBRT.
 Patient 3 initially received targeted therapy (nilotinib) to reduce tumour size 
and to allow a more limited surgical resection. After 1 year of systemic treatment, 
the patient had stable disease which continued for over 5 years after discontinua-
tion. She did not have surgery. To date, no systemic treatment is approved for 
TGCT, however inhibition of CSF1/CSF-1 receptor (CSF-1R) signalling has shown 
efficacy in the treatment of locally advanced and recurrent diffuse TGCT.15,66 
Larger cohorts, preferably randomized trials, are needed to evaluate the effect of 
systemic therapy targeting the CSF1/CSF1-receptor axis (imatinib, nilotinib, 
emactuzumab, and PLX3397 (pexidartinib)).16
 Damodar et al.133 reported earlier treatment inclines to have a better prognosis 
based on a literature review of 42 cases. However, two of our patients with a 
treatment delay of 3 and 4 years had stable disease for over 1-year, possibly 
according to systemic treatment. An expectative course for TGCT-TMJ can be 
considered in stable disease or relatively few clinical complaints, in contrast to 
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mutilating operations involving significant morbidity. The lesions can behave 
aggressively locally and show high recurrence rates, but malignant transformation 
or distant metastasis are only incidentally reported.196
 According to our analyses of the literature, in diffuse TGCT-TMJ cases most 
patients had surgical resection (98%), some with adjuvant EBRT (14%) without 
accurate data regarding recurrence rates. It is difficult to predict recurrence rates 
because of the heterogeneity of the patient group and the lack of long-term 
follow-up information. We calculated an overall progression free survival (PFS) of 
99% (95% CI 0.96–1), 80% (95% CI 0.68–0.94), 67% (95% CI 0.51–0.90) after 1, 5 and 10 
years of follow-up, respectively, including 14% recurrences at a median follow-up 
of 24 (range 1–240) months (figure 4). The duration of follow-up in most cases is 
relatively short. Local recurrence rates would be expected to be higher with a 
longer follow-up. In the knee, recurrence rates over 50% are described with an 
overall PFS for diffuse TGCT of 68%, 32%, 25% and 16% after 1, 5, 10 and 15 years, 
respectively.42
Figure 4   Kaplan–Meier survival curve showing progression-free survival of diffuse-type 
tenosynovial giant cell tumours in the temporomandibular joint.
Kaplan–Meier survival curve calculated from our own literature review. Uncertainty is shown by 95% 
confidence interval and a number-at-risk Table 1. Ninety-five diffuse-type cases were identified, 11 had 
recurrent disease at a mean time of 24 (range 1–240) months.
Time (months)
0 20 40 60 80 110 140 170 200 230
Pr
og
re
ss
io
n 
fr
ee
 s
ur
vi
va
l
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
87 69 55 35 28 17 15 12 11 8 7 7 6 6 5 5 4 2 2 2 2 2 2 1 1
524982-L-bw-Verspoor
Processed on: 3-10-2018 PDF page: 165
165
9
TGCT OF THE TEMPOROMANDIBULAR JOINT
Tumour progression was managed by 6-monthly MR imagings. Carlson et al.197 
advised an MR imaging 3 months following surgery as a baseline, thereafter 
annually. However, 3 months after surgical treatment postoperative changes 
might still be present. We recommend an MR imaging, 6 months postoperatively, 
as a baseline scan to observe changes when symptoms arise. These symptoms 
might present after a long period of time, as TGCTs can recur after many 
asymptomatic years. No evidence exists that an annual MR imaging is 
contributory.76 When there are no complaints, residual or recurrent disease, 
detected by scans is likely without treatment consequences.
In conclusion, TGCT-TMJ is rare. It should be diagnosed by MR imaging scanning, 
if necessary with additional CT to evaluate the extent of disease. When in doubt, 
an open biopsy is conclusive for the diagnosis. The treatment for localized disease 
is an excision biopsy. For diffuse TGCTs several treatment options are available, 
which should be individualized by a multidisciplinary team (head and neck 
surgeon, (radiation-) oncologist, oncologic orthopaedic surgeon, neurosurgeon) 
depending on age, severity of symptoms, extent of disease and additional growth, 
expected mutilation of surgical interference, and the current systemic treatment 
options. In stable disease a ‘wait-and-see’ policy, with 6-monthly clinical follow-ups, 
is a viable option. With symptomatic complaints an MR imaging is indicated. 
Additional treatments, such as EBRT should be reserved for symptomatic 
irresectable tumours or where incomplete resection leaves residual disease with 
persistent complaints. Long-term clinical follow-up is recommended.
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Table 1  Descriptive of patients with diffuse-type tenosynovial giant cell tumours in  
the temporomandibular joint of the current literature review.
Number of patients (%) 95 (90.5)
Gender n (%) Female 43(41), male 62(59)
Median age, years (range) 45 (8–85)
Surgical treatment n (%) 93 (98)
Additional EBRT n (%) 13 (14.3)
Follow-up, months (range) Mean 42, median 24 (1–240)
EBRT, external beam radiation therapy.
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CHAPTER 10
Abstract
Adequate documentation of the outcome of treatment of pigmented villonodular 
synovitis (PVNS) is sparse. Available case series show relatively short follow-up 
times and often combine locations or subtypes to increase patient numbers. This 
article describes the long-term follow-up of a single institution’s large consecutive 
series of PVNS.
 Retrospectively, 107 PVNS patients were identified between 1985 and 2011 by 
searching pathology and radiology records. Treatment complications, recurrences 
and quality of life were evaluated. Most patients (85.2%) were primarily or 
secondarily treated at our institution.
 Both subtypes, localized PVNS [29 (27%)] and diffuse PVNS [75 (70%)] were 
represented. The knee was affected in 88% of patients. Treatments received were 
surgery, external beam radiotherapy, radiosynovectomy, targeted therapy, 
immunotherapy or combinations of these. Forty-nine (46%) patients had prior 
treatment elsewhere. The mean follow-up from diagnosis until last contact was 7.0 
years (range 0.3-27.4) for localized PVNS and 14.5 years (range 1.1-48.7) for diffuse 
PVNS. The 1- and 5-year recurrence-free survival rates for diffuse PVNS were 69% 
and 32%, respectively. Quality of life, estimated by 36-item Short Form Health 
Survey (SF-36) scores, were not significantly different between localized and 
diffuse PVNS. However, both patient groups scored lower than the general 
population norms on the general health component (59.2 and 56.3, respectively, P 
< 0.05).
 Recurrence rates of PVNS increase with time. Long-term follow-up shows, 
particularly in diffuse PVNS, it is a continually recurring problem, and over time 
it becomes increasingly difficult to cure. The quality of life is decreased in patients 
with PVNS compared with the general population.
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OUTCOME OF PRIMARY AND RECURRENT DISEASE
Introduction
Pigmented villonodular synovitis (PVNS) is a rare, benign tumour originating 
from the synovial membrane. 2,4 The approximate annual incidence is 1.8 patients 
per million US inhabitants.4 There is a predilection for weight-bearing extremities, 
with the knee joint being particularly affected.31,252 PVNS is characterized by an 
aggressive clinical behaviour, with progressive destruction of affected joints.
 Two main subtypes are identified based on clinical and radiological 
presentation.8,30 The localized (L-PVNS) form is characterized by discrete nodular 
or pedunculated lesions. Clinically it simulates a mechanical derangement and 
L-PVNS rarely recurs (0-15%).3,5,75,116,253 The diffuse (D-PVNS) form is most common 
and involves the intra- articular soft tissue lining and presents as a more chronic 
process. Reported recurrence rates after D-PVNS treatment range from 9% to 46%, 
depending on follow-up time.4,19,36,39,41,51,52,54,55 PVNS may result in a long course 
of disease associated with multiple interventions leading to loss of joint function, 
early secondary osteoarthritis and treatment complications.4,51,54,55
 Over the  last 100 years, limited progress  has been achieved in treatment 
strategies.76 Generally PVNS is treated by surgical removal of all pathological 
tissue.55 In cases of residual or recurrent disease, other treatment modalities have 
been tried, such as external beam radiation therapy39,120, radiation synovectomy55, 
cryosurgery49, total joint arthroplasty44,119 and immune141 or targeted therapy64,68.
 Due to the small number of patients affected, no large prospective clinical 
trials on treatment results exist. All currently available evidence is based on 
retrospective case series. Outcome measures such as recurrence rates, recur-
rence-free survival (RFS) and joint function scores are often contaminated by 
combining subtypes, locations, treatments and both primary and recurrent 
disease to increase patient numbers, which leads to difficulties in interpretation 
and comparability of results.4,44,50,75,119,120 To the best of our knowledge, there is 
no information available on quality of life (QoL), an important measure in a disease 
as destructive as PVNS. We performed a retrospective study on a relatively large 
number of patients with respect to recurrence rates, RFS, complications and QoL.
Patients and methods
We retrospectively searched pathology and radiology patient databases on PVNS, 
nodular tenosynovitis, local tenosynovitis and giant cell tumour (GCT) of the 
tendon sheath. Between 1985 and 2011, a total of 184 patients were identified. 
After careful evaluation of the database records, 58% of patients were found to 
have PVNS. The 33% of GCT patients and 9% of patients that did not fit the 
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histological or MRI description of PVNS were excluded. Twenty-seven per cent of 
PVNS patients were classified as L-PVNS, 70% as D-PVNS and 3% as unknown. The 
demographics of the 104 L-PVNS and D-PVNS patients included in this study are 
provided in table 1. All cases were monoarticular.
 Medical records were studied on clinical, pathological, radiological, treatment 
and follow-up information by two independent reviewers (F.G.M.V. and A.A.G.Z.). 
Any disagreements were resolved by consensus with a third reviewer (H.W.B.S.). 
QoL was evaluated by using the Dutch translation of a generic QoL instrument, the 
36-item Short Form Health Survey (SF-36).254. The SF-36 is an instrument for 
measuring general health. It includes scales for physical functioning, social 
functioning, role physical functioning, role emotional functioning, mental health, 
vitality, bodily pain, general health and health change. All patients were contacted 
by telephone to take the SF-36 questionnaire. Sixty-two (57%) patients responded. 
The remaining patients could not be contacted because they had moved or changed 
telephone numbers. The study was approved by the institutional review board of 
the Radboud University Medical Center, Nijmegen (file number CMO 2012/555) and 
was carried out in line with the Declaration of Helsinki. Written informed consent 
was obtained from each patient
Table 1  Demographics.
L-PVNS D-PVNS
Patients,  n (%) 29 (100) 75 (100)
Sex
Male, n (%) 9 (31) 36 (48)
Age at diagnosis, mean (S.D.), years 39.7 (13.3) 32.1 (10.1)
Females, n (%) 20 (69) 39 (52)
Age at diagnosis, mean (S.D.), years 36.5 (14.4) 35.7 (13.6)
Primary, n (%) 23 (79) 33 (44)
Referred, n (%) 6 (21) 42 (56)
Location, n (%)
Knee 27 (93) 64 (85)
Hip 1 (3) 5 (7)
Ankle 0 6 (8)
Elbow 1 (3) 0
Follow-up from diagnosis, mean (S.D.), years 7.2 (7.0) 13.9 (10.3)
Follow-up from index treatment, mean (S.D.), years 6.6 (6.7) 11.2 (9.8)
Index treatment: first treatment in a tertiary centre; L-PVNS: localized pigmented villonodular synovitis; 
D-PVNS: diffuse pigmented villonodular synovitis.
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OUTCOME OF PRIMARY AND RECURRENT DISEASE
Recurrences, treatment complications and current QoL were analysed according 
to PVNS subtype, location and primary and recurrent disease. Since the knee was 
affected in 88% of patients, analyses focused on this group. Recurrences are 
expressed as rates. The primary patient group received all treatments at our 
institution, while the referred patient group had their initial treatment(s) 
elsewhere and was treated at our institution for recurrent disease. The length of 
follow-up was defined as the period between the first pathology confirmation of 
diagnosis and the most recent patient contact. The time to recurrence was 
calculated as the time from the last treatment until histologically  proven 
recurrent  disease.  Statistical  analyses were performed using SPSS version 18.0 
(SPSS, Chicago, IL, USA). Descriptive statistics were used for demographic data and 
patient characteristics. Between-group differences in SF-36 scores were compared 
using one-way analysis of variance followed by Bonferroni post hoc comparison 
tests. RFS analyses were performed using the Kaplan-Meier method and compared 
using log-rank tests. Survival estimates are presented as RFS (S.E.). Assumptions for 
individual tests were checked before the analyses were performed. For all data 
sets, differences were considered statistically significant at P-values <0.05.
Figure 1  Kaplan-Meier curves showing recurrence-free survival for localized and diffuse 
pigmented villonodular synovitis.
Uncertainty is shown by 95% CI and a number-at-risk table below the graph. Recurrences were more 
frequent for diffuse pigmented villonodular synovitis. L-PVNS: localized pigmented villonodular 
synovitis; D-PVNS: diffuse pigmented villonodular synovitis
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Results
Localized pigmented villonodular synovitis
The localized group contained 69% females [mean age 36.5 years (range 19.4-71.7)] 
and 31% males [mean age 39.7 years (range 17.1-53.3)]. The knee joint was affected 
in 93% of patients.
Treatments and recurrences
Twenty-two affected knees were primary L-PVNS patients and five patients were 
referred. In 83% diagnosis was confirmed by MRI. In 34% diagnosis was preoperatively 
determined by biopsy. All patients were treated by open or arthroscopic surgical 
excision. In three of these patients, PVNS was an accidental finding during prosthetic 
surgery. Six patients needed additional surgical treatment, five for recurrent disease, 
two of which were first treated at our centre, two who received initial treatment 
elsewhere and one who received both treatments elsewhere. One patient was operated 
on four times due to residual pain and hydrops; however, recurrent disease was 
never demonstrated. Another patient initially received yttrium radioisotopic synovior - 
thesis, then recurrent disease developed and surgical excision was successfully 
applied. One patient who developed recurrent disease after surgical intervention 
had a successful yttrium radioisotopic synoviorthesis.
Follow-up
The mean overall follow-up from diagnosis until last patient contact was 7.0 years 
(range 0.3-27.4). Of these knee patients, 15% of recurrences occurred within the 
first year and 22% within 5 years. The overall 1- and 5-year RFS was 83% and 69%, 
respectively (figure 1). For primary patients the RFS was 89% and 80%, respectively.
Complications
Three patients had postoperative complications after surgical excision of L-PVNS 
tissue—two after initial treatment, one of which had a superficial wound infection 
successfully treated with antibiotics. The other patient had a deep infection that 
was treated by two operations and one manipulation under anaesthesia because of 
stiffness. Another patient suffered from a femoral nerve neuropathy after a second 
surgical excision, but recovered spontaneously.
Quality of life
The SF-36 score was obtained for 70% of L-PVNS knee patients on average 6.1 years 
(range 1.2-19.9) after the first treatment. Table 2 shows the mean scores of all SF-36 
scales. Compared with the general population154, L-PVNS patients scored significantly 
lower on mental health (P = 0.05), vitality (P= 0.02) and general health (P= 0.005).
524982-L-bw-Verspoor
Processed on: 3-10-2018 PDF page: 179
179
10
OUTCOME OF PRIMARY AND RECURRENT DISEASE
Diffuse pigmented villonodular synovitis
The D-PVNS group contained 52% females [mean age 35.7 years (range 14.4-62.2)] 
and 48% males [mean age 32.1 years (range 16.7-52.9)]. The knee joint was most 
affected, in 85% of patients (table 1). In 25% of patients the diagnosis was obtained 
by biopsy, while in the remaining cases diagnosis was conclusive by MRI.
Treatments and recurrences
Twenty-seven affected knees had primary lesions and 37 had recurrent disease 
after treatment(s) elsewhere. All primary D-PVNS patients, except for one, initially 
received surgical excision of PVNS tissue. Of these 27 primary D-PVNS patients, 6 
had one recurrence and another 6 had two or more recurrences (table 3 and see 
supplementary Table S1, available at Rheumatology Online). Their mean follow-up 
from diagnosis was 13.0 years (range 1.1-48.7).
 Of the 37 referred patients, 26 initially received surgical excision of PVNS 
tissue. Six patients initially received yttrium radioisotopic synoviorthesis. In two 
patients, it was not possible to retrieve information on initial treatment(s). 
Subsequent treatments and recurrences of all D-PVNS knee patients are described 
in table 3 (also see supplementary table S1, available at Rheumatology Online). Of 
two patients solely treated elsewhere, one patient was advised a complete 
synovectomy, but it remains unclear whether it was performed because this 
patient was lost to follow-up. In another patient, symptoms disappeared 
spontaneously after two biopsies. Of the 37 referred patients, 8 patients developed 
Table 2   Outcome quality of life for pigmented villonodular synovitis knee patients compared 
with the general population at last follow-up.
SF-36 subscale L-PVNS, 
mean (SD)
D-PVNS, 
mean (SD)
General population, 
mean (SD)
Physical functioning 72.4 (27.0) 68.2 (26.8)* 81.9 (23.2)
Social functioning 82.2 (27.7) 86.8 (25.6) 86.9 (20.5)
Role physical 68.4 (43.2) 69.1 (38.5) 79.4 (35.5)
Role emotional 87.7 (31.8) 91.2 (26.3) 84.1 (32.3)
Mental health 67.6 (18.9)* 70.1 (15.4)* 76.8 (18.4)
Vitality 55.5 (19.4)* 55.7 (20.4)* 67.4 (19.9)
Bodily pain 68.7 (34.7) 74.0 (26.7) 79.5 (25.6)
General health 59.2 (18.0)* 56.3 (18.6)* 72.7 (22.7)
Health change 55.3 (15.8) 48.5 (19.4) 52.4 (19.4)
*Significant P-value <0.05 different compared with the general population. L-PVNS: localized pigmented 
villonodular synovitis; D-PVNS: diffuse pigmented villonodular synovitis. General population data 
reproduced from VanderZee KI et al.153
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OUTCOME OF PRIMARY AND RECURRENT DISEASE
one recurrence and 26 had two or more recurrences (see supplementary table S1, 
available at Rheumatology Online). This last group contains all recurrences, 
including known recurrences treated elsewhere. Their mean follow-up was 14.6 
years (range 1.1-43.0).
 When only recurrences that occurred after treatment at our tertiary centre 
were considered in the referred patients, 16 patients had no recurrences, 5 patients 
had one recurrence and 6 patients had two or more recurrences. The mean 
follow-up was 12.1 years  (range 1.6-38.5). Recurrences  were  treated  by  different 
(combinations) treatments, outlined in detail in supplementary table S1 (available 
at Rheumatology Online).
Follow-up
The overall 1-, 5-, 10- and 15-year RFS for all D-PVNS knee patients was 68% (S.E. 6), 
32% (S.E. 7), 25% (S.E.7) and 16% (S.E. 7), respectively (figure 1). The primary group 
had a 1- and 5-year RFS of 92% (S.E. 5) and 65% (S.E. 10), respectively. The referred 
patients had a 1- and 5-year RFS of 47% (S.E. 9) and 10% (S.E. 5), respectively. 
Figure 2  Kaplan-Meier curves showing recurrence-free survival for primary and referred 
diffuse pigmented villonodular synovitis.
Uncertainty is shown by 95% CI and a number-at-risk table below the graph. The referred patients are 
represented in two groups. One group shows recurrence-free survival from the initial treatment, the other 
shows recurrence-free survival after the initial treatment in a tertiary centre. Recurrences were more 
frequent for referred patients initially treated elsewhere. D-PVNS: diffuse pigmented villonodular synovitis.
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The 1- and 5-year RFS for this last patient group from the first treatment at our 
centre until the last follow-up was 93% (S.E. 5) and 60% (S.E. 11), respectively (figure. 2).
Complications
Perioperative complications after surgical excision of D-PVNS and their treatments 
are described in table 4. In only four patients did the complication occur after the 
initial treatment (see supplementary table S1, available at Rheumatology Online).
Quality of life
SF-36 scores were obtained for 53% of D-PVNS knee patients, on average 10.1 years 
(range 2.4-28.8) after the first treatment. Table 2 shows the mean scores of all nine 
SF-36 scales. Compared with the general population154, D-PVNS patients score 
significantly lower on physical functioning (P= 0.006), mental health (P= 0.02), 
vitality (P= 0.002) and general health (P < 0.001).
Discussion
The limited available knowledge of the long-term outcome of PVNS treatment 
based on a few small studies and the lack of QoL measures motivated us to analyse 
our large patient group. We were able to identify 107 patients over the last 25 
years. We retrospectively studied the treatment results of the knee patients by 
identifying recurrences, RFS, complications and QoL. These results were analysed 
by subgroup and primary or recurrent disease
Table 4   erioperative complications after surgical excision of diffuse pigmented 
villonodular synovitis.
Complication Number  
of patients
Treatment of complication (number patients)
Delayed wound heeling 2 Spontaneous recovery
Local paraesthesia 1 Spontaneous recovery
Stiffness 5 Manipulation under anaesthesia (1); 
adhesiolysis (1); clinical
Superficial wound infections 4 mobilizations (2); unknown (1) Antibiotics
Neurolysis 1 Unknown
Haematoma 3 Unknown
Deep wound infections 2 Surgical drainage
Percutaneous fistula 1 Unknown
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OUTCOME OF PRIMARY AND RECURRENT DISEASE
Diffuse pigmented villonodular synovitis
This study, with a long follow-up, shows an overall recurrence rate of 72% in 
D-PVNS of the knee. The recurrence rate was 44% for patients first treated at our 
institution and 92% for referred patients. Blanco et al.39 reported a recurrence rate 
of 14% in 22 prospectively followed primary D-PVNS knee patients treated by 
partial arthroscopic synovectomy combined with radiation therapy. Their mean 
follow-up was 33 months (range 26-76). Flandry et al.51 retrospectively reported an 
8% recurrence rate of D-PVNS in 23 knee patients (19 primary, 4 recurrent) treated 
by complete synovectomy, with a mean follow-up of 58 months (range 20-126).
 Chin et al.55 described 40 patients with recurrent D-PVNS of the knee: 10 received 
a surgical synovectomy and the other 30 received additional external beam 
radiation therapy. The recurrence rate was 18% with a mean follow-up of 5 years 
(range 1.7-8). These three articles seem to show a trend towards the longer the 
follow-up, the greater the number of recurrences, corresponding to our results.
Localized pigmented villonodular synovitis
Dines et al.116 reported no recurrences in 84 primary L-PVNS patients, of whom 29 
were excluded as they were incidental findings and only 26 of the remaining 
patients were evaluated. Our results show recurrence rates of 22% in 27 L-PVNS 
patients over an average 7.2 years. Two of them had already been treated elsewhere.
Both subtypes mixed
Byers et al.3 described recurrence rates of almost 50% over 3-35 years, however, 
both subtypes were combined and it is unclear whether only primarily affected 
patients were included. As in our patient group, their patients received different 
treatments, including synovectomies and external beam radiotherapy.
 Other relatively large case series have analysed PVNS of the knee but did not 
differentiate between the two subtypes.4,5,36,50,54 Recurrence rates of between 
20% and 36% were reported in 25-75 patients with a mean follow-up of 0.3-13.5 years. 
For these studies it is not known whether these patients were primary or recurrent 
cases.
Recurrence-free survival
Chiari et al.75 reported 23 primary L-PVNS patients with a 1- and 5-year RFS of 
100% and 88%, respectively, after surgical excision for all joints. For 19 primary 
D-PVNS patients they reported a 1- and 5-year RFS of 80% and 27%, respectively, 
after surgical excision. However, they combined different locations, like knees, 
hips and ankles, which can behave differently.50,58 Hips are more affected at 
diagnosis, caused by more joint space.50 The mean follow-up was 80 months (range 
26-294).
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Our analyses focused on the knee. We found an overall 1- and 5-year RFS of 83% 
and 69% for L-PVNS patients, respectively. For primary L-PVNS patients, this was 
89% and 80%, respectively. Similar differences were found for D-PVNS patients, 
with an overall 1- and 5-year RFS of 68% and 32%, respectively, and 92% and 65%, 
respectively, for patients first treated at our centre. These results not only confirm 
the importance of discerning  primary from recurrent patients in analyses, but it 
also underlines the possibility of a biologically aggressive subgroup. However, 
predictive markers for biologically more aggressive behaviour have not yet been 
found.
Complications
The nature and number of complications agreed with the literature,3,5,51,55 mostly 
consisting of infections and stiffness requiring manipulation. Not only the disease 
itself, but also its treatments, can cause loss of joint function. This is due to stiffness 
as a result of fibrosis, but also the development of OA. As a result, some patients 
even change career.
Quality of life
We found a significant impact on QoL scores compared with the general 
population.154 Both subgroups, L-PVNS and D-PVNS, scored low on mental health, 
vitality and general health compared with the general population.154 The D-PVNS 
patients also scored low on physical functioning, which might be attributed to 
impaired joint function due to multiple treatments with or without complications. 
To our knowledge, there are no QoL measurements published for PVNS patients. 
The SF-36 questions were asked at various times after treatment and patients 
received various treatments, and because of the relatively small group, all ages 
were analysed together. Nevertheless, there were significant differences.
Strengths and limitations
Related to the retrospective character of this study, there were missing data and 
some patients were lost to follow-up. However, a large number of PVNS patients 
were included and complete information regarding their treatments was available 
for all primary patients and almost complete for referred patients, including 
long-term follow-up.
 Unfortunately, no information was available from patients who were treated 
first in other centres and had no recurrences. Our tertiary centre receives primary 
PVNS cases from other centres either centres that do not treat or because the 
patients are difficult to treat (i.e. patients with recurrences or with extensive 
disease). Therefore our results might be an overestimate. However, comparing our 
large series with published incidence numbers suggests we received most patients.4 
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In addition, our results show an increase in RFS of patients first treated at our 
centre compared with patients first treated elsewhere. The above mentioned 
emphasizes the importance of centralization of care for this rare disease. 
Centralization may result in an increase in patient numbers treated, thereby 
increasing experience with specific treatments, notable effects of treatments and 
quality of patient registration/ follow-up.
 To the best of our knowledge, this is the first study that included QoL measures 
in PVNS patients. Measurement of QoL is increasingly important in today’s health 
care. Further studies should demonstrate whether or not the decreased QoL in 
PVNS patients in the present study is a consequence of the disease itself or of the 
(multiple) treatment(s) the patients received. However, it should be noted that not 
all patients completed the SF-36 questionnaire (70% of the L-PVNS vs 53% of the 
D-PVNS patients). To get an estimate of potential non-response bias, values known 
from all patients (age, sex, follow-up time and type of PVNS) were compared with 
the values that prevailed in the subgroup of those who answered. No significant 
difference was found between the groups, indicating that there might be no 
non-response bias.
Conclusions
Recurrence rates of PVNS deteriorate with time. Long follow-up rates underline 
that D-PVNS in particular is a continually recurring disease that over time is 
increasingly difficult to treat. Our findings confirm the importance of differentiating 
PVNS subtypes and also suggest that patients should receive treatment(s) at 
tertiary centres because of its rarity and destructiveness. Recurrence rates and RFS 
are not the only important measurements in this potentially disabling disease. 
The SF-36 is a useful tool, in addition to functional scores, to express treatment 
results. In order to design an optimal treatment, we have started a prospective 
study where clinical parameters, function and QoL are being studied at regular 
intervals pre- and postoperatively.
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Abstract
To evaluate health-related quality of life (HRQoL) and joint function in TGCT 
patients before and after surgical treatment.
 This prospective cohort study run in two Dutch referral centres, assessed 
patient- reported outcome measures (SF-36, VAS and WOMAC) in 359 consecutive 
patients with localized- and diffuse-type TGCT of large joints. Patients with 
recurrent disease (N=121) and a wait-and-see policy (N=32) were excluded. Collected 
data were analysed at specified time intervals pre-(baseline) and/or postoperatively 
up to 5 years.
 In total 206, 108 localized- and 98 diffuse-type, TGCT patients were analysed. 
Median age at diagnosis of localized- and diffuse-type was 41 (IQR 29-49) and 37 
(IQR 27-47) years, respectively. SF-36 analyses showed statistically significant and 
clinically relevant deteriorated preoperative- and direct postoperative scores 
compared with general population means, depending on subscale and TGCT 
subtype. After 6 months of follow up, these scores improved to general population 
means and continued to be fairly stable the following years. VAS scores, for 
both-subtypes, showed no clinically relevant differences pre- or postoperatively. 
Pain experience varied hugely between patients and also over time. WOMAC 
scores, for both TGCT subtypes, showed no clinically relevant differences pre- 
versus postoperatively. However, in diffuse-type patients WOMAC pain and 
physical function scores showed a trend towards improvement postoperatively.
 Patients report a significant better HRQoL after surgery in TGCT whereas joint 
function showed a trend towards improvement. Pain scores –which vary hugely 
between patients and in patients over time- did not improve. A disease specific 
patient-reported outcome measure would help to decipher impact of TGCT on 
patients’ daily life and functioning in more detail.
Level of evidence: 2
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Introduction
Tenosynovial giant cell tumours (TGCT) of large joints, historically known as 
pigmented villonodular synovitis (PVNS), are rare colony stimulating factor-1 
(CSF-1)-driven proliferative, mono-articular disorders. They affect the joints or 
tendon sheaths at all ages, however mostly at young adulthood. It most commonly 
affects large, weight bearing joints such as knees, ankles and hips.41,42 The 
incidence rate of localized-extremity (excluding digits) and diffuse-type TGCT is 
10 and 4 per million person years, respectively.18 Localized-type comprises a single 
nodule and has a favourable course after surgical treatment. Diffuse-type involves 
the synovial lining as well as surrounding structures. It can behave locally 
aggressive and is challenging to remove completely. There is a significant risk of 
recurrence after surgical treatment (>50% depending on follow up times).1,42,68
 Diffuse-type TGCT often requires one or multiple synovectomies, or at times a 
joint replacement, and rarely even amputation.41-43 In patients with extensive 
and/or recurrent TGCT, other available treatment modalities include radiation 
synovectomy46, external beam radiation therapy47, and cryosurgery174 of which 
the effects are controversial.76 More recently, systemic therapy has been 
introduced, targeting the CSF-1 receptor. At first treatment with the multi 
targeting tyrosine kinase inhibitor imatinib started, very recently more promising 
data of a CSF-1 specific targeting agent were presented.16,65,255 Systemic treatment 
may need to be given for one to several years, but the optimal treatment duration 
has still to be determined. Despite the variety of treatments, it is unclear which 
one is the most effective with the least impact on quality of life.
 A limitation of most clinical TGCT studies is the absence of disease specific 
and validated patient-reported outcome measures (PROMs) to document disease 
and treatment related functioning and symptomatology. Overall survival is the 
primary endpoint in oncologic clinical trials, however this is not appropriate for 
TGCT, which is rarely lethal.71 Alternate treatment endpoints in TGCT include 
response rates, progression free survival, and avoidance of morbid therapies. As 
indicated, quality of life (QoL) and functional scores are of utmost importance, but 
they are mostly not reported or only described for small, heterogeneous patient 
groups.20,42 The impact of therapies and the relevance of treatment outcomes to 
patients’ quality of life is therefore essential especially in a benign but locally 
aggressive disease.72,66
 The aim of our study is to investigate HRQoL, pain and joint function in 
surgically treated non-recurrent TGCT patients, pre- and/ or postoperatively over 
time.
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Methods
This prospective cohort study was conducted at two Dutch referral centres; 
Radboud University Medical Center (RadboudUMC) and Leiden University Medical 
Center (LUMC). Between 2011 until 2018 patients diagnosed with primary 
therapy-naïve or recurrent TGCT (magnetic resonance imaging (MRI) and 
histological confirmed) of large joints, were asked to participate. Large joints were 
defined as all joints except the digits. Three hundred and fifty-nine consecutive 
patients were identified; 136 (38%) with localized TGCT, 223 (62%) with diffuse 
TGCT. During regular outpatient clinic visits, patients who consented were 
requested to complete PROMs questionnaires. To further reduce heterogeneity of 
the group, patients with recurrent disease at presentation, treated conservatively 
(wait-and-see policy) and patients in absence of QoL and function scores after 
primary surgery, were excluded from this analysis (figure 1). Also, if patients 
developed relaps after surgical treatment, they were excluded from this time on. 
Hundred-and-eight localized- and 98 diffuse-type therapy-naïve patients were 
used for final analyses (figure 1).
 The study protocol (RadboudUMC (file number CMO 2012/555) and LUMC (file 
number CMO P13.029)) was approved by the local institutional ethical review 
boards and was carried out in the Netherlands in accordance with the applicable 
rules concerning the review of research ethics committees and informed consent. 
Patients provided written informed consent when they completed questionnaires 
(SF-36, VAS and WOMAC).
 The used PROMs included the Dutch translation of a generic HRQoL 
instrument, the 36-item Short Form Health Survey (SF-36)154, a Visual Analog Scale 
(VAS) for pain and the Western Ontario and McMaster Universities Osteoarthritis 
Index (WOMAC). SF-36 is an instrument for measuring general health, including 
eight subscales: Physical functioning (PF), Social functioning (SF), Role limitations 
due to physical problems (RP), Role limitations due to emotional problems (RE), 
General mental health (MH), Vitality (VT), Bodily pain (BP) and General health 
(GH). SF-36 scores were computed by summing the item scores and transforming 
the scores onto a 100-point scale (0= “worst health” and 100= “best health”). VAS for 
worst pain was used to estimate patients pain intensity of the affected joint for the 
past 24 hours, using a series of 0- to 10-point (0= “no pain” and 10= ”pain as bad as 
you can imagine”).256 The Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC) was used to evaluate affected joint function.156 The 
WOMAC is a 24-item instrument assessing pain, stiffness and difficulty performing 
daily activities originally designed for osteoarthritis. All items are measured on a 
5 point scale; ranging from “no” up to “worst imaginable”. The WOMAC data were 
standardized to a range of values from 0-100, for which lower values indicate more 
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pain, more stiffness, or worse physical functioning. Gelhorn et al. 72 used a 
modified version of WOMAC for TGCT patients.
 Patient demographics and clinical, histological, radiological, treatment and 
follow-up data were extracted from individual patients’ files at each institution by 
the local investigator (FGMV or MJLM) and were provided in an anonymous form 
for analyses. Definitive histological diagnosis was performed at the centre of 
origin by dedicated pathologists with extensive experience in mesenchymal 
tumours. Recurrences and PROMs were analysed according to TGCT subtype. Data 
were described using percentages for qualitative variables and medians with 
interquartile ranges (IQR) for continuous variables.
 As patient questionnaires were completed at different points in time they 
were categorized in the following time intervals: pre-surgery (=0 or baseline), 
post-surgery after 0-3, 3-6, 6-12, 12-24, 24-36, 36-48, 48-60 months. At final analyses 
we did not have questionnaires in all time intervals for each individual patient, 
some had solely pre- or post-operative scores. In case of recurrent disease after 
primary treatment in a therapy-naïve patient, QoL and functions scores were used 
up to recurrence development, confirmed on MR imaging. Follow-up time was 
defined as the period between first TGCT confirmation (MR imaging and histologic) 
and most recent patient contact. Time to recurrence was calculated as time from 
first treatment until proven (MR imaging and histologic) first recurrent disease.
 Differences between QoL scores (SF-36, VAS, WOMAC) were tested using t-tests. 
SF-36 scores were compared with Dutch general population scores154, and WOMAC 
and VAS baseline (preoperative) scores were compared with postoperative scores.
 To estimate the clinical relevance, the mean differences were compared with 
the minimal clinically important difference (MCID). MCID is a QoL measure that 
represents the smallest difference or change beyond statistical significance in an 
outcome measure score that would be considered clinically relevant by the value 
patients place on change.257 The MCID for SF-36 has been estimated at to be 10 
points by Escobar et al258 in patients undergoing total knee replacement. For VAS 
pain a MCID of 2 was used.259 The MCID for standardized WOMAC values has been 
estimated at around 15-20 points258, with relative improvements of 21-41% for its 
subscales259-261. We used a MCID for WOMAC of 20 points based on consensus in 
the project team and the study of van der Wees et al.262
 All statistical analyses were performed using R version 3.4.0 (R Foundation for 
Statistical Computing, Vienna, Austria). P-values <0.05 were considered statistically 
significant.
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Results
Patients
After exclusion of patients with recurrent disease (N=121) and patients with a 
wait-and-see policy (N=32), 206 patients remained for further analyses (figure 1). 
Median age at diagnosis of localized- (N=108) and diffuse-type (N=98) TGCT was 41 
(IQR 29-49) and 37 (IQR 27-47) years, respectively. The majority of patients were 
female (localized N=62 (57%)), had diffuse-type TGCT N=64 (65%)), and had the 
knee as the most common affected joint in both subtypes (localized N=84 (78%)) 
and diffuse N=72 (74%)). Pain (localized N=61 (57%) and diffuse N=58 (60%)) and 
swelling (localized N=66 (61%) and diffuse N=65 (67%)) were the most prevalent 
clinical symptoms at diagnosis for both subtypes (Table 1).
Treatments
As primary treatment, three (3%) localized-type patients were treated with 
arthroscopic synovectomy, 103 (95%) with one-staged synovectomy and two (2%) 
with (endo-)prosthesis. Seven patients (6%) had a first recurrence after median 2.9 
(2.1-5.6) years. Overall median follow up of localized therapy-naïve patients was 2.0 
(IQR 0.7-4.6) years. At final follow up, 104 (96%) patients had no evidence of disease, 
4 (4%) patients were alive with disease, without planned treatment.
 Diffuse-type patients were treated with arthroscopic (N=3 (3%)), one-staged 
(N=75 (76%)) or two-staged (N=18 (19%)) synovectomy. Two patients received an 
(endo-) prosthesis. Twenty-seven patients (28%) had a first recurrence after median 
1.3 (1-3) years, thereafter they were excluded from further analyses. Overall 
median follow up of diffuse-type patients was 2.7 (IQR 1.4-4.9) years. At final follow 
up, 70 (71%) patients had no evidence of disease, 27 (28%) patients were alive with 
disease and one patient died of another disease.
HR Quality of life
Compared to Dutch general population means,154 localized-type patients preoperatively 
scored significantly lower on PF (13.2(95%CI 6.0-20.5)), SF (18.7(95%CI 10.3-27.2)), RP 
(25.8(95%CI 11.9-39.8)), RE (20.6(95%CI 7.3-34.0)) and BP (21.2(95%CI 12.7-29.8)). 
These differences were also clinically relevant (mean difference > MCID 10). This 
effect lasted up to 3 months postoperatively on RP (40.1(95%CI 16.7-63.5)) and 
BP(17.2 (95%CI 2.2-32.1)). Thereafter, these means improved to general population 
means and continued fairly stable during the following years.
 Diffuse-type patients preoperatively scored statistically significant and 
clinically relevant (mean difference > MCID 10) lower on PF (23.7(95%CI 16.7-30.8)), 
SF (15.6(95%CI 8.8-22.5)), RP (37.4(95%CI 25.3-49.5)), VT (10.0(95%CI 3.5-16.4)) and BP 
(21.6(95%CI 14.7-28.5)) compared to general population means. This difference 
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Figure 1  Flowchart of consecutive patients with TGCT, included for quality of life analyses.
*Additional cryosurgery in two localized- and five diffuse-type TGCT patients
Evaluated TGCT patients
N=359
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Recurrent TGCT
Localized N=9
Diffuse N=81 
Therapy-naïve patients
Localized N=127
Diffuse N=142 
Localized-type TGCT
N=108
Arthroscopic synovectomy N=3
One-staged synovectomy N=103*
Prothesis N=2
Diffuse-type TGCT
 N=98
Arthroscopic synovectomy N=3
One-staged synovectomy N=75*
Two-staged synovectomy N=18
Prothesis N=2
Excluded:
No PROMs available prior to
first recurrence
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Diffuse N=25
Excluded:
'wait-and-see policy'
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Table 1  Characteristics of therapy-naïve TGCT patients. 
Localized N (%) Diffuse N (%)
Total 108 98
Median age at diagnosis (IQR), yrs. 41 (29-49) 37 (28-47)
Sex
Male 46 (43) 34 (35)
Female 62 (57) 64 (65)
Tumor localization
Knee 84 (78) 72 (74)
Ankle 10 (9) 10 (10)
Hip 1 (1) 7 (7)
Other 13 (12) 9 (9)
Pre-surgery symptoms
Pain 61(57) 58 (60)
Swelling 66 (61) 65 (67)
Loss of function 8 (7) 20 (21)
Stiffness 5 (5) 14 (14)
Recurrent disease
No 101 (94) 71 (72)
Yes 7 (6) 27 (28)
Median time to first recurrence (IQR) 2.9 (2.1-5.6) 1.3 (1-3)
Complications
None 106 (98) 91 (93)
Deep wound infection - 2 (2)
Superficial wound infection 1 (1) 2 (2)
Hemorrhage - 1 (1)
Joint stiffness 1 (1) 1 (1)
Neurovascular damage - 1 (1)
Median follow up time (IQR), yrs 2.0 (0.7-4.6) 2.7 (1.4-4.9)
Abbreviations: TGCT= Tenosynovial Giant Cell Tumors, N= Number of patients, mo=months, yrs= years, 
IQR= inter quartile range, other= Foot, shoulder, elbow, wrist or temporomandibular joint, AWD= alive 
with disease.
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with the general population remained significant for up to 3 months postopera-
tively on PF (21.9(95%CI 5.0-38.8)), SF (19.9(95%CI 3.0-36.9)), RP (40.1(95%CI 
16.2-64.1)), VT (13.0(95%CI 1.5-24.5)) and BP (22.4(95%CI 5.3-39.4)) and up to 6 
months postoperatively on PF (14.8(95%CI 3.3-26.4)). Thereafter, the mean SF-36 
scores of diffuse-type patients improved to Dutch general population means and 
continued fairly stable the following years. Compared to general population means 
diffuse-type patients scored statistically significant and clinically relevant lower 
on GH 3-6 months (10.6(95%CI 9.8-23.2)), 6-12 months (10.3(95%CI 2.3-18.9)) and 
24-36 months (10.7(95%CI 4.5-16.9)) postoperatively.
Visual analog scale for pain
No statistical significant nor clinical relevant difference in pain scores were found 
in localized-type patients preoperatively (median VAS score 4, IQR 1-6) versus 3 
months postoperatively (median VAS score 3.5, IQR 1-5), which in fact remained 
the same up to five years follow up. Median VAS scores in diffuse-type patients 
showed no clinical relevant difference preoperatively (median VAS score 4, IQR 
2-6) versus 3 months postoperatively (median VAS score 2, IQR 1-4), and also here 
the scores remained the same up to five years follow up. Pain experience in both 
subtypes TGCT varied widely between and within patients over time (range 0-7 
years follow up).
Joint function
Mean WOMAC scores on pain, stiffness and physical functioning for both localized- 
and diffuse-type patients showed no significant differences pre-(baseline) versus 
postoperatively. Patients of both subtypes scored significantly better at some 
postoperative time intervals compared to baseline scores, however mostly clinically 
irrelevant (mean difference < 20) (table 3a and b).
 In diffuse-type patients (table 3b) WOMAC pain and physical function scores 
showed a trend towards improvement in scores from preoperatively (baseline) to 
postoperative up to 5 years follow-up.
Discussion
To our knowledge, this study provides the largest prospective cohort, including 
longest follow up time, to report on PROMs in therapy-naïve patients with localized- 
and diffuse-type TGCT of large joints followed up until relapse of disease or end 
of study. In both TGCT subtypes HRQoL (SF-36) was statistically significant and 
clinically relevant decreased before surgical treatment on the main physical 
domains (RP, PF, BP) and some mental domains (SF, RE, VT) compared to general 
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CHAPTER 11
population means. These low scores lasted for up to 6 months postoperatively 
depending on TGCT subtype and SF-36 subscale. Thereafter, all SF-36 subscales 
improved to general population means and continued fairly stable the following 
years. Pain experience (VAS) in both subtypes varied widely between and within 
patients over time. Mean function (WOMAC) scores on pain, stiffness and physical 
functioning for both subtypes TGCT showed no clinically relevant difference pre- 
(baseline) versus postoperatively. However, in diffuse-type patients WOMAC pain 
and physical function scores showed a trend towards improvement in scores from 
preoperatively (baseline) to postoperatively up to five years follow-up.
 TGCT can behave locally aggressive causing joint destruction and provoke 
significant pain, swelling, decrease in range of motion, and stiffness.16 This 
morbidity can lead to impairment of HRQoL and function because of pain, 
medication use, disability, the knowledge of having a tumour (despite its benign 
character), and loss of working hours.72 To improve these consequences, treatments 
Figure 2A  SF-36 scores of localized-type, therapy-naïve, TGCT patients  
Spider plot showing SF-36 scores preoperative (baseline),  6-12 months postoperatively and of Dutch 
general population means153: physical functioning (PF), social functioning (SF), role limitations due to 
physical problems (RP), role limitations due to emotional  problems (RE), general mental health (MH), 
vitality (VT), bodily pain (BP) and general health (GH).
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are performed, which –unfortunately- might contribute to further joint 
destruction.76 The prolonged course of the disease and the need for multiple 
surgeries has been reported to result in a worse joint function for many patients.11 
In addition to the physical and financial burden for the patient, TGCT also involves 
high healthcare burden.6 Finding an efficient treatment is important.
 This study reported on the loss of HRQoL in patients with TGCT compared to 
general population means. The improvements in HRQoL after surgical resections 
were present 3-6 months after surgery. This could be explained by the morbidity of 
an operation and the associated recovery time.
 We did not find statistically significant and clinically relevant differences in 
pain experience. This might be explained by a variability in symptom experience 
as described by Gelhorn et al.72 They found that not all patients experience all 
symptoms and there was variability in how patients experienced symptoms 
within and among days.
Figure 2B  SF-36 scores of diffuse-type, therapy-naïve, TGCT patients
Spider plot showing SF-36 scores preoperative (baseline),  6-12 months postoperatively and of Dutch 
general population means153: physical functioning (PF), social functioning (SF), role limitations due to 
physical problems (RP), role limitations due to emotional  problems (RE), general mental health (MH), 
vitality (VT), bodily pain (BP) and general health (GH).
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Table 3a   WOMAC scores of localized-type, therapy-naïve, TGCT patients preoperatively 
and postoperatively up to 5-years follow up.
WOMAC scores  
(mean (SD))
Time intervals in months
0
N=35
0-3
N=12
3-6
N=9
6-12
N=14
12-24
N=9
24-36
N=8
36-48
N=5
48-60
N=5
Pain 73.1
(20.9)
74.2
(17.4)
86.7*
(13.7)
83.9 
(16.5)
70.0 
(22.4)
85.0*
(11.0)
81.0 
(29.2)
95.0*
(5.0)
Stiffness 73.5
(25.1)
59.4
(19.3)
77.8
(21.4)
79.5
(25.8)
59.7
(32.3)
67.2
(25.8)
85.0
(22.4)
80.0
(11.2)
Physical 75.0
(21.4)
76.5
(19.4)
88.1*
(13.1)
89.8*
(11.8)
74.7 
(20.6)
86.0
(11.6)
82.1 
(33.9)
92.6*
(7.1)
Total 74.7
(20.1)
74.6 
(17.8)
87.4* 
(13.5)
87.7*
(13.0)
72.5
(21.3)
84.2
(10.6)
82.1 
(31.8)
92.1*
(6.6)
WOMAC= standardized Western Ontario and McMaster Universities Osteoarthritis Index. In the 
standardized WOMAC (0-100) sum scores, higher values indicate less pain, stiffness or better physical 
functioning. N= number of questionnaires.*=statistically significant, underlined scores are clinically 
relevant (mean difference > MCID 20). WOMAC questionnaires were categorized in the following time 
intervals: pre-surgery (0), post-surgery after 0-3, 3-6, 6-12, 12-24, 24-36, 36-48, 48-60 months.
Table 3b   WOMAC scores of diffuse-type, therapy-naïve, TGCT patients preoperatively  
and postoperatively up to 5-years follow up.
WOMAC scores 
(mean (SD))
Time intervals in months
0
N=31
0-3
N=11
3-6
N=10
6-12
N=9
12-24
N=12
24-36
N=11
36-48
N=10
48-60
N=9
Pain 59.8
(20.9)
68.2
(23.5)
73.5
(17.2)
75.6 
(21.0)
79.6* 
(22.7)
77.7*
(20.8)
77.5* 
(22.8)
85.0*
(21.2)
Stiffness 60.9
(24.1)
62.5
(17.7)
76.3
(24.6)
69.4
(19.9)
68.8
(22.3)
69.3
(18.8)
72.5
(21.1)
75.0
(25.8)
Physical 63.9
(18.8)
68.3
(18.7)
73.7
(22.2)
82.7*
(15.7)
81.0* 
(23.1)
76.7
(21.5)
82.1* 
(18.2)
84.2*
(19.5)
Total 62.8
(18.7)
67.8 
(18.4)
73.9 
(20.3)
80.1* 
(16.1)
79.7*
(22.4)
76.3
(20.2)
80.3* 
(18.0)
83.6*
(19.4)
WOMAC= standardized Western Ontario and McMaster Universities Osteoarthritis Index. In the 
standardized WOMAC (0-100) sum scores, higher values indicate less pain, stiffness or better physical 
functioning. N= number of questionnaires.*=statistically significant, underlined scores are clinically 
relevant (mean difference > MCID 20). WOMAC questionnaires were categorized in the following time 
intervals: pre-surgery (0), post-surgery after 0-3, 3-6, 6-12, 12-24, 24-36, 36-48, 48-60 months.
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The lack of clinically relevant improvement in joint function (WOMAC) could be 
explained by the destruction the disease already caused, or by the small number of 
questionnaires left after exclusion of many patients to optimize the homogeneity 
of the patient group. The lack of  disease specific instruments to evaluate adequate 
PROMs for TGCT, may have led to underreporting disease specific issues.
 SF-36 was developed to get more general insight into patients’ health and as a 
means of making comparisons across conditions.263 VAS was developed as a pain 
assessment tool used for cancer patients.256 The WOMAC was originally developed to 
evaluate the outcome of a total knee replacement in patients with osteoarthritis.156 
SF-36, VAS and WOMAC are a good start in assessing the patients perspective in 
TGCT, since they are validated, easy to apply and globally known. These measures 
are frequently used for other diseases, allowing to compare TGCT patients with other 
patient groups, for example patients with joint replacements for osteoarthrosis.108,258,264 
Gelhorn et al. investigated ‘patient-reported symptoms of TGCT’. They concluded 
that pain (VAS), swelling, stiffness and impaired joint function (WOMAC) are 
important PROMs.
 Van der Heijden et al. 20 evaluated 30 patients with therapy-naïve and recurrent 
diffuse-type TGCT at a mean of 8 (range 2-32) years after diagnosis. HRQoL 
impairment (SF-36) was seen in all patients initially treated with arthroscopic 
synovectomy (62 range 26-94) and an open synovectomy (80 range 63-98), compared 
to healthy controls.20 The patient population was small and heterogeneous, in 
which outcome measures were assessed at different time points after treatment. 
In the study of Verspoor at al.42, which experienced similar limitations, HRQoL 
(SF-36) scores were not significantly different between localized- and diffuse-type 
TGCT. However, both patient groups had impaired HRQoL compared to general 
population means one the general health subscale. Diffuse patients also scored 
significantly lower on other subscales (PF, MH and VT). The current study, with a 
more homogenous, larger patient cohort and measurements at categorized time 
intervals, showed a similar impairment in therapy-naïve patients on PF pre-
operatively for both subtypes and up to 6 months postoperatively in diffuse-type 
patients who generally need more extensive surgery compared to localized-type 
TGCT.
 Case series reporting on joint function before treatment often included both 
subtypes, various localizations, a mixture of therapy-naïve and recurrent TGCT 
including multiple treatments.11,20,80,132,265 Therefore, it is extremely challenging 
to perform a meta-analysis to prove treatment effect(s) in the rare disease TGCT. 
Through the emergence of systemic treatments for TGCT, attention for additional 
outcome measures besides recurrences has been raised, such as HRQoL and joint 
function. International cooperation has been initiated, resulting in large registries 
including QoL and joint function.266 In the recent years targeted therapy has been 
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added to the armamentarium. At ASCO 2018 results of pexidartinib (PLX3397)65, a 
selective inhibitor of CSF-1 receptor, KIT, and FLT3-ITD, were promising in a 
randomized, placebo controlled, phase 3 study. Pexidartinib compared to placebo 
resulted in an significantly improved overall response rate (39.3% vs 0%) and 
PROMIS physical function (4.06 vs 0.89), after a median 6 months follow up.65 In 
this study range of motion, PROMIS physical function, worst stiffness and pain 
response were secondary endpoints. 65
 The joint localization of TGCT might influence physical function.59,267 
Therefore, a sensitivity analysis was performed on our patients with TGCT 
affecting the knee, which showed similar results to our primary analysis. In a 
univariate analyses on TGCT locations with recurrent disease as outcome, 
Palmerini et al.38 did not find a difference between knees, hips and ankles.
 Two crowdsourcing studies21,268, using an online patient support-group, 
reported on physical function and HRQoL in TGCT patients. In patients with 
diffuse-type TGCT, recurrences requiring repeated surgery and joint replacement 
were reported to have a lower HRQoL and functional outcome.21,268 Because of 
selection bias, it is possible that severe cases including (additional) recurrences 
were more likely to be online to complete the e-survey. However, all studies, 
including the current one suggest an impaired effect on HRQoL and function in 
patients with TGCT. The challenge remains to find the exact quantification 
method.
 This study has some limitations that need to be discussed. Because of the 
rarity of TGCT, it is challenging to perform a prospective study with adequate 
patient numbers. To reduce heterogeneity of the patient group, we chose to exclude 
recurrent patients, at the expense of decreasing patient numbers. Still, heterogeneity 
in severity and duration of illness remained.
 Selection bias should be taken into account, because this study only contains 
patients from two tertiary Dutch referral centres. Overrepresentation of extensive 
disease, could have resulted in an overestimation of the impact on HRQoL and 
joint function. Also, patients with complaints more often visit the outpatient 
clinic completing questionnaires. These patients might have more extended, 
metastatic, disease. By excluding patients with recurrent TGCT, this possible bias 
was reduced. On the contrary, patients who do well, like localized-type TGCT 
patients, were discharged early reducing their follow up time and number of 
questionnaires.
 It should be noticed that HRQoL and function scores were taken at variable 
points after treatment for individual patients, which reduced  numbers at some 
specific time points. Not all patients had preoperatively and postoperative available 
measures, causing an  increase in the range of these outcome measures. 
Furthermore, it is preferred to adjust SF-36 measures for age, because of physiolog-
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ically declined HRQoL and joint function decrease in ageing.154,254In the current 
study correction for age could not be achieved by differences in ages per time 
interval and the age distribution within time intervals.
 Patients with localized-type TGCT generally do not have a high burden of 
their disease. The question is whether PROMs are essential in patients with 
localized disease, who can generally be treated curatively with a radical excision 
and are not eligible for systemic therapy. To date, surgical resection remains the 
treatment of choice for TGCT, but is associated with high recurrence rates and 
multiple additional surgeries in diffuse-type disease.76 The balance between 
increased morbidity of multiple or invasive surgeries20,77, alternative therapeutic 
options, and daily symptoms of the tumour is challenging. A more aggressive 
resection or other multimodality treatments, such as external beam radiation 
therapy, may adversely affect QoL, joint function and the development of 
osteoarthrosis, which are, given the young adult age group, factors of major 
importance.38,42 Use of a control group and of specific and validated PROMs will 
better document treatment-induced symptomatic, functional and economic (back 
to work) consequences of these treatments.72
 When systemic treatments show tumour growth arrest and symptomatic 
improvements, a less invasive approach would be justified.16 The recent studies on 
targeted therapy used a control group and as secondary outcome measure PROMIS 
physical function.65
 These measures are critical endpoints in demonstrating clinical relevance and 
impact of treatments for benign diseases in which death is no outcome variable.72 
Clinical benefit necessitates objective measures to correlate with tumour 
reduction. When significant changes in TGCT specific developed outcome measures 
are found, one should try to specify if this is the consequence of the disease itself, 
of the ‘multiple’ treatment(s) received, or of other factors, such as comorbidities, 
the knowledge of having a tumour or issues not related to disease.
Conclusion
Patients report a significant better HRQoL after surgery in TGCT whereas joint 
function showed a trend towards improvement. Pain scores –which vary hugely 
between patients and in patients over time- did not improve. A disease specific 
patient-reported outcome measure would help to decipher impact of TGCT on 
patients’ daily life and functioning in more detail.
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SUMMARY
The aim of this thesis was to investigate the incidence, diagnosis, treatment 
options and outcome parameters in patients with TGCT of the joints. In chapter 1, 
an overview of the current knowledge was presented. TGCT are rare benign 
tumours arising from the synovium, tendon sheaths or bursae, and are divided 
into two known subtypes; localised (either digits or extremities) and diffuse. Our 
understanding of TGCT incidence was previously based on one single-country (US) 
study in 1980, which indicated annual incidences of 9 and 2 per million people for 
the localised (including digits) and diffuse-type TGCTs, respectively.
Incidence
The nationwide study presented in chapter 2 utilised five years of data obtained 
from the Dutch Pathology Registry (PALGA), from which worldwide incidence 
rates in the digits, localised-extremity and diffuse-type TGCTs were calculated to 
be 29, 10 and 4 per million person-years, respectively. TGCT is still a rare condition, 
but these results show it is a more common disease than was previously reported. 
Both types showed a predilection for the knee joint, a slight predisposition in 
females (male:female ratio 1:1.5), a median age at first treatment of 47 years, and 
for both types, patients were primarily treated with an open resection.
 The research presented in chapter 3 reviewed all published paediatric cases in 
1990–2016, incorporated data from children younger than 18 years of age taken 
from the nationwide TGCT incidence study in chapter 2, and used clinical data 
from our nationwide bone and soft tissue tumour data registry from 1995–2015 to 
evaluate TGCT in children. A standardised paediatric TGCT incidence rate of 2.4 
and 1.1 per million person-years was found in localised- (excluding digits) and 
diffuse-type TGCTs, respectively. The symptoms in both children and adults were 
swelling, pain and a limited range of motion. The median diagnostic delay (initial 
clinician consultation until diagnosis) was 12 (range: 1–72) months. No differences 
were found between children and adults in terms of the sex ratios of patients, 
symptoms, first treatment, recurrent disease, follow-up status, or median time to 
follow up.
Diagnosis
MRI is the most discriminate imaging technique in diagnosing, preparing for 
surgery (evaluating the extent of disease) and evaluating TGCT during the follow up. 
MRI can reveal the conspicuous nodular (localised) or villous proliferation of the 
synovium (diffuse); however, no discriminating features describing or quantifying 
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tumour extent in relation to clinical outcome had previously been reported. 
Uniform MRI descriptions are important for clinical and research purposes; 
therefore, potentially distinguishing MRI parameters for assessing the extent of 
disease were defined and tested by field experts in chapter 4. These included the 
type of TGCT, articular involvement, cartilage-covered bone invasion, and the 
involvement of muscular/tendinous tissue, ligaments or neurovascular structures. 
With the exception of cartilage-covered bone invasion and neurovascular 
involvement, these parameters were evaluated in two different study populations 
to establish four TGCT severity subgroups based on the risk of recurrence. The 
proposed TGCT severity classification informs physicians and patients about the 
extent of disease and the risk of recurrence after surgical treatment. By defining 
the most severely affected patients (those with the highest risk of disease 
recurrence), the patients eligible for other treatment modalities could be identified 
and properly evaluated as part of a more homogenous patient population.
Treatments
At present, the treatment strategy for patients with localised- and diffuse-type 
TGCTs in large joints is a surgical resection of all pathological tissue, with the 
additional use of other treatment modalities where required. These strategies are 
not (always) sufficient; there are high recurrence rates, especially for diffuse-type 
TGCT. In Chapter 5, a systematic review of the literature was presented, describing 
all known treatment options for TGCTs of large joints and their clinical results. 
Over the past century, progress has been limited. The available treatment options, 
which revealed varying success rates and morbidities, were surgical versus non- 
surgical, partial versus complete synovectomies, open versus arthroscopic 
synovectomies, radiosynovectomy, external beam radiotherapy, and target treatments. 
Furthermore, additional or self-contained treatments were also available, including 
cryosurgery, immunotherapy, arthroplasty, arthrodesis or amputation. 
 These various treatments have been proposed and applied to treat TGCT; however, 
due to the low incidence of the disease, randomised clinical trials are lacking and 
treatment efficacies are hard to compare. Treatment guidelines were established to 
improve the future comparability and aggregation capabilities of study results from 
different centres, as well as to support physicians in making the optimal treatment 
decisions. An international registry generated through existing networks would 
provide better insights into the outcomes of this disease; therefore, a key set of data was 
proposed for investigation and ideally incorporation into a registry.
 The results of arthroplasty and cryosurgery were retrospectively investigated 
in more detail. Chapter 6 described the outcomes of patients with TGCT who had 
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received a knee or hip arthroplasty for extended disease or osteoarthritis. It 
confirmed that arthroplasty is a treatment option after surgical synovectomy; 
however, disease recurrences, implant loosening and other complications do 
occur, even after years of follow up.
 In Chapter 7, the results of cryosurgery in addition to surgical resection were 
described. This study confirmed the difficulty of research using small, retrospective, 
heterogeneous patient groups. Cryosurgery may serve as an additional treatment 
for diffuse TCGT in selected cases; however, the presented study did not find an 
advantage for additional cryosurgery over surgical resection except in the 
reduction of recurrences.
 Diffuse-type TGCT often causes significant morbidity due to local recurrences 
necessitating multiple surgeries. Targeted therapy, if effective and with acceptable 
toxicities, might prevent surgery with unacceptable morbidity risk or permit less 
invasive surgeries in a neoadjuvant setting. TGCTs are CSF-1-driven proliferative 
disorders; therefore, the international multi-institutional retrospective study 
presented in chapter 8 was performed to investigate the long-term effects of using 
imatinib mesylate, a CSF-1R blocker, for patients with locally advanced and 
recurrent diffuse-type TGCT. In the patients who benefitted from the imatinib 
mesylate treatment, a prolonged activity on TGCT symptoms was confirmed, even 
after the discontinuation of the treatment; however, high rates of treatment 
interruption and additional treatments were also recorded.
 TGCT can affect any synovial joint and can rarely occur in the temporo-
mandibular joint. The management of TGCT in the temporomandibular joint is 
similar to treating the disease in the large joints, requiring a complete synovectomy 
to remove all pathologic tissue, combined with other treatment modalities when 
required. The location of the temporomandibular joint can mean that the complete 
removal of TGCTs in this region has unacceptable morbidity rates in terms of a 
mutilating surgery however, and the effect of multimodal treatment(s) is unknown. 
Chapter 9 reported the results of three cases with TGCT of the temporomandibular 
joint, and a review of the relevant literature was presented. TGCT of the temporo-
mandibular joint is diagnosed using MRI, with additional CT if necessary to 
evaluate the extent of disease. When in doubt, an open biopsy might be necessary 
to confirm the diagnosis. The treatment for the localised-type disease is an excision 
biopsy, while treatments for diffuse-type disease should be individualised 
depending on the patient age, symptom severity, extent of disease and progression, 
expected mutilation of surgical interference, and current systemic treatment options. 
In stable disease, a ‘wait and see’ policy is a viable option. Additional treatments 
should be reserved for symptomatic, irresectable tumours or residual disease after 
surgical treatment and or persistent complaints.
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Outcome
Chapter 10 described the long-term follow-up of a single institution’s large 
consecutive series of patients with TGCTs in large joints. The mean age at the time 
of diagnosis was 37.5 (range: 17.2–71.7) years and 33.9 (range: 14.4–62.2) years 
for localised- and diffuse-type TGCT, respectively. The knees were most commonly 
affected (88% of patients). The treatments received were surgery, external 
beam radiation therapy, radiosynovectomy, systemic therapy, immunotherapy 
or combinations of treatments. A total of 49 patients (46%) had received prior 
treatment elsewhere. The mean follow-up time from diagnosis until last contact 
was 7.0 (range: 0.3–27.4) years for localised-type TGCTs and 14.5 (range: 1.1–48.7) 
years for diffuse-type TGCT of the knee. The recurrence rates of TGCT deteriorated 
with time, particularly for the diffuse-type disease; for the knee, the one- and 
five-year recurrence-free survival (RFS) rates were 69% and 32%, respectively. Long 
follow-up times confirmed that diffuse-type TGCT is often a continually recurring 
problem, and over time it becomes increasingly difficult to cure.
 Besides recurrences and RFS rates, the QoL and functional scores are critical 
endpoints in demonstrating the clinical relevance and impact of treatments for 
benign diseases in which death is not an outcome variable. Chapter 11 describes 
the largest prospective cohort, including the longest follow-up time, to report on 
patient-reported outcome measures (PROMs) in therapy-naïve patients with 
localised- and diffuse-type TGCTs in large joints. For both TGCT subtypes, patient 
QoL (SF-36) was significantly and clinically relevantly decreased before the surgical 
treatment, including on the main physical domains and some mental domains, 
in comparison with the general population means. Three-to-six months post-
operatively, all SF-36 subscales improved to the level of the general population 
means and continued to be fairly stable over the following years. The pain 
experience (VAS) in both subtypes differed tremendously between patients and 
over time. The mean function (WOMAC) scores for pain, stiffness and physical 
functioning in both TGCT subtypes revealed no clinically relevant differences in 
patients before (baseline) and after their surgery; however, in patients with 
diffuse-type TGCT, the WOMAC pain and physical function scores showed a trend 
of improvement postoperatively, for up to five years of follow-up. These findings 
showed that patients with TGCT need three to six months after surgery to recover 
to a QoL similar to the general population mean. Joint function improvement 
showed a similar trend, although the results lacked clinical relevance. Surgery 
had no influence on the pain experienced, confirming the importance of surgery 
as a treatment for TGCT.
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DISCUSSION AND FUTURE PERSPECTIVES
Discussion
TGCT is a rare proliferative joint disease, mostly affecting young adults, and often 
causes significant morbidity due to local recurrences necessitating multiple 
surgeries. Adding to and improving the knowledge about rare diseases is a great 
challenge, and the existing literature yields mostly small retrospective case series. 
The research presented in this thesis clarifies some aspects of TGCT.
Standardisation of TGCT subtypes is essential
TGCT is more common than previously believed (chapter 2), but it is still rare. To 
increase patient numbers in studies of TGCT, the two forms, localised-(extremity) 
and diffuse-type, are often merged,4,35,44,50,74,121,122 despite the decades-long 
consensus that these two entities behave biologically differently.2 Making a 
clinical distinction between localised- and diffuse-type TGCTs can be difficult, 
especially for clinicians not familiar with this rare disease.51 A recent Danish 
registry-based TGCT study on incidence,269 published roughly at the same time as 
the pathology-based incidence study presented in this thesis (chapter 2), confirmed 
the difficulty of diagnosing and categorising TGCT subtypes. Both studies used 
different subtype definitions, despite the efforts of the WHO to uniformly classify 
TGCT1, and came up with different incidence rates. 
 Localised TGCT of digits (localised-digits) were analysed as a distinct entity to 
the other localised-type TGCTs (chapter 2), because the majority of lesions localised to 
joints distal to the metacarpal or metatarsal bones arise from the tendon sheath 
and less frequently from the synovial lining of the digital joints. In our opinion 
and that of others, localised-digits TGCT is a distinct subtype within the same 
disease spectrum.74,75 The Danish registry-based TGCT study included patients 
with TGCT of the digits, who comprised over half of their patients with localised- 
type TGCTs. Even when all patients with TGCT (localised-digits, localised extremity 
and diffuse-type) were combined in the present study, the incidence of TGCT 
(worldwide incidence rate: 43 per million person-years) found here (chapter 2) differs a 
little from that of Denmark (39 per million person-years).18,269 
 Even if the different subtypes were always classified in the same way, the 
presented ‘severity classification’ (chapter 4) suggests that subdividing between 
localised-extremity and diffuse-type TGCTs is an oversimplification, and fails to 
estimate the differences in recurrence rates for individual patients. There is a 
difference in the risk of developing recurrent disease between mild-localised, 
severe- localised, moderate-diffuse and severe-diffuse forms of TGCT, with the 
latter behaving the most aggressively.
 In contrast to other studies,4,162 we found that females showed a slight pre-
disposition to both types of TGCT (male:female ratio 1:1.5) (chapter 2), in accordance 
524982-L-bw-Verspoor
Processed on: 3-10-2018 PDF page: 216
216
CHAPTER 13
with the preliminary results of an international retrospective registry study with 
over 2,000 patients (abstract for EMSOS 2018).266 Ehrenstein et al. confirmed this 
slight predisposition of females (61%) for localised-type TGCTs, but reported an 
equal sex prevalence (females 51%) in diffuse-type TGCT patients. 
Influence of anatomical locations on tumour behaviour
The anatomic site of TGCT may have significant influence on its clinical 
behaviour;2,8,59 however, whether this variation in behaviour is caused by the 
location itself or by the existence of undefined subtypes is unknown. According to 
Chung et al.,58 bone invasion is more likely to occur in joints without large synovial 
recesses to accommodate the expanding synovial masses, such as the hip. 
Furthermore, because of the deeper location, the diagnosis of TGCTs in this region 
may be delayed. Schwartz et al.50 found higher recurrence rates in affected knees 
than any other location. In chapter 6, which described arthroplasties for patients 
with TGCTs, patients with affected hips received a prosthesis over 20 years earlier 
than patients with TGCT of the knee. This might be caused by a higher incidence 
of bone erosions and cyst formation in TGCT hips compared to knees. Nevertheless, 
all locations are combined in most outcome measurements to increase patient 
numbers.3,19,44,50,75,120
 In contrast, other studies did not show a (significant) difference in recurrence 
rates for both localised- and diffuse-type TGCTs when comparing the knee with 
other joints.37,38,75,111 In this thesis, all large joints (including the knees, hips and 
ankles) were included to sub-classify the disease severity of TGCT (chapter 4), to 
investigate efficacy of imatinib mesylate (chapter 8), and for measurements of pa-
tient-reported outcomes (chapter 11). The presented incidence study of this thesis 
(chapter 2) showed a predominance for the knee joint in adult patients with 
localised- (46%) and diffuse-type (64%) TGCTs, in line with the affected joints in 
children (chapter 3) and those of the patients presented in the long-term follow-up 
study (chapter 10). The preliminary results of the international retrospective 
registry study with over 2,000 patients revealed no effect of TGCT location on the 
risk of developing recurrent disease.266
Heterogeneously treated patients
There is a large diversity in the treatment options for TGCT; in most case series, 
more than three different treatments are described.3,19,44,50,54,75,117 If the already 
relatively heterogeneous patients were further divided into the different treatment 
groups, the groups would be too small to draw adequate conclusions. To minimise 
heterogeneity in patients and treatments, only patients primarily treated with 
open synovectomies were included in the TGCT severity classification study 
(chapter 4). In chapters 6, 7 and 8, the heterogeneity of prior treatments was a 
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limitation. The presented long-term follow-up results of this thesis (chapter 10) 
therefore included detailed information on each patient, which will enable future 
reviews to better analyse subsets of patients who received specific treatments.
 In the assessment of treatments, patient groups consist of newly diagnosed 
patients (therapy-naïve) and patients already treated elsewhere.5,19,41,50,51 Some 
studies focus on this topic and describe the treatments that patients received 
before arrival in their centre,19,50,51,55 while others do not report the composition 
of their patient groups at all.3,44 This leads to bias in outcome measurements, such 
as the overall recurrence rates, which appear higher than they really are in 
comparison with case series comprising only therapy-naïve cases. Schwartz et al.50 
described this manipulation as referral bias, which is mostly present in patient 
populations from tertiary centres. They showed that patients who had received 
previous treatment had more recurrences than therapy-naïve patients (p < 0.01); 
however, the patients with previous procedures had unusual cases of TGCT. Their 
prior operations may have affected the disease recurrence in some way, or their 
disease may have had biologically aggressive characteristics or been located in 
joints less amenable to surgical eradication. The presented long-term follow-up 
results (chapter 10) and the preliminary results of an international retrospective 
registry study with over 2,000 patients (abstract for EMSOS 2018)266 confirmed 
that patients with TGCT do worse when they have already been treated elsewhere.
 By studying the incidence rates of TGCT (chapter 2), it was discovered that 
Dutch referral centres only treat ‘the tip of the iceberg’; only 18% of diffuse-type 
TGCTs were primarily treated in one of the four tertiary orthopaedic oncology 
centres. This might be the case worldwide, and must therefore be kept in mind 
when interpreting research results. It is likely that only the referral centres only 
treat the worst patients, who would also be most prone to develop recurrent 
disease. Most of the centres involved in the international retrospective study of 
over 2,000 patients were tertiary referral centres,266 meaning that even a study 
involving a large number of patients with a rare disease might have a significant 
patient selection bias that should be taken into account when considering the 
results of this study. For now, however, these data represent the best information 
available. Furthermore, most patients underwent surgery as a first treatment, the 
results of which are dependent on surgeon experience. 
 In patients with locally advanced or recurrent TGCTs, systemic therapies 
targeting the CSF-1/CSF-1R axis have been investigated (nilotinib, imatinib, 
pexidartinib (PLX3397), emactuzumab (RG7155) and cabiralizumab (FPA008)). 
Some of these systemic treatments have been studied and proven effective,63,64 
while novel and more potent agents are still under investigation.16,66,255 Patients 
included in these trials, as well as those in the international long-term follow-up 
study of imatinib mesylate (chapter 8), were very heterogeneous. Strict patient 
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selection for trial inclusion is desirable to accurately evaluate the effect of these 
treatments; however, patient selection for trial inclusion is currently decided by 
the preferences of the treating physician and might differ between centres. Also, 
the inclusion criteria differ between countries, depending on the availability and 
reimbursement of drugs and the availability of clinical trials. Using the MRI-based 
severity classification (chapter 4), more aggressive TGCT subtypes were defined in 
an attempt to include more uniformly defined patients in future clinical trials. 
Also, the evaluation of the effect of treatments would benefit from clear agreements 
about response monitoring.
Heterogeneous outcome measures
Some studies used various outcome measures, including recurrence rates, RFS 
percentages, numbers of secondary osteoarthritis and the rate of complications, 
while others used only broad outcome terms (good, excellent, fair, poor, etc.). 
Unfortunately, the largest case series (> 20 patients) used different outcome 
measures or provided incomplete descriptions.76 In our study of the long-term 
follow-up results (chapter 10), the recurrence rates, RFS percentages and 
complications were described, in addition to the QoL (SF-36). Ideally, SF-36 values 
should be corrected for age; however, because of the small number of patients and 
the presence of treatment bias, this was not applied. In chapter 11, data were 
collected from consecutive patients for years, but the number of patients was still 
relatively small for demonstrating a clinically relevant and/or significant 
treatment effect on HRQoL and joint function. This might be explained by (1) high 
levels of variability in the HRQoL and joint function results, (2) a small effect of 
surgery on HRQoL and joint function, (3) the use of patient outcome measures 
(SF-36, VAS and WOMAC) that were not sensitive enough to measure HRQoL and 
joint function in TGCT. These patient outcome measures are broadly used to assess 
diseases such as osteoarthritis and their treatment effects.258,264 After recurrence 
rates, QoL and joint function are the most important measures to quantify and 
compare the treatment effects on patients with TGCT.
Definition of recurrent disease
Some studies accept clinical symptoms and radiographs to detect recurrent 
disease,3,5 while others insist on MRI or even histological confirmation before 
designating a relapse, and only a few studies differentiated between residual 
disease and recurrences.19,117 Again, a decision needs to be made about whether 
clinical symptoms are considered sufficient evidence for recurrent disease, or 
whether MRI and histological confirmations are needed. What are the treatment 
implications of residual or recurrent disease detected using MRI in the absence of 
clinical symptoms? Should additional treatment(s) occur, or is a conservative ‘wait 
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and see’ approach sufficient? The incidence study of this thesis (chapter 2) was 
pathology-based, and patients with TGCT were not represented if they had not 
undergone a biopsy or treatment. As a result, both the incidence and recurrence 
rates are likely underestimated. 
 Further, a clear differentiation between true recurrent disease and operations 
for other reasons is essential. Not all operations in the same joint indicate recurrent 
TGCT, as they are frequently performed for secondary osteoarthritis requiring 
arthroplasty or stiffness requiring manipulation under anaesthesia. After arthroplasty, 
diagnoses of recurrent disease can be challenging because of MRI artefacts caused 
by the prostheses themselves. Recurrent disease could be suspected from clinical 
complaints in combination with ultrasonography; however, only histopathology 
could confirm recurrent disease. 
 Finally, TGCT can recur after many years; therefore, the follow-up times used 
in many studies are often too short.59 Due to the retrospective character of these 
studies, data are missing and contact is lost with many patients. The long-term 
follow-up study presented in this thesis (chapter 10) confirms the importance of 
reporting the time at which outcome measures such as recurrence rates and RFS 
rates were evaluated; the recurrence rates increased over time, making studies of 
these rates without indications of the time relatively useless.
Future perspectives
The most severely affected patients, with the highest risk of morbidity due to 
extended disease and/or multiple recurrences, are also the most in need of effective 
treatment(s). Efforts should be made to identify these patients (with the biologically 
aggressive subgroup of TGCTs) using radiological, clinical, histopathological and 
molecular approaches. The MRI severity classification presented in this thesis 
(chapter 4) may be a good start, but it requires further investigation and fine- 
tuning. Relationships between radiology imaging and clinical symptoms, such as 
the locations of the initial TGCT, growth of recurrences and osteoarthritis, might 
be of great importance. 
 The role of systemic treatment in TGCT requires further exploration. The patients 
who would benefit most from systemic therapy should be identified based on 
molecular tumour features sensitive to that specific treatment. Subsequently, an 
optimal treatment strategy should be developed. The combination of a short 
treatment period with a durable effect after discontinuation should be pursued, as 
even minor toxicities mean it is challenging to maintain compliance for years. The 
use of CSF-1R inhibitors in the perioperative setting still requires further 
exploration. To prevent unnecessary systemic treatment, the development of local 
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treatments, such as intra-articular injections against TGCT that do not interfere 
with cartilage and have no systemic side effects, would be of major value.
 The impact of TGCT and its treatments on QoL and joint function must be 
further defined. Specific TGCT patient-reported outcome measures should be 
developed to enhance the quantity and quality of the treatment effects, especially 
with the arrival of systemic treatments. It is vital that uniform time intervals are 
used for each patient and that objective joint-specific function measurements are 
explored. The chronic appearance of TGCT, particularly the diffuse type, in 
relatively young adults of working age will probably have an incredible impact on 
healthcare burden and costs; however, these aspects remain undefined and have 
not been subject of research.
 Finally, given the rarity of the disease, randomised studies are not to be 
expected, but the establishment of an international registry (such as was initiated 
with the TGCT Observational Platform Project from Daiichi Sankyo) through 
existing networks would provide better insights into the outcomes of this disease. 
We therefore proposed a ‘key outcome set’ of data to be investigated and ideally 
reported in such a registry or in case series. This would allow case series from 
different centres to be compared and analysed together, resulting in a higher level 
of evidence for the optimal treatment of TGCT.
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In dit proefschrift worden de incidentie, diagnostiek, behandelmogelijkheden en 
uitkomstparameters bij patiënten met een reusceltumor van de weke delen 
(Tenosynovial Giant Cell Tumour, TGCT) beschreven. In hoofdstuk 1 wordt een 
overzicht van de huidige inzichten gegeven. TGCT is een zeldzame, goedaardige 
tumor uitgaande van gewrichtskapselslijmvlies, een peesschede of een slijmbeurs. 
Er zijn twee vormen bekend, namelijk de lokale vorm en de diffuse vorm, waarbij 
de lokale vorm nog verder onderverdeeld kan worden in TGCT in vingers en tenen 
of in de grote gewrichten (ofwel in ledematen proximaal van vingers en tenen 
zoals in de knie, de heup, de enkel etc.). Kennis over de incidentie van TGCT was 
voorheen gebaseerd op een onderzoek uit 1980 dat was verricht in één land (de 
Verenigde Staten). In dit Amerikaanse onderzoek werd een jaarlijkse incidentie 
van 9 per 1.000.000 mensen (de lokale vorm) en 2 per 1.000.000 mensen (de diffuse 
vorm) gevonden.
Incidentie
In hoofdstuk 2 wordt een nationale studie gepresenteerd die verricht is in Nederland. 
Hierin zijn  gegevens gebruikt uit het Pathologisch-Anatomisch Landelijk Geauto-
matiseerd Archief (PALGA) die een periode van vijf jaar bestrijken. Op basis hiervan 
zijn mondiale incidentiecijfers berekend voor de lokale vorm in de vingers en 
tenen, de lokale vorm in de grote gewrichten en de diffuse vorm. Deze zijn respec-
tievelijk 29, 10 en 4 per 1.000.000 persoonsjaren. Dit betekent dat hoewel TGCT 
nog steeds valt onder de zeldzame aandoeningen (ziekte komt bij minder dan 1 op 
de 2000 mensen voor), uit deze resultaten blijkt dat de ziekte vaker voorkomt dan 
voorheen werd verondersteld. Beide vormen kwamen het vaakst voor in het knie- 
gewricht, en traden iets vaker op bij vrouwen, namelijk anderhalf keer vaker dan bij 
mannen. Patiënten waren gemiddeld 47 jaar toen ze voor het eerst werden behandeld. 
Voor beide vormen geldt dat een open resectie de primaire behandeling was.  
 In hoofdstuk 3 wordt een onderzoek gepresenteerd waarin een overzicht 
wordt gegeven van alle gegevens van pediatrische patiënten met TGCT die zijn 
gepubliceerd in de periode 1990-2016. In dit onderzoek zijn ook de gegevens van 
kinderen jonger dan 18 jaar uit de nationale studie naar de incidentie van TGCT, 
die eerder zijn gepresenteerd in hoofdstuk 2, opgenomen. Daarnaast werden 
klinische gegevens uit de periode 1995-2015 van TGCT bij kinderen in kaart 
gebracht met behulp van de nationale database van bot- en weke delen tumoren. 
Het genormaliseerde frequentiecijfer voor TGCT bij kinderen was 2,4 per 1.000.000 
persoonsjaren (de lokale vorm, met uitzondering van vingers en tenen) en 1,1 per 
1.000.000 persoonsjaren (de diffuse vorm). Zowel bij kinderen als volwassen 
bestonden de symptomen uit zwelling, pijn en een beperkte beweeglijkheid. De 
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diagnostische vertraging (d.w.z. de periode tussen het eerste artsenconsult en het 
moment waarop de diagnose werd gesteld) bedroeg gemiddeld 12 maanden 
(variërend van 1 tot 72 maanden). Er werden geen verschillen gevonden tussen 
kinderen en volwassenen wat betreft de geslachtsverhouding van de patiënten, 
symptomen, eerste behandeling, recidivering van de ziekte, follow-up status of 
gemiddelde duur van de follow-up.
Diagnostiek 
MRI is de meest onderscheidende beeldvormende techniek om de diagnose TGCT 
te stellen, de operatie technisch goed voor te bereiden (door de mate van uitbreiding 
van de ziekte in kaart te brengen) en de ziekte te evalueren tijdens de follow-up. 
Aan de hand van MRI-beelden kan de opvallende nodulaire proliferatie (bij de 
lokale vorm) of de villeuze proliferatie van het gewrichtskapselslijmvlies (bij de 
diffuse vorm) worden aangetoond. In het verleden zijn echter nog geen onderschei-
dende kenmerken gerapporteerd op basis waarvan de mate van tumoruitbreiding 
in relatie tot de klinische uitkomst kan worden beschreven of gekwantificeerd. 
Het is uit klinisch en wetenschappelijk oogpunt belangrijk dat MRI-beelden 
eenduidig worden beschreven. In hoofdstuk 4 hebben vakinhoudelijke deskundigen 
daarom mogelijk onderscheidende MRI-parameters gedefinieerd om de mate van 
ziekte-uitbreiding te kunnen vaststellen. Tot deze parameters behoren het subtype 
van de ziekte, de mate waarin de gewrichten zijn aangedaan, de mate waarin het 
kraakbeen is aangedaan, en de betrokkenheid van spier-/peesweefsel, ligamenten 
of neurovasculaire structuren. Deze parameters werden aan de hand van twee 
verschillende studiepopulaties geëvalueerd, met uitzondering van betrokkenheid 
van het kraakbeen en neurovasculaire structuren. Zo werden vier subgroepen 
onderscheiden met ieder een verschillende mate van ernst van de ziekte, waarbij 
ernst werd gedefinieerd op basis van het recidiefrisico. Op basis van de voorgestelde 
classificatie krijgen artsen en patiënten informatie over de mate van ziekte-uit-
breiding en het recidiefrisico na operatief ingrijpen. Door de patiënten op deze 
manier in te delen, kunnen degenen met de ernstigste vorm (d.w.z. degenen met 
het hoogste recidiefrisico) worden geïdentificeerd. Dit is belangrijk omdat zij in 
aanmerking komen voor andere dan standaardbehandelingen. Bovendien is het 
relevant omdat behandelingen in een dergelijke, meer homogene, risicogroep op 
deze manier beter geëvalueerd kunnen worden.
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Behandelingen
Momenteel bestaat de behandeling van TGCT uit het operatief verwijderen van al 
het aangedane weefsel, zo nodig aangevuld met andere behandelingen. Deze 
aanpak is niet (altijd) afdoende. Het recidiefrisico is hoog, vooral bij de diffuse 
vorm. In hoofdstuk 5 wordt een systematisch literatuuroverzicht gepresenteerd. 
Hierin worden alle bekende behandelmethoden voor TGCT in de grote gewrichten 
en de klinische resultaten van deze behandelingen beschreven. De afgelopen eeuw 
is slechts weinig vooruitgang geboekt. De behandelopties die voorhanden waren, 
hadden wisselend succes en leidden in wisselende mate tot morbiditeit. Deze 
behandelingen waren een partiële of complete synovectomie (wegsnijden van het 
gewrichtskapselslijmvlies), een open of arthroscopische synovectomie, radiosy-
novectomie, externe beam radiotherapie (uitwendige bestraling) en systemische 
behandelingen met doelgerichte medicatie Daarnaast waren er ook aanvullende 
of op zichzelf staande behandelingen, waaronder cryochirurgie, immunotherapie, 
artroplastiek (gewricht vervangen voor een prothese), artrodese (aangedaan 
weefsel verwijderen en het gewricht vastzetten) of amputatie.
 Al deze verschillende behandelingen zijn toegepast bij TGCT. Vanwege de lage 
incidentie van de ziekte zijn er echter geen gerandomiseerde klinische trials 
uitgevoerd en is het moeilijk om de behandelingen met elkaar te vergelijken wat 
betreft de mate van effectiviteit. Er werden behandelrichtlijnen opgesteld om 
toekomstige studieresultaten van verschillende centra beter met elkaar te kunnen 
vergelijken en samenvoegen, en om artsen te helpen de beste behandeling te 
kiezen. Een internationaal register zou meer inzicht kunnen geven in de 
uitkomsten van deze ziekte. Daarom werd voorgesteld van alle TGCT patiënten 
dezelfde basisgegevens bij te houden voor onderzoek en om - in het ideale geval - op 
te nemen in een internationaal register.
 De resultaten van artroplastiek en cryochirurgie zijn retrospectief meer in 
detail onderzocht. In hoofdstuk 6 worden de uitkomsten van patiënten met TGCT 
beschreven bij wie een knie- of heupprothese werd geplaatst vanwege een 
uitgebreide vorm van de ziekte of artrose. Aan de hand van deze uitkomsten werd 
bevestigd dat artroplastiek succesvol kan worden toegepast na een operatieve 
synovectomie. Hierbij dient opgemerkt te worden dat recidivering van de ziekte, 
het losraken van de prothese en andere complicaties zich zelfs na jaren follow-up 
nog kunnen voordoen.
 In hoofdstuk 7 worden de resultaten van cryochirurgie als aanvulling op het 
chirurgisch verwijderen van de tumor beschreven. Deze studie onderstreept de 
beperkingen van het verrichten van onderzoek met kleine, retrospectieve en 
heterogene patiëntgroepen. Cryochirurgie kan in geselecteerde gevallen dienen 
als aanvullende behandeling voor de diffuse vorm van TCGT. Toch kwam uit de 
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gepresenteerde studie geen voordeel naar voren van additionele cryochirurgie ten 
opzichte van het enkel chirurgisch verwijderen van tumorweefsel, behalve wat 
betreft het verminderen van het aantal recidieven. 
 De diffuse vorm veroorzaakt vaak aanzienlijke morbiditeit vanwege lokale 
recidieven met als consequentie meerdere operaties ter behandeling hiervan. 
Systemische behandeling in de vorm van doelgerichte therapie, mits effectief en 
met een acceptabele mate van toxiciteit, kan een operatie met een onacceptabele 
kans op morbiditeit voorkomen of leiden tot minder invasieve operaties. TGCT is 
een proliferatieve aandoening met een verhoogde expressie van het gen voor 
colony- stimulating factor 1 (CSF-1). In hoofdstuk 8 wordt een internationale 
retrospectieve multicenter studie gepresenteerd met als doel het langetermijn-
effect van het gebruik van imatinib, een medicijn dat o.a. CSF1R remt, te 
onderzoeken bij patiënten met TGCT in lokaal gevorderde en recidiverende diffuse 
vorm. Bij patiënten die baat hadden bij de behandeling met imatinib werd een 
langdurig effect op de ziektesymptomen waargenomen, zelfs na het stoppen van 
de behandeling. De behandeling werd echter vaak onderbroken, bijvoorbeeld i.v.m. 
bijwerkingen, en er werden ook vaak andere behandelingen achteraf gegeven. 
 TGCT kan voorkomen in elk synoviaal gewricht, soms ook in het kaakgewricht. 
De aanpak van TGCT in het kaakgewricht is vergelijkbaar met die van TGCT in de 
grote gewrichten. Al het aangedane weefsel dient te worden verwijderd met een 
complete synovectomie, zo nodig gecombineerd met andere behandelingen. 
Vanwege de locatie van het kaakgewricht kan het volledig verwijderen van TGCT 
weefsel leiden tot onacceptabele morbiditeit in de vorm van verminking. Daarnaast 
is het effect van multimodale behandeling(en) onbekend.  In hoofdstuk 9 worden 
de resultaten van drie gevallen met TGCT in het kaakgewricht gepresenteerd. 
Daarnaast werd een overzicht van de relevante literatuur gegeven. De diagnose 
TGCT in het kaakgewricht wordt gesteld met behulp van MRI, zo nodig aangevuld 
met een CT-scan om de mate van ziekte-uitbreiding in kaart te brengen. Bij twijfel 
kan het noodzakelijk zijn een biopt te nemen om de diagnose te bevestigen. De 
behandeling van de lokale vorm bestaat uit een excisiebiopt. De behandeling van 
de diffuse vorm dient afgestemd te worden op basis van de leeftijd van de patiënt, 
de ernst van de symptomen, de mate van ziekte-uitbreiding en voortgang, de 
verwachte mate van verminking als gevolg van operatief ingrijpen en de huidige 
systemische behandelmogelijkheden. Indien de ziekte stabiel is, is een afwachtend 
beleid een reële optie. Aanvullende behandelingen moeten alleen worden toegepast bij 
tumoren die symptomen veroorzaken en niet chirurgisch kunnen worden verwijderd 
of bij resttumor na het operatief verwijderen en/of aanhoudende klachten.
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Uitkomsten
In hoofdstuk 10 wordt de lange termijn follow-up van een grote serie van 
opeenvolgende patiënten (N=107) met TGCT in de grote gewrichten binnen één 
instelling beschreven. Op het moment waarop de diagnose werd gesteld, was de 
gemiddelde leeftijd van de patiënten met de lokale vorm 37,5 jaar (variërend van 
17,2 tot 71,7 jaar). De gemiddelde leeftijd van de patiënten met de diffuse vorm was 
op het moment waarop de diagnose werd gesteld 33,9 jaar (variërend van 14,4 tot 
62,2 jaar). De knieën waren het vaakst aangedaan (dit gold voor 88% van de 
patiënten). De volgende behandelingen werden toegepast: chirurgie, uitwendige 
bestraling, radiosynovectomie, systemische therapie, immunotherapie of combi-
natiebehandelingen. In totaal hadden 49 patiënten (46%) al elders therapie 
ondergaan. De gemiddelde duur van follow-up vanaf het moment waarop de 
diagnose werd gesteld tot het laatste contact bedroeg 7,0 jaar (variërend van 0,3 tot 
27,4 jaar) bij patiënten met de lokale vorm en 14,5 jaar (variërend van 1,1 tot 48,7 
jaar) bij patiënten met de diffuse vorm in de knie. Het recidiefrisico van met name 
de diffuse vorm nam na verloop van tijd toe. De recidiefvrije overleving na één en 
vijf jaar voor TGCT in de knie bedroegen respectievelijk 69% en 32%. Tijdens lange 
follow-up perioden bleek dat de diffuse vorm vaak een terugkerend probleem is, 
en dat  patiënten met deze vorm na verloop van tijd steeds moeilijker kunnen 
worden genezen. 
 Naast recidivering van de ziekte en recidiefvrije overleving vormen ook de 
kwaliteit van leven en functionele scores belangrijke eindpunten. Hiermee worden 
de klinische relevantie en het effect van behandelingen aangetoond bij goedaardige 
ziekten waarbij de dood geen uitkomstvariabele is. In hoofdstuk 11 wordt de 
grootste prospectieve cohortstudie met de langste follow-up periode naar patiënt 
gerapporteerde uitkomstmaten (patient-reported outcome measures, PROMs) 
beschreven bij therapie-naïeve patiënten (primaire patiënten zonder eerdere 
behandelingen) met de lokale en diffuse vorm van TGCT in de grote gewrichten. 
Bij beide subtypen van de ziekte was de kwaliteit van leven van patiënten (gemeten 
met de SF-36 vragenlijst) significant en klinisch relevant afgenomen voorafgaand 
aan operatief ingrijpen in vergelijking met de gemiddelde waarden voor de 
algemene bevolking. Dit gold ook voor de voornaamste fysieke domeinen en een 
aantal psychische domeinen. Drie tot zes maanden na de operatie waren de scores 
voor alle sub-schalen van de SF-36 weer op hetzelfde niveau als de gemiddelde 
waarden voor de algemene Nederlandse bevolking. In de daaropvolgende jaren 
bleven de scores vrij constant. Voor beide vormen gold dat er enorme verschillen 
bestonden, zowel tussen patiënten onderling als na verloop van tijd, wat betreft 
ervaren mate van pijn (gemeten met de VAS-score). De gemiddelde functiescores 
volgens WOMAC voor pijn, stijfheid en fysiek functioneren toonden voor geen van 
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beide vormen klinisch relevante verschillen bij patiënten vóór (baseline) en na de 
operatie. Bij patiënten met de diffuse vorm verbeterden de WOMAC-scores voor 
pijn en fysiek functioneren echter wel na de operatie. Deze trend was tot vijf jaar 
na de operatie waarneembaar. Uit deze bevindingen blijkt dat initieel therapie- 
naïeve patiënten met TGCT drie tot zes maanden na de operatie weer dezelfde 
kwaliteit van leven ervaren als de algemene Nederlandse bevolking. Ook de 
 gewrichtsfunctie verbeterde significant drie tot zes maanden na de operatie, maar 
deze resultaten waren niet klinisch relevant.  Operatief ingrijpen had geen effect 
op de mate van ervaren pijn. Dit onderstreept het belang van chirurgie 
als behandeling voor therapie-naïeve TGCT patiënten. Patiënt gerapporteerde 
uitkomst maten voor patiënten met uitgebreide- of recidiefziekte zijn nog niet 
onderzocht. Het is te verwachten dat deze patiënten minder baat hebben bij alleen 
chirurgische behandeling. 
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Abbreviations
ACL= anterior cruciate ligament
AWD= alive with disease
BIG= Bone impaction grafting 
CBS= central bureau of statistics
CI= confidence interval
CIS20r= 20-item checklist individual strength questionnaire
CME= institutional review board
CML= chronic myeloid leukaemia
CR= Cruciate retaining
CSF-1= colony stimulating factor 1 
CSF-1R= colony stimulating factor 1 receptor
CT= computed tomography
D-PVNS= diffuse pigmented villonodular synovitis
DTGCT= diffuse tenosynovial giant cell tumour
Dt-GCT= diffuse tenosynovial giant cell tumour
EBRT= external beam radiation therapy
FPA008= cabiralizumab
GBA= gemeentelijke basis administratie
GCT-TS= giant cell tumour of the tendon sheath
GIST= gastrointestinal stromal tumours
GRE= gradient echo
HHS= harris hip score
HP= hemi arthroplasty knee 
HR=hazard Ratios
ID= patient identification
IM= imatinib mesylate
IQR= inter quartile range
IR= incidence rate
KSS= knee society score
L-PVNS= localized pigmented villonodular synovitis
LTGCT= localized tenosynovial giant cell tumour
Lt-GCT= localized tenosynovial giant cell tumour
ME= partial meniscectomy
Mo= months
MRI= magnetic resonance imaging 
MSTS= musculoskeletal tumor society
MUA= manipulation of the knee under anesthesia
N= number of patients 
NA= not available 
NED= no evidence of disease 
OSM= osteosynthesis material
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SD= standard deviation
SE= surgical synovectomy
SF36= 36-item short form health survey
SPSS®= statistical package for social sciences statistics
SVP= synovitis (villo)nodularis pigmentosa
PALGA= pathologisch-anatomisch landelijk geautomatiseerd archief (Dutch pathology registry)
PCL= posterior cruciate ligament
PET= FDG-positron emission tomography
PF= patella femoral arthroplasty
PFC= patella femoral component
PLX3397= pexidartinib 
PFS= progression-free survival
PS = posterior stabilized
PVNS= pigmented villonodular synovitis
QoL =quality of life 
RG7155= emactuzumab 
ROM= range of motion
RT= external beam radiation therapy
THA= total hip arthroplasty
TGCT= tenosynovial giant cell tumours
TKA= total knee arthroplasty 
TMJ= temporomandibular joint 
TNF= tumour necrosis factor
TTF= time to treatment failure
WHO= World Health Organization
WOMAC= Western Ontario and McMaster Universities osteoarthritis index
yrs= years
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nog veel van je te mogen leren bij de oncologische orthopedie.
 Prof. dr. van der Graaf, beste Winette, je brede ervaring en scherpe klinisch- 
wetenschappelijke blik hebben mij bijzonder goed geholpen. Ik heb er veel respect 
voor hoe je keer op keer met vernieuwende ideeën kwam, wat de kwaliteit van 
mijn artikelen ten gunste kwam. Hartelijk dank voor je bijdrage en begeleiding.
 Aan de basis van dit proefschrift liggen twee belangrijke personen ten grondslag, 
die zich dat misschien niet (meer) realiseren. Prof. dr. van Swieten, beste Henry, 
met jou heb ik mijn eerste wetenschappelijke publicatie geschreven. We hebben 
samen fantastische cardio-thoracale operaties uitgevoerd. Ik heb je daarbij meermaals 
horen zeggen, ‘dit heb ik nog nooit gezien’. Ik heb van je geleerd op vele fronten 
creatieve oplossingen te vinden om problemen op te lossen. Jij hebt me voorgesteld 
aan René Veth en Bart Schreuder, onder andere uit dit contact is mijn proefschrift 
en opleiding tot orthopeed voortgekomen. Prof. dr. Veth, beste René, in jouw laatste 
jaren als hoofd van de afdeling orthopedie in het Radboud UMC, droeg je het idee 
om onderzoek te doen naar gepigmenteerde villo-nodulaire synovitis aan me voor, 
alsof het een speciaal kindje van je was. Je hebt je hier duidelijk veel mee bezig 
gehouden, het ziektebeeld boeide je, ondanks het feit dat je omringd werd door 
patiënten met maligniteiten met de dood als gevolg. Ik hoop dat ik met dit proefschrift 
je verwachtingen heb waargemaakt.
 Dr. Hannink, beste Gerjon, co-promotor; dank voor de onvoorwaardelijke, 
 bewonderenswaardige steun die je me al die jaren gegeven hebt. Naast alle eindeloze- 
tijdrovende-ingewikkelde analyses waar we ons letterlijk doorheen geworsteld 
hebben, kon ik ongeremd-ongegeneerd alle frustraties waar onderzoek- maar ook 
opleiding mee gepaard kunnen gaan bij je kwijt. Jij wist alles nuchter aan te horen 
en te relativeren. We hebben dan ook regelmatig samen in een deuk gelegen en 
uiteindelijk een prachtig stukje werk afgeleverd, ‘al zeg ik het zelf’. Veel dank 
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hiervoor. En hopelijk is er nu dan eindelijk tijd om de MTB weer tussen de 
spinnenwebben uit te halen!
 Dr. Van der Geest, beste Ingrid, co-promotor; ik vind het indrukwekkend hoe 
jij je weg bewandelt als oncologisch orthopeed en opleider. Je bent ambitieus en 
staat je mannetje. Daarnaast ben je altijd  vriendelijk en toegankelijk. Ik heb veel 
van je geleerd, zowel op klinisch als op wetenschappelijk gebied. Ik hoop dat ik 
ook in de nabije toekomst met je mag blijven samenwerken.
 Leden van de manuscript commissie, hartelijk dank voor de nauwkeurige 
beoordeling en goedkeuring van mijn proefschrift.
 Mijn collega A(N)IOS en stafleden; dank voor jullie bijdrage aan de verdieping 
in de orthopedie en mijn persoonlijke ontwikkeling in de afgelopen jaren. Ik ben 
blij jullie het werk te kunnen presenteren waar ik al die jaren naast de opleiding 
mee bezig was.
 Dank aan alle patiënten die direct of indirect hebben meegewerkt aan dit 
proefschrift. Zonder jullie was het tot stand komen van dit proefschrift niet 
mogelijk geweest. Dit betreft lokale, nationale en internationale bijdragen.
 Petra Veldman en Karin te Plate; zonder jullie toewijding aan de oncologische 
orthopedie en in dezen het signaleren en includeren van TGCT patiënten op 
oncologie besprekingen en op de polikliniek, was het ‘kwaliteit van leven’ artikel 
nog lastiger geweest te bewerkstelligen. Ik heb erg veel respect voor het feit dat 
jullie naast jullie drukke agenda’s toch tijd konden vinden dit project zo goed 
mogelijk te stroomlijnen. Natuurlijk ook dank aan de medewerkers van het 
klinisch scoring station die met enthousiasme en toewijding data bij patiënten 
hebben verzameld.
 Na het scoren, kwam de bulk met data die ingevoerd moest worden in de acces 
database die ik met behulp van Mark Leummens in elkaar gezet heb. Mark dank 
voor de vele keren dat je me weer even op gang hebt geholpen wanneer ik wéér 
aanpassingen wilde, voor wéér een nieuw project. Anniek van der Zee en Anouk 
Scholte dank voor jullie hulp bij de data invoer en het schrijven van enkele 
artikelen. Ook Neeltje Verspoor en Selina van der Wal dank voor de tijd die jullie 
hiervoor vrij gemaakt hebben.
 Meermaals is een samenwerking met Leiden voorgesteld, om de patiënten 
aantallen en hiermee de kwaliteit van de TGCT onderzoeken te verhogen. Dit is 
met goed resultaat gelukt. Monique Mastboom, we hebben samen een brug weten 
te smeden tussen het Leidse en Nijmeegse wat best wat voeten in aarde had. Door 
goede duidelijke afspraken te maken en bij stroefheden direct de angel eruit te 
halen en zaken weer goed op een rij te zetten, hebben we in relatief korte tijd 
bergen werk verzet. Ik ben trots op je. We waren een goede aanvulling op elkaar, 
door jouw enthousiasme, het gemakkelijke contact dat je wereldwijd legde, je 
super snelle mail-antwoorden en grondige revisie van teksten. Gedachten die bij 
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het doen van statusonderzoek bij me naar voren kwamen in de beginfase van mijn 
onderzoek, werden ook door jou gesignaleerd waardoor deze sneller en met veel 
grotere patiënten aantallen onderzocht konden worden. Zoals het idee dat 
hormonen misschien van invloed waren op het beloop van TGCT en of het beeld bij 
kinderen zich agressiever gedroeg. Onze gedachten over nieuwe projecten waren 
niet te stuiten, waardoor we ons moesten beperken tot hoofdzaken. Hopelijk 
komen de pathologie, de radiologie en de ideeën over maligne TGCT nog wel van 
de grond. Dank voor de fijne en zeer productieve samenwerking. Michiel van der 
Sande ook jij bedankt voor het medebewerkstelligen van deze samenwerking en 
voor je zeer grondige commentaar, wat de kwaliteit van de onderzoeken ten goede 
kwam. Ik heb veel bewondering voor de manier waarop jij de oncologische 
orthopedie, kinderorthopedie, trauma, wetenschap, sport en je gezinsleven weet 
te combineren. Indrukwekkend op welk niveau je dit alles weet vol te houden. Ik 
hoop in de toekomst nog veel van je te leren.
 Akkie Rood, je was en bent mijn steun en toeverlaat voor, tijdens en waarschijnlijk 
ook na de opleiding tot orthopeed. Het is heerlijk zo’n maatje te hebben dat je niet 
van alles uit hoeft te leggen, maar dat gewoon in alle opzichten in hetzelfde 
schuitje zit; opleiding, onderzoek, jonge kinderen, etc. Ik weet zeker dat we nog 
veel van elkaar gaan leren, proosten op vreugde, klagen over ellende en lol blijven 
maken. ‘Of heb ik het volledig verkeerd ingeschat?!’ 
 Lieve vrienden en familie, bedankt dat jullie me eraan blijven herinneren dat 
er ook een leven is naast mijn werk. Ik zie niet iedereen zo vaak als ik zou willen, 
maar jullie gezelschap is heel belangrijk voor mij. Bedankt! Judith Bons en Selina 
van der Wal, dank voor jullie bijdrage aan dit proefschrift door teksten van 
commentaar te voorzien en voor het feit dat ik altijd op jullie kan rekenen. Larissa 
Meerman ik heb erg veel bewondering voor jouw enorme veerkracht.
 Lieve tante Riet en ome Karel, dank voor alle goede zorgen. Tante Riet, ik heb altijd 
genoten van het knutselen en klussen samen, luisterend naar radio 2 en roddelend 
over alles en iedereen. Het was een heerlijke uitlaatklep en er kwamen prachtige 
werken uit voort. Ik denk altijd met veel plezier terug aan de tijd die we samen 
doorbrachten en de snacks die ik altijd in mijn handen gedrukt kreeg voor thuis.
 Ome Jaap, dank voor al het vertrouwen dat je altijd in me had en dank voor 
alles uitstapjes die we maakten. Ik zal je nooit vergeten. Jammer dat je niet meer 
bij de bevestiging kan zijn; het is gelukt!
 Lieve schoonouders, Coby en Ger, bedankt voor alles. Ik ben jullie zeer 
erkentelijk voor alle goede zorgen voor Tigo en Mischa. Jullie staan al jaren dag en 
nacht voor ons klaar. Ik hoop echt dat jullie gezondheid het toe laat dat jullie nog 
zo lang mogelijk van de jongens kunnen genieten en visa versa. 
 Lieve mama, bedankt voor je oneindige interesse in voor wat ik allemaal doe. 
Het ontging me niet hoe trots je aan jan en alleman vertelde waar ik me mee bezig 
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hield. Bedankt dat je samen met Arno altijd voor mij en de kinderen klaar staat. 
Het is geweldig te zien hoe dol Tigo en Mischa op jullie zijn.
 Lieve papa, dit werk had ik geloof ik niet neer kunnen zetten zonder het door-
zettingsvermogen dat ik van jouw meegekregen heb. Wat heb ik onderweg veel 
aan je gedacht. Je zei altijd; “nicht ärgern, nur wunderen” wat me op veel lastige 
momenten een kleine innerlijke glimlach bezorgde. Ik mis je.
 Lieve Tigo en Mischa, als ik met jullie speel vergeet ik alles om me heen, ik ben 
zo intens gek en trots op jullie. Het is bizar hoe snel jullie groot worden. Het is zo 
leuk dat jullie nu nog denken dat papa en mama alles kunnen en overal de grootste 
en de besten in zijn. Ik kijk erg uit naar alles wat we de komende jaren samen gaan 
beleven. Bedankt dat ik jullie mama mag zijn.
 Ten slotte wil ik mijn lieve partner Bas Derks bedanken voor alles! Je hebt al 
mijn verhalen aangehoord over werk, onderzoek, artikelen, cursussen, presentaties, 
onderwijs, roosters etc. Je hebt me voortdurend gesteund waar je kon, al duurde 
het oneindig lang. Voor mij het belangrijkste, je bent een fantastische vader voor 
onze jongens. Ik ben heel erg gelukkig met jou en weet zeker dat we samen met de 
jongens een hele mooie toekomst tegemoet gaan.
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